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ABSTRACT 
 
Background: 
The earliest possible initiation of reperfusion therapy is necessary to reduce 
morbidity and mortality from acute STEMI. Therefore improving the time to 
thrombolysis where percutaneous coronary interventional facilities are limited or 
do not exist is critical.  The most effective system would integrate three key 
components to deliver continuous patient care, including: 1) from time of call for 
help through to emergency response; 2) transportation to and admission to 
hospital; 3) assessment and initiation of thrombolytic therapy. The purpose of this 
prospective study is: to develop a chest pain awareness education programme 
appropriate for the South African context; to assess safe initiation of thrombolytic 
therapy by emergency care practitioners for STEMI; and to compare the 
performance of emergency care practitioner thrombolysis with historical control 
data. 
 
Methods: 
A document study was undertaken on existing chest pain awareness programmes 
(in international settings) that led to the development of a culturally sensitive and 
affordable chest pain awareness programme. An investigation was conducted in 
two international settings, where pre-hospital thrombolysis is within the scope of 
practice of advanced life support paramedics. This led to the development of best 
practice guidelines for pre-hospital thrombolysis in South Africa. The study 
population consisted of two groups of STEMI patients, namely: 20 patients 
iv 
 
thrombolysed by the researcher (ECPT group); historical data obtained from 
previous research on 78 patients who were thrombolysed in-hospital by doctors 
(IHDT group). Demographic data and time to treatment complications encountered 
during hospital stay and at day 30 were recorded from patients’ ambulance report 
forms, hospital records and 30-day telephonic patient interviews. 
 
Results: 
A poster, an information booklet and a video on heart attack awareness were 
developed after studying documentation from the United Kingdom, Canada, 
Australia and South Africa. The study population of 98 (100%) patients comprised 
20 patients in the ECPT group and 78 patients in the IHDT group (73.5% of whom 
were males). The median age of the study population was 57.8 years, with a clear 
male dominance (73.5%). The majority of patients were of Indian origin (82.7%). 
Common conventional risk factors evident in all patients included smoking 
(56.1%), hypertension (52%) and diabetes (41.8%). The mean time from symptom 
on-set to thrombolysis for the ECPT group was 272 ± 79 minutes; the mean time 
from symptom on-set to thrombolysis for the IHDT group was 486 ± 373 minutes 
(p = 0.055). The mean door-to-needle time for the ECPT group was 124.9 ± 58.64 
minutes; the mean door-to-needle time for the IHDT group was 288.01 ± 261.44 
minutes (p = 0.003). The most common complications observed between the 
ECPT and IHDT groups during hospital stay and at 30-day follow-up included: 
cardiac failure (10.2% versus 12.2%); death (9.2% versus 7.1%); recurrence of 
angina (10.2% versus 6.1%); and recurrent myocardial infarction (1% versus 
3.1%).  
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Conclusion: 
If the goal for the future is defined as effective myocardial reperfusion within two 
hours of symptom on-set in all patients with STEMI, attempts to change the 
actions of individuals experiencing AMI symptoms should continue. While 
thrombolysis by emergency care practitioners offers a significant improvement in 
reducing symptom-to-needle time in treating STEMI, systems to facilitate various 
approaches need to be implemented. Prompt recognition of STEMI and shortening 
the time from first patient contact to initiation of thrombolytic drug therapy will most 
likely improve survival.  
 
Keywords: 
Acute myocardial infarction, heart attack, ST-elevation myocardial infarction, 
fibrinolysis, thrombolysis, pre-hospital thrombolysis. 
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NOMENCLATURE 
 
1. Acute coronary syndrome (ACS) 
Symptoms related to the obstruction of the coronary arteries. 
 
2. Acute myocardial infarction (AMI) 
Commonly known as a heart attack; it results from interruption of blood supply to a 
part of the heart and often results in myocardial death. 
 
3. Advanced life support (ALS) 
Provision of advanced life-saving emergency medical care that typically involves 
invasive techniques (such as advanced airway, ventilation and circulatory 
management). 
 
4. Alert Voice Pain Unresponsive (AVPU) 
The AVPU scale is a system by which a health care provider can measure and 
record a patient's responsiveness and which indicates the level of consciousness. 
 
5. Aspirin (ASA) 
Also known as acetylsalicylic acid, it is used: as an analgesic to relieve minor aches 
and pains; as an anti-pyretic to reduce fever; as an anti-inflammatory medication. It 
has an anti-platelet effect. 
 
6. Baccalaureus Technologiae: Emergency Medical Care 
xxi 
 
A four-year degree qualification for advanced life support emergency care 
practitioners in South Africa. 
 
7. Blood pressure (BP) 
The pressure exerted on the walls of blood vessels by circulating blood - one of the 
principal vital signs. 
 
8. Coronary care unit (CCU) 
A specialised intensive care hospital ward dedicated to the care of cardiac 
patients. 
 
9. Culturally sensitive 
The South African population is made up of many different race groups, cultures, 
linguistic groups and ethnic groups. All require slightly different approaches to 
health care. To deliver complete health care requires awareness of these cultural 
differences: culturally sensitive care targets the entire person not just the physical 
ailment. 
 
10.  “call-to-needle” time 
The time from on-set of pain to the time the patient is thrombolysed. 
 
11. “door-to-needle” time 
The time taken from the time the patient arrives at the hospital to the time of 
thrombolysis. 
 
xxii 
 
12. Electrocardiogram (ECG) 
Electrical activity of the heart recorded by an external device over a period of time; 
it is detected by electrodes attached to the outer surface of the skin on the chest. 
 
13. Emergency care practitioner (ECP) 
Baccalaureus Technologiae: Emergency Medical Care (a four year degree). 
Qualified persons are registered with the HPCSA in the designated registration 
category Emergency Care Practitioner. 
 
14. Emergency medical services (EMS) 
A broad term for an emergency service dedicated to providing out-of-hospital acute 
medical care, transport to definitive care and other medical transport to patients 
with illnesses and injuries that prevent patients from transporting themselves. 
 
15. Emergency Medical Rescue Services (EMRS) 
The public sector ambulance service that provides an emergency pre-hospital 
healthcare service. 
 
16. General practitioner (GP) 
A medical doctor who provides comprehensive general medical care to patients. 
 
17. Glucose measurement (GM) 
Measurement of glucose levels using a blood or urine sample.  
 
18. Glyceryl Trinitrate (GTN) 
xxiii 
 
A drug used for the treatment of angina, acute myocardial infarction and severe 
hypertension. 
 
19. Health Professions Council of South Africa (HPCSA) 
The statutory body responsible for regulating health care professionals in South 
Africa. 
 
20. Inkosi Albert Luthuli Central Hospital (IALCH) 
A tertiary level hospital located in the Ethekwini Health District. 
 
21. In-hospital 
All activities undertaken after a patient is admitted to hospital. 
 
22. Mahatma Gandhi Memorial Hospital (MGMH) 
A district level hospital located in the northern sub-district of Phoenix, in the 
Ethekwini Health District. 
 
23. Non-ST-elevation myocardial infarction (NSTEMI) 
Acute myocardial infarction that does not present with ST segment elevation on an 
electrocardiograph monitor. 
 
24. Paramedic 
A Critical Care Assistant or someone with a National Diploma: Emergency Medical 
Care (3-year qualification). These are qualified persons registered with the HPCSA 
xxiv 
 
in the designated registration category of Paramedic; they practice within the 
advanced life support scope of practice. 
 
25. Phoenix (PHX) 
A northern sub-district in the Ethekwini Health District. 
 
26. Pre-hospital 
All activities involving the patient outside the hospital environment. 
 
27. Pre-hospital thrombolysis (PHT) 
Thrombolytic therapy undertaken outside the hospital environment. 
 
28. Primary hospital 
The initial hospital the patient attends for medical treatment – usually within the 
same health district (district hospital). 
 
29. Primary percutaneous coronary intervention (PPCI) 
A surgical procedure that involves insertion of a catheter into a coronary artery. 
 
30. Professional Board for Emergency Care (PBEC) 
The professional board of the HPCSA responsible for the regulation of emergency 
care providers in South Africa. 
 
xxv 
 
31. Referral hospital 
The hospital that the patient is referred to for further medical attention within the 
same health district (regional hospital). 
 
32. Streptokinase (STK) 
A first generation, effective and inexpensive thrombolytic agent used for acute 
STEMI and pulmonary embolism.  
 
33. ST-elevation myocardial infarction (STEMI) 
A myocardial infarction involving the full thickness of the heart muscle seen on an 
electrocardiograph monitor by ST segment elevation. 
 
34. Subcutaneous (SC) 
A subcutaneous injection is an injection in which a needle is inserted just under 
the skin.  
 
35. Tenecteplase (TNK) 
An enzyme used as a fibrin specific thrombolytic agent. 
 
36. Thrombolytic / fibrinolytic agent 
A pharmacological agent intended to breakdown fibrin with the use of enzymes. 
 
37. Thrombolysis 
The process of destroying or breaking up of a blood clot – thrombus. 
xxvi 
 
 
38. Wentworth Hospital (WW) 
A district level hospital located in the southern sub-district Wentworth of the 
Ethekwini Health District. 
 
39. 30-day follow-up 
The follow-up done on a patient 30-days after the patient has been discharged 
from hospital. 
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CHAPTER 1 
BACKGROUND AND LITERATURE REVIEW 
1.1 Introduction 
1.1.1 Global burden of coronary heart disease 
The World Health Organisation (WHO) reported that cardio-vascular diseases 
(mainly heart disease and stroke) cause approximately 17 million (30%) of the 58 
million deaths that occur worldwide annually. Cardiovascular disease death rates 
(per 100 000) in the middle-age category (30-69 years) are: low in developed 
countries such as Canada (120) and United Kingdom (180); and high in 
developing countries like Brazil (320), China (280), Pakistan (400), Nigeria (410), 
Russia (680) and India (405) (1).  
 
Coronary heart disease (CHD) is one of the leading causes of death 
internationally, with more than 60% of the global burden of CHD occurring in 
developing countries. CHD is decreasing in many developed countries, but is 
increasing in developing and transitional countries, partly as a result of increasing 
lifespan, urbanisation and lifestyle modification (2). WHO has predicted that heart 
disease and stroke will become the leading cause of death and disability 
worldwide, with the number of fatalities increasing to over 20 million per annum 
and to over 24 million per annum by 2030 (2). WHO statistics have also shown 
that CHD has the: highest mortality rates in high income countries (1.33 million, 
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16.3%); second highest rates in middle income countries (3.4 million, 13.9 %); is 
lowest in low income countries (2.47 million, 9.4%) (3). 
 
1.1.2 South African burden of coronary heart disease 
According the Medical Research Council (MRC) of South Africa, cardiovascular 
disease is the second leading cause of death (17%) in the list of ten leading 
causes of death in South Africa (4). Death from cardiovascular disease accounts 
for 15% of total deaths in KwaZulu-Natal (5). About 195 South Africans die each 
day from heart disease.  Of these, acute myocardial infarction (AMI) is responsible 
for approximately 33 deaths per day and it is twice as prevalent in men as it is in 
women (6). 
 
CHD has reached epidemic proportions amongst the White and Indian populations 
in South Africa (7).  An analysis of CHD mortality for the period 1978 to 1982 
showed markedly different rates for the Indian, White and Coloured population 
groups, namely: 780 per 100 000 for Indians; 688 per 100 000 for Whites; and 419 
per 100 000 for Coloureds (8).  Blacks were excluded from the analysis because 
of a lack of reliable data for this ethnic group (9).  
 
In a study conducted on 2290 Indians admitted with acute coronary syndromes 
(ACS) to the R. K. Khan Hospital during a 6-year period (1996 to 2002), significant 
differences in risk factor status were found between genders as well as for 
different age groups (10).  Twenty percent of these patients were < 45 years old.  
3 
 
In addition, these patients revealed aggressive disease on angiographic studies, 
with 48% having triple vessel disease (TVD). 
 
1.1.3 Epidemiological transition 
In a recent study undertaken in KwaZulu-Natal, although the proportion of African 
patients was relatively low, 10 of 120 (8.3%), the data may herald the emergence 
of a new epidemic of coronary disease in the Black African population: 8.3% of the 
study cohort represents Black South African patients with STEMI only (11). 
Previous statistics reported at least 3 identified patients per annum approximately 
50 years ago. This number increased to 5 about 25 years ago.  The annual 
incidence of ACS among Black Africans in Soweto has increased rapidly. Between 
1975 and 1980, 54 patients were diagnosed with AMI at Chris Hani Baragwanath 
Hospital in Soweto: in 2004 there were 64 new cases diagnosed with acute 
coronary syndromes (12-14).  In a community awareness project conducted at 
several taxi ranks in Soweto involving 1691 participants, 78% of the so called 
‘healthy population’ had more than one major risk factor for heart disease (15). 
 
The recently published “The Heart of Soweto Study” reports 4 162 patients with 
cardiovascular disease presenting to the cardiology outpatient department and 
coronary care unit at Chris Hani Baragwanath Hospital during 2006. Of the 1 593 
de novo cases, CHD occurred in 6% of the Black African population. Also in this 
registry, however, the prevalence of risk factors for CHD was high, with 87% 
having one risk factor or more (16). The INTERHEART investigators evaluated risk 
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factors for acute myocardial infarction in nine sub-Saharan countries and showed: 
the risk factors for myocardial infarction are the same, regardless of ethnic origin 
(17). However, Black Africans suffering myocardial infarction: were younger; had a 
lower rate of family history; had more single coronary artery disease; and the risk 
with hypertension and abdominal obesity was higher. This was in comparison with 
the overall INTERHEART group. The strongest risk factors were smoking and 
stress. The risk for myocardial infarction in Black Africans with a higher education 
and higher income increased - in contrast to the risk in Coloureds, Indians and 
Whites. 
 
These observations raise the question of an epidemiological transition amongst 
the African population in a post-apartheid era (16).  This is possibly due to 
urbanisation, change in the traditional Black African diet to a consumption of “fast 
food” (high in saturated fats) and the effect of emerging affluence due to economic 
growth in South Africa.  This continued trend implies an additional burden on an 
already over-burdened health system. 
 
1.1.4 Delays to definitive treatment 
Prompt restoration of blood flow is the primary treatment goal in acute STEMI. It 
has been known for more than 20 years that a delay (between symptom on-set 
and treatment) of less than 60 minutes is ideal (18). There are three key 
components to the initiation of prompt and effective reperfusion therapy. 
Addressing patient delay would result in the overall symptom-to-needle time being 
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significantly reduced, e.g. by improving patient and bystander knowledge of 
symptoms, increasing utilisation of the ambulance service and addressing 
prolonged in-hospital treatment delays. The patient is probably the most important 
factor in the time delay between on-set of AMI and the start of reperfusion 
treatment. Patient delays have proven to be difficult to challenge as it requires a 
continuous education programme. Interventions to reduce delays have been met 
with limited success (19). 
 
1.1.5 Reperfusion treatment for STEMI 
Reperfusion therapy is a cornerstone of treatment for patients with acute STEMI 
(20). Several studies have demonstrated that acute STEMI can be aborted if 
reperfusion of the occluded coronary artery is achieved before the heart muscle is 
irreversibly damaged (21).  Reperfusion is accomplished either: mechanically, by 
primary percutaneous coronary intervention (PPCI); or pharmacologically, by 
administration of a thrombolytic agent as soon as possible after diagnosis of 
STEMI (20, 22).  Both methods: have been shown to be successful in the 
treatment of acute STEMI; have contributed significantly to a reduction in mortality; 
and have a Class IA recommendation from the European Society of Cardiology  
(22, 23). 
 
Many randomised clinical trials have shown that PPCI is superior to thrombolytic 
therapy in the treatment of patients with STEMI (24).  However, PPCI has several 
limitations, the most important of which is that it must be performed by an 
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experienced interventionist less than 2 hours from presentation of chest pain (25).  
Therefore, PPCI is typically offered only at specialist centers. Such facilities are 
not common in South Africa, especially in public sector hospitals.  
 
Due to the limited availability of PPCI, pharmacological reperfusion therapy using 
thrombolytic agents remains an important therapeutic modality in the management 
of acute STEMI.   
 
 
 
 
 
 
Figure 1: Time benefit curve  
Source: (26) 
 
Thrombolytic drugs must be administered rapidly after the infarction has started, 
as the benefit of treatment decreases rapidly as the time from clot formation 
increases.  An overview of early randomised trials has shown that 65 lives can be 
saved per 1 000 patients treated if treatment is administered in the first hour (“the 
golden hour”) after symptom on-set.  This benefit is reduced to 29 lives and 20 
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lives saved for every 1 000 patients treated between 3-6 hour and 7-12 hour 
intervals after symptom on-set, respectively (Figure 1 above) (26). 
 
Therefore, improving the time to thrombolysis is critical in the management of 
acute STEMI in order to reduce morbidity and mortality.  Although many hospitals 
have improved their “door-to-needle” time to a practical minimum in recent years, 
further reduction in the “call-to-needle” time are essential to minimise the time to 
thrombolysis. 
 
1.1.6 Justification of the study – South African context 
There is currently limited data describing awareness, delays and application of 
definitive treatment for acute STEMI within South Africa. A study was conducted 
by the researcher as part of a Master of Science in Cardiology degree to assess 
the time interval from first patient contact to initiation of thrombolytic treatment and 
possible reasons for treatment delay in patients presenting with acute STEMI. The 
study population comprised 120 patients with acute STEMI, presenting to 20 
different hospitals in Durban and surrounding regions during the period August to 
December 2006. Demographic data, time to treatment, reasons for non-treatment 
and complications encountered during hospital stay and at day 30 were also 
obtained from hospital records and patient interviews. 
 
This study showed that of the 120 patients: 65% were thrombolysed; at least 45% 
of these patients being thrombolysed within 6 hours of on-set of symptoms. The 
8 
 
time to definitive treatment from symptom on-set for all patients was: 55 (45.8%) 
treated within 6 hours; 85 (70.8%) treated within 12 hours; and 35 (29.2%) treated 
in the greater than 12 hour category. This suggests an overall delay in treatment of 
patients. In a sub-group analysis, the treatment time frame for patients 
thrombolysed 78 (65%) was: 42 (35%) up to 6 hours; 60 (50%) up to 12 hours; 
and 18 (15%) in the greater than 12 hours category. These proportions are not in 
keeping with trends in other settings: the United Kingdom Myocardial Infarct 
National Audit Plan database shows: more than 75% of patients were treated 
within 6 hours; approximately 7% of patients treated in the category ‘greater than 
12 hours’ from symptom on-set (27).  It is a Class I recommendation that 
thrombolytic therapy be initiated within 12 hours, although it may be appropriate to 
initiate thrombolysis after 12 hours (Class IIa) (especially in young patients and 
patients with persistent chest pain that indicates the possibility of a collateral blood 
supply in the infarcted area or ante-grade flow (20, 28-30)). In the Second 
International Study of Infarct Survival, Streptokinase reduced mortality when given 
13 to 24 hours after the on-set of pain (31). Furthermore, of the 120 patients, 42 
(35%) were not thrombolysed and of these 37 (88.1%) were outside treatment 
time for thrombolytic therapy.  The mean time to definitive treatment from symptom 
on-set was 8.36 ± 5.57 hours, which constitutes a major delay when compared to 
the symptom-to-needle time recommendation of less than 60 minutes (22).  
 
The patient delay often constitutes the longest period to delay to treatment (32). 
The mean time taken for the patients to summon help was 3.32 ± 5.26 hours, as 
shown in the researcher’s previous study (11). Many patients reported that they 
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were not sure was causing the pain and did not think that it was serious.  General 
practitioner referral to hospital of a total of 30 (25%) patients took a mean of 0.37 ± 
1.31 hours. None of these patients were thrombolysed by the general 
practitioners. The mean time taken to transfer patients to a regional hospital by the 
primary hospital was 7.05 ± 4.58 hours.  It took a mean time of 5.18 ± 6.36 hours 
for patients to receive definitive treatment at a regional hospital. This delay is 
unacceptable, considering that the international recommendation for time to 
thrombolysis in hospital is less than 30 minutes (30).   
 
While the reasons for delay to treatment within the hospital environment are not 
within the scope of this study, most patients reported long waiting periods in the 
emergency department. The ambulance transport and private vehicle transport 
times were not analysed because this data was not always recorded.  It would 
have been beneficial to assess: mean time of ambulance arrival from time of 
ambulance notification; mean ambulance transport time from patient pick up point 
to hospital; and the contribution of these times to treatment delay.  This could be 
especially important in rural areas where there are lengthy transportation times. 
 
The majority of patients that were not thrombolysed were in the ‘greater than 12 
hours’ category (17 (14.2%)), with a further 12 (10%) of patients being in the 6 to 
12 hour category. The main reason why patients did not receive thrombolysis was 
patients being outside the treatment period. 
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A retrospective review of case notes was conducted by Roshan et al (33) from 
January 2008 to July 2010 of all patients receiving thrombolytics for AMI in the 
emergency centres of three Cape Town hospitals. The total door-to-needle time 
was calculated and the following analysed: patient demographics and 
presentation, physician qualification, clinical symptomology and reasons for delays 
in thrombolytic administration. 
 
The findings of this study showed that of 161 acute STEMI patients, the median 
door-to-needle time achieved was 54 minutes (range 13 - 553 minutes). Also seen 
was: door-to-needle time of 30 minutes or less achieved in 33 (20.5%) patients; 
51.3% of patients arrived by ambulance; 34% of patients had a pre-hospital 12-
lead ECG; and 88.8% had typical symptoms of myocardial infarction. This study 
concluded that a significant number of patients were not thrombolysed within 30 
minutes of presentation. 
 
The findings of these South African studies show there is a prolonged time to 
treatment in each component, that is: the patient, the general practitioner, the 
primary hospital and the regional hospital. This results in either non-thrombolysis 
or delayed thrombolysis. 
 
From the findings of these studies it can be extrapolated that one possible strategy 
to reduce symptom-to-needle time would be to implement thrombolysis by 
emergency care providers and utilise emergency medical services. The overall 
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symptom-to-needle time could be significantly reduced in all components, affecting 
definitive treatment with effective use of the emergency medical services. 
 
1.1.7 Purpose of this study  
The purpose of this prospective study is to develop a chest pain awareness 
education programme through document analysis and to safely initiate 
thrombolytic therapy by ECPs in order to help reduce morbidity and mortality from 
acute STEMI.  
 
1.1.8 Objectives of this study 
The objectives of this study are to: 
1. Develop a culturally sensitive and affordable chest pain awareness 
education programme. 
2. Plan, design, implement and evaluate thrombolysis for acute STEMI by 
emergency care practitioners. 
3. Assess the performance of a developed treatment algorithm in 20 patients 
and compare this to own historical control data. 
 
1.1.9 Critical questions answered by this research 
1. What chest pain awareness education programmes exist nationally and 
internationally? 
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Through a literature search and document analysis, this question aims: to 
determine if such programmes do exist; and to seek guidelines from 
existing material to inform the development of a programme that will be 
sensitive to South African needs. 
2. What education programmes exist nationally and internationally for pre-
hospital management of acute STEMI (with particular emphasis on 
thrombolysis)? 
The aim of this question is to determine whether South African education 
programmes for the management of acute STEMI are of adequate levels 
compared to established international programmes. This will lead to the 
development of an educational programme and an evidence-based protocol 
for implementation within South Africa. 
3. How long does it take for a patient to call for help from the on-set of 
symptoms? 
This question aims to determine the influence of patient awareness on time 
to definitive treatment. 
4. How long does it take for the patient to receive definitive treatment? 
The aim is to determine the extent to which location, transportation and in-
hospital factors impact on time to definitive treatment. 
5. What is the impact of ECP thrombolysis on 30-day morbidity and mortality 
outcomes? 
The aim is assess the impact of ECP thrombolysis on patient morbidity and 
mortality outcomes at 30 days post-acute STEMI. 
13 
 
 
1.2 Literature review 
1.2.1 Delays to definitive treatment 
Delay time is usually defined as the total time taken from first awareness of 
symptoms to initiation of definitive treatment; it is divided into three phases of 
delay: patient/bystander recognition; pre-hospital; and in-hospital. The total pre-
hospital delay period consists of two components: time taken by patients to 
recognise that their symptoms are serious and to contact medical help (decision 
time); and the time taken from requesting help to hospital admission (home-to-
hospital delay).  Various factors may affect the recognition of symptoms and time 
taken to hospital admission (34). Pre-hospital delays, however, remain 
unacceptably long with median intervals averaging 2 to 4 hours (35-38). 
 
Patient-associated delays from on-set of symptoms (suggestive of AMI) to hospital 
arrival affect the timely receipt of reperfusion interventions and (potentially) the 
post-discharge outcomes associated with AMI. The following are some of the 
numerous studies done on time from symptom on-set to hospital arrival, which 
have reported considerable variation.  
 
The REACT trial was a multi-centre, randomised community-based trial designed 
to reduce patient delay (during a baseline period from December 1995 to March 
1996). Data from 3 783 hospital records of patients hospitalised for AMI symptoms 
in 20 communities were analysed. The median pre-hospital delay in patients 
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hospitalised for evaluation of heart attack symptoms was 2.0 hours, with 25% of 
patients delaying longer than 5.2 hours. Delay was: longer for Blacks than for 
Whites; longer in older age groups; and shorter in patients who were transported 
to hospital by ambulance. The findings of this trial supported the notion that 
demographic, cultural and socio-economic barriers impact on timely hospital 
presentation (39). 
 
The results of the Worcester Heart Attack Study (35) (a population based study) 
suggest that a large proportion of patients with AMI continue to exhibit prolonged 
delay. This longitudinal study of 3 837 residents with AMI in Worcester examined 
trends in time to hospital presentation and the factors associated with prolonged 
delay. The mean, median and distribution of delay times showed either 
inconsistent or no changes over the study period.  In 1986, the mean and median 
pre-hospital delay was 4.1 and 2.2 hours respectively. Just over a decade later (in 
1997) these times were 4.3 and 2.0 hours respectively. No significant differences 
were noted over the study period.  Approximately 44% of these patients presented 
to hospital within 2 hours of on-set of symptoms of AMI. In the 1997 study year, a 
delay of more than 2 hours was associated with increasing age, pre-existing 
angina or diabetes and on-set of symptoms in the afternoon or evening.  While the 
socio-demographic characteristics of this study generally represented the 
population of the United States, the results could not be generalised as the 
majority of the population in the Worcester Study were White.  
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A study done in Glasgow in the United Kingdom sought to determine: reasons for 
delay in calling for help during AMI; and reasons for choice of first medical contact. 
The study involved a review of medical records and one-to-one semi-structured 
interviews.  Of the 313 patients included in the study: 25% called for help within 
one hour of symptoms; 41% did so within two hours; 60% did so within four hours;  
20% delayed calling for help for more than four hours; while 12% of the patients 
exceeded 24 hours i.t.o. time to summon help. The most common reasons for the 
delay were: patients did not recognise the pain as cardiac in origin; they did not 
regard the pain as serious and thought that it would go away. Only 25% of patients 
made the first call for medical help to the ambulance services; 55% called their 
general practitioner; and 20% of patients self-presented to the nearest hospital 
emergency department (40).  The study was done in an area where there was an 
established general practitioner service. The data collection methods were 
reasonable and the inclusion of a semi-structured interview made provision for 
data that might have been missing in patient records. 
 
A number of other United States of America and European studies published 
between 1969 and 1987 found that median pre-hospital delay times ranged from 
2.5 hours to 7 hours (41). In different registries of patients with STEMI, the time 
from symptom on-set to hospital presentation was ≥ 4 hours in 50% - a value that 
has changed very little from 1987 to 2000 (38). 
 
Perkins-Porras et al (42) collected patient delay data on 228 patients with ACS 
from patient hospital records and through semi-structured interviews.  The results 
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of the study showed that shorter total pre-hospital delays and decision times were 
associated with STEMI, early recognition of symptoms as cardiac in origin, being 
married, symptom on-set outside the home and the presence of a bystander. 
Shorter home to hospital delays were more likely among: younger patients; those 
experiencing STEMI; and patients with a greater number of symptoms.  Shorter 
delays and decision times were also noticed for patients who utilised the 
emergency medical service.  This study corroborated the  findings of other studies 
in that various factors were associated with shorter times in the decision time and 
in the home to hospital components (43).  The study concluded that greater 
understanding of these factors may help target interventions more effectively to 
reduce pre-hospital delays. 
 
There is currently limited data describing delays and the application of definitive 
treatment for acute STEMI within Africa. In a study done in Morocco, an analysis 
of a register for 2 566 patients admitted with unstable angina or AMI showed that 
the mean time from on-set of chest pain to hospital admission was 111 ± 38 hours. 
This study identified problems relating to transportation from home to hospital; 
concluding that patient awareness of chest pain, organised transportation and 
reducing waiting time in the emergency room were central to national policy 
development to shorten time to definitive treatment (44). In a multi-national survey 
involving 3 North African countries (Algeria, Morocco and Tunisia) 42% (419/989) 
of acute STEMI patients did not receive any form of reperfusion therapy (45). The 
study did not assess the reasons for non-initiation of reperfusion therapy. 
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In a local study undertaken in KwaZulu-Natal (11), significant delays were noted in 
overall symptom-to-treatment time with delays in all components, i.e.: time taken 
for patients to call for help’ time taken by the general practitioner to refer a patient 
to hospital; time taken by the primary hospital to transfer a patient to a regional 
hospital; and time taken for patients to receive definitive treatment at a regional 
hospital; however, this study did not assess the reasons for delay in the individual 
components. 
 
In a more recent retrospective analysis done in Cape Town, South Africa on 238 
eligible acute STEMI patient records: 77 (32%) did not receive thrombolysis; of 
which 49 (64%) missed the thrombolytic window. Only 33 (20.5%) of the 161 
patients thrombolysed were treated within the recommended 30 minutes door-to-
needle time due to: a lack of senior doctors; difficulty in interpreting ECGs; atypical 
presentation; and system delays (33). 
 
1.2.2 Patient delay in symptom recognition 
Many patients may not be aware that they are having a heart attack and often 
dismiss the symptoms as indigestion or heartburn (46, 47). A number of factors 
were associated with the patients’ decision time, including: the type of acute 
coronary syndrome; the nature and localisation of the symptoms; the area where 
the symptoms occurred; the patient’s interpretation of symptoms; and knowledge 
of AMI (48). Many patients believe that the AMI starts suddenly and dramatically 
with severe chest pain (49). 
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In a telephone interview of 2 316 patients conducted in King County, Washington, 
the main reasons for delay were because: the patient thought the symptoms would 
go away; the symptoms were not severe enough; and the patient thought that the 
symptoms were caused by another illness (50). 
 
In a study conducted by Perry et al (36), the pre-hospital delay time was closely 
related to the mismatch between expected and experienced symptoms.  Delay 
was reduced when the patient conversed with someone about the symptoms 
during symptom on-set. The data from this study suggested the need for a public 
education programme on symptoms of AMI - not only to individuals at risk, but also 
to the general public, given the critical role of another person in facilitating the 
decision to seek help timeously. 
 
Another study, conducted from September 2004 to March 2005, aimed to obtain a 
deeper understanding of how AMI patients and their relatives think and act during 
and after on-set of symptoms; this through six focus group interviews.  The results 
revealed that AMI patients experienced a variety of symptoms and both patients 
and their relatives were unsure about the origin of the symptoms. Both parties 
interpreted the symptoms as being less serious and tried to self-remedy the 
discomfort. Patients sought the assistance of family members only when the 
symptoms persisted.  An important recommendation from this study was that the 
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public and AMI patients and their relatives should be given information about AMI 
symptoms and the recommended action to be taken (51). 
 
1.2.3 Impact of age, gender, socio-economic factors, existing clinical 
conditions and ethnic group on patient delay 
Delay is greatest in: the elderly; the low socio-economic and ethnic minority 
groups; and in those whose symptoms occur between 6 pm and 6 am (39, 52). 
 
While some studies have shown that increased age is associated with longer pre-
hospital delay (53, 54), others did not find any statistical significance of the 
influence of age on delay (49, 55). Early explanations for delay in presentation by 
women were related to perceptions of the prevalence of coronary heart disease in 
women in general (56). More recent studies have shown that there is no major 
gender difference in pre-hospital delay or type of symptoms; but musculo-skeletal 
symptoms, the experience of symptoms and how these are interpreted and 
assessed have a stronger impact on men than on women (57-59). 
 
Data obtained from the Northern Sweden MONICA myocardial infarction registry 
also showed that older patients (65-74 years) - and more prominently women - 
had a longer delay and less typical symptoms (59). Data was used from the 
Cooperative Cardiovascular Project, which involved beneficiaries of a funded 
medical system who were: aged > 65 years; hospitalised with a confirmed AMI 
between January 1994 and February 1996. This was to identify patients who 
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presented “late” to hospital, that is, ≥ 6 hours after symptom on-set.  Of 102 339 
patients, 30 087 (29.4%) arrived late, while 11 905 (11.6%) presented within 6 to 
12 hours and 18 213 (17.8%) arrived after 12 hours.  Significant predictors of late 
arrival included diabetes, and a history of angina; prior AMI, angioplasty, bypass 
surgery and cardiac arrest predicted early presentation.  In addition, initial 
evaluation at a clinic and presentation during the day predicted late arrival.  Other 
risk factors for delay were female gender and Black ethnic group. (54). This study 
reported that poverty was a significant determinant of prolonged pre-hospital 
delay. Similarly, Okhravi (60) found that patients who delay for more than six hours 
from symptom on-set had a low income and low education level. 
 
Data on impact of age, gender, socio-economic factors, existing clinical conditions, 
race and ethnic group on patient delay in South Africa is not available, as this is an 
under-researched area. The South African population is made up of many different 
race groups, cultures, linguistic groups and ethnic groups, which may require 
slightly different approaches to health care in general. To deliver complete health 
care, and more specifically, to address reasons for patient delay, sensitivity to 
these factors must be considered when designing and implementing awareness 
programmes. 
 
1.2.4 Transport delay 
International guidelines suggest activation of emergency medical services (EMS) 
by patients or bystanders for patients with symptoms consistent with AMI (61). 
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Activating the EMS is a rapid and effective means of obtaining medical care. 
The use of EMS: 
1. Leads to faster receipt of initial reperfusion interventions (62). 
2. Facilitates early alerting of the receiving hospital.  This results in shorter 
treatment delay as clinical decisions to treatment and preparation thereof 
can be made more effectively (63, 64). 
3. Most ambulances or EMS systems are equipped with defibrillators and 
paramedics who are trained to advanced life support levels, thereby 
increasing the chances of survival should cardiac arrest or life-threatening 
arrhythmias occur (61). 
4. Reduces long waiting periods in queues at the presenting hospital when 
the patient self-presents.  With the use of EMS, the patient is handed over 
from one health care professional to another (65, 66) . 
 
Despite these advantages, only 40% to 60% of patients with AMI choose to initiate 
emergency medical care by using EMS (38, 67, 68). In the National Registry of 
Myocardial Infarction 2, just over half (53%) of patients with STEMI were 
transported to the hospital by ambulance (62).  In KwaZulu-Natal, EMS use is 
even lower. In a study undertaken by the researcher (11), the majority of patients 
(105 (87.5%)) were transported to hospital privately, while only 12 (10%) utilised 
ambulance services. This figure is low compared to other studies (38, 68). This 
local study also demonstrated that time to treatment for the ambulance group 
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resulted in quicker initiation of definitive care - on average 2 hours and 45 minutes. 
These findings are similar to those of a study undertaken by Hutchings et al (65), 
where transportation by EMS resulted in shorter elapsed time to thrombolytic 
administration compared with patients using private transportation.  The door-to-
needle time to definitive treatment in the EMS transported group versus private 
transportation was 32 versus 49 minutes respectively (p = 0.01); and the time from 
decision to seek care until definitive treatment was 75 versus 92 minutes 
respectively (p = 0.042) (65). 
 
The belief that self-transport is faster or the perception that symptoms are not 
serious enough is the response that leads people not to choose an ambulance 
(50, 67). 
 
In Sweden, a national observational study was conducted in 11 hospitals between 
April 2001 and February 2003 to define the factors influencing the use of an 
ambulance by patients with AMI. A little more than half (n = 958) of the patients 
went to hospital by ambulance. Symptoms, patient characteristics, ACS 
characteristics, and perceptions and knowledge were associated with ambulance 
use in AMI. Patients who did not call for an ambulance thought self-transportation 
would be faster and did not believe that they were sick enough (69). A substantial 
number of patients do not call for an ambulance as their first medical contact after 
on-set of symptoms of AMI.  A public education programme on the benefits of 
ambulance transportation and early treatment is required. 
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1.2.5 General practitioner delay / primary hospital delay 
Further delays in time to reperfusion treatment occur when patients seek help from 
general practitioners and at local clinics and local hospitals that do not provide 
thrombolytic therapy (11, 70, 71). In-hospital delays are due to: lack of capacity; 
delay by the doctor; delay with acquisition of the drug; and overall system 
admission to treatment delays. 
 
A study was conducted at Vancouver General Hospital to evaluate in-hospital 
door-to-needle time for thrombolysis for acute STEMI and the factors associated 
with time prolongation through a retrospective chart review. 140 patients were 
included in the study.  A door-to-needle time of less than: 30 minutes was 
achieved in 24.3% of patients; 30 to 40 minutes in 24.3%; 40 to 60 minutes in 
22.1%; and > 60 minutes in 29.3%. A number of in-hospital factors identified that 
further delayed the time to delivery of thrombolytic therapy included: delay from 
arrival to patient admission; delay from time of admission to initial evaluation of 
patient; delay from time of obtaining and interpreting the electrocardiogram to 
ordering the drug; and delay from time of ordering the drug to administration of the 
thrombolytic agent (66). 
 
The South African District Health System (72) lends itself to significant delays in 
receiving reperfusion treatment as: most of the district level hospitals initiate 
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thrombolytic treatment inconsistently; all district and regional hospitals do not have 
PPCI facilities. 
 
1.2.6 Public awareness education programmes for AMI 
Based on an understanding of the factors that influence pre-hospital delay, it is 
important to implement public awareness programmes that focus on the 
importance of early symptom recognition and quick call for assistance. Early 
attempts to change the actions of individuals experiencing AMI symptoms did not 
produce encouraging results.  Despite several expensive public education media 
campaigns to reduce delay, individuals suffering AMI symptoms still delay their 
decision to seek treatment (19, 73, 74). A study conducted by Ho et al (73) 
showed that a short-duration education campaign may increase knowledge of 
AMI, but does not significantly shorten patient delay in seeking care. However, 
individual education and counselling programmes aimed at those at high risk for 
AMI, or those who have had an AMI, have produced more positive results in 
changing health behaviour (75-77). Randomised control trials, designed to test 
whether an intervention designed specifically for patients with ACS via a one-on-
one delivery mode, found that the education and counselling intervention did not 
lead to reduced pre-hospital delay or increased ambulance use (78, 79). As the 
aim of such programmes is a reduction in delays and promoting appropriate 
management for AMI, programme content should focus on: awareness and 
recognition of symptoms; the importance of seeking help quickly by calling for an 
ambulance or notifying a family member (80).  
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Studies aimed at increasing public knowledge of warning signs of stroke have 
shown that high intensity programs and use of television rather than newspapers 
increased knowledge and the need to call emergency medical services for specific 
symptoms (81, 82). 
 
In South Africa, awareness programs driven by non-governmental 
organizations like September Heart Awareness Month and Think RED 
campaigns focus on risks and prevention of cardiovascular disease. Some 
programmes like those on the National Department of Health website brief ly 
mention symptoms of heart attacks, lacks the action to be taken by the 
individual and the use of EMS. However a program that focuses on 
awareness and recognition of symptoms; the importance of seeking help quickly 
by calling for an ambulance or notifying a family member and use of emergency 
number is non-existent. Almost two decades of political transition in South Africa 
has seen a rise in non-communicable diseases like cardiovascular disease, type 2 
diabetes, cancer, chronic lung disease and depression. Prevention and treatment 
of non-communicable diseases are currently marginalised in South Africa, possibly 
due to the overwhelming prevalence and increase in communicable diseases like 
HIV, AIDS and tuberculosis (4, 83).  
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1.2.7 Reperfusion therapy 
Several studies have demonstrated that acute STEMI can be aborted if 
reperfusion of the occluded coronary artery is achieved before the heart muscle is 
irreversibly damaged (21, 84). Injured but viable myocytes are potentially 
salvageable if an adequate blood supply can be re-established after acute 
coronary occlusion. The goals of reperfusion therapy, therefore, would be to limit 
the infarct size and prevent future infarctions - and thereby improve patient 
survival (85). Reperfusion is accomplished either mechanically (by percutaneous 
coronary interventions (PCI)) or pharmacologically (by the administration of a 
thrombolytic agent) as soon as possible after confirmation of diagnosis of STEMI 
(Figure 2) (22).  Regardless of mode of reperfusion, early treatment, especially 
within the first ‘golden hour’, has a significant mortality benefit (22, 86, 87). 
 
Figure 2: Reperfusion strategies  
Source: (22) 
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1.2.7.1 Percutaneous coronary interventions 
The role of PCI during the first hours of management of acute STEMI can be 
divided into: primary PCI; PCI combined with pharmacological reperfusion therapy; 
and “rescue PCI” after failed pharmacological reperfusion (88). Primary PCI is the 
preferred therapeutic option when it can be performed by an experienced team 
within two hours (25, 89). 
 
A meta-analysis of 23 randomised trials undertaken by Keeley (87), which 
assigned 7 739 thrombolytic-eligible patients with STEMI to either primary PCI or 
thrombolytic medication, revealed that primary PCI was better than thrombolytic 
therapy at reducing: overall short-term (4-6 weeks) death (9.3% versus 7.0%, p = 
0.0002); non-fatal re-infarction (6.8% versus 2.5%, p < 0.0001); total stroke (2.0 
versus 1.0%, p = 0.0004); and the combined endpoints of death, non-fatal re-
infarction and stroke (14.5 versus 8.2%, p<0.0001).  During long-term follow-up (6-
18 months), the results seen with primary PCI remained better than those seen 
with thrombolytic therapy with: 12.8% versus 9.6% for death; 10.0% versus 4.8% 
for non-fatal AMI; and 19% versus 12% for the combined endpoints of death, non-
fatal re-infarction and stroke. 
 
However, primary PCI has several limitations, the most important of which is that it 
must be performed by an experienced team timeously after presentation of chest  
  
28 
 
pain. An experienced team not only includes interventional cardiologists, but also 
skilled support staff (89). Other limitations include: major bleeding from the femoral 
artery access site; the need for vascular repair; and acute renal failure (87). 
 
Therefore, primary PCI is typically restricted to hospitals with established 
interventional cardiac specialist centers that use primary PCI as a routine 
treatment option for patients presenting with signs and symptoms that suggest 
acute STEMI. Centres with a high volume of PCI procedures have demonstrated 
lower mortality rates (90, 91). Fewer than 1 in 5 hospitals in the United States and 
1 in 10 hospitals in Europe have cardiac catheterisation facilities; and even fewer 
hospitals are equipped to perform primary PCI on a full-time emergency basis 
(24). 
 
Such facilities are lacking in South Africa, especially in public sector hospitals. As 
an example, the province of KwaZulu-Natal has just one public sector hospital 
(lnkosi Albert Luthuli Academic Hospital (IALAH)) with such facilities.  KwaZulu-
Natal is an area of approximately 94 500 square kilometres, with a population of 
approximately 9 924 000, i.e. a population density of approximately 105 people per 
square kilometre (92). According to the latest mid-year estimates released by 
Statistics South Africa in 2011 (93), KwaZulu-Natal has the second largest share 
of the South African population: 10.8 million (21.4%) of 50.5 million. IALAH is a 
referral hospital and it is conceivable that a patient requiring PCI may only be 
attended to after 24 hours of first symptoms. 
29 
 
 
1.2.7.2 Pharmacological reperfusion 
Due to the limited availability of PPCI, pharmacological reperfusion therapy using 
thrombolytic agents remains the most important therapeutic modality and the most 
utilised form of reperfusion therapy worldwide in the management of acute STEMI. 
Timely thrombolytic therapy can re-establish coronary flow and salvage 
jeopardised myocardium.  Thrombolytic drugs must be administered rapidly after 
the infarction has started, since the benefit of treatment decreases rapidly as the 
time from clot formation increases.  
 
The introduction of thrombolytic therapy in the late 1950’s was a major advance in 
treatment of acute STEMI. It was not until a meta-analysis of smaller studies 
undertaken in the 1980’s that a significant mortality benefit was suggested (94). 
Interest in thrombolytic therapy developed in the mid-1980’s, when it became 
possible to assess the effectiveness of thrombolytic therapy with angiography (95-
97). 
 
Large randomised clinical trials have clearly demonstrated a statistically significant 
mortality benefit with thrombolytic therapy. The first large scale trial, GISSI -1 Trial 
(18), conducted over 17 months, randomly assigned 11 712 patients suspected of 
acute STEMI within 12 hours of symptoms, to either Streptokinase (STK) or 
standard treatment. In-hospital mortality at 21 days was: 10.7% in the STK group 
and 13% in the control group - a 17.6% risk reduction (p = 0.0002, RR = 0.81). A 
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follow-up study demonstrated that improved survival was sustained at 1 - 2 years. 
The large sample size (drawn from more than 175 coronary care units) makes the 
results of this study statistically significant and generalisable; however, this was 
not a blind study, which may have led to treatment bias. 
 
The Fibrinolytic Therapy Trialists (FTT) Collaborative Group (98) undertook a 
meta-analysis of nine major randomised trials that had more than 1 000 patients 
each (totalling 58 600 patients), with a view to determining the safety and benefit 
of thrombolytic therapy in a wide variety of patient sub-groups.  The results 
showed that treatment was helpful regardless of the following: gender; if systolic 
blood pressure was less than 180 mm Hg; previous AMI; or diabetes mellitus.  
Therapeutic benefit was noted when administration was initiated for up to 12 hours 
after first symptoms, but was greatest when administered within 3 hours. 
Approximately 30 early deaths were prevented per 1 000 patients treated; and if 
treated between 7 and 12 hours after symptom on-set, 20 deaths were prevented 
per 1 000 patients treated.  The FTT Group found a ‘straight-line relationship’ 
between absolute mortality and time to treatment from on-set of symptoms. The 
large size of the FTT Collaborative Group database provided the statistical 
strength to analyse the benefits of thrombolysis in sub-sets of patients.  
 
An overview of 22 randomised trials undertaken between 1983 and 1993, which 
included 50 246 patients, showed that 65 lives per 1000 patients treated can be 
saved if treatment is administered in the first hour after symptom on-set (“the 
golden hour”).  This benefit is reduced to 29 lives and 20 lives saved for every 1 
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000 patients treated at the first 3 – 6 hours and 7 - 12 hour intervals after symptom 
on-set, respectively (26). This study demonstrated that the benefit/time regression 
line was non-linear: steep to start and then tapering off after 2 hours. Furthermore, 
twice as many lives were saved when thrombolytic therapy was started within the 
first hour of on-set of symptoms, in comparison with the 7 to 12 hours (44% versus 
20%). 
 
The GUSTO-I study (99) comprised four treatment groups with approximately 10 
000 patients in each. The trial was designed to compare new thrombolytic 
regimes, consisting of the use of: Streptokinase and subcutaneous Heparin; 
Streptokinase and intravenous Heparin; accelerated tissue plasminogen activator 
(t-PA); and intravenous Heparin or a combination of Streptokinase plus t-PA.  
Regardless of thrombolytic strategy used, the study demonstrated the importance 
of early thrombolysis on the 30-day mortality primary end-point of the study.  When 
thrombolytic agents were given less than 2 hours after on-set of pain, there was a 
30-day reduction in mortality of 5,5%, as opposed to 9% if administration was 
delayed for more than four hours.  
 
More than 50 000 patients have been randomised in trials comparing various 
thrombolytic agents to a placebo or control and it was shown in the meta-analysis 
that when these agents are administered early, the benefit is substantially higher 
(26). Therefore, improving time to thrombolysis is critical in the management of 
acute STEMI in order to reduce morbidity and mortality.  Although many hospitals 
have, in recent years, improved their “door-to-needle” time to a practical minimum, 
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further reductions in “call-to-needle” time are essential to minimise the time to 
thrombolysis. 
 
1.2.8 Pre-hospital thrombolysis 
Pre-hospital thrombolysis is well-established in developed settings internationally. 
Research in pre-hospital thrombolysis is on-going. A large international 
pharmaceutical company is currently conducting a study called STREAM 
(Strategic Reperfusion Early After Myocardial Infarction) in 112 locations 
worldwide. This study aims at evaluating (in a proof of concept approach) the 
outcome of pre-hospital patients presenting with acute STEMI within 3 hours of 
symptom on-set. Following randomisation, a treatment strategy of early (pre-
hospital) Tenecteplase and additional anti-platelet and anti-thrombin therapy, 
followed by catheterisation within 6-24 hours, with timely coronary intervention as 
appropriate (or by rescue coronary intervention if required) in Group A, will be 
compared to PPCI performed according to local standards in Group B 
(http://clinical trials.gov.show/NCT00623623). Pre-hospital thrombolysis is a Class 
IIa therapy recommended for acute STEMI by leading international cardiology 
societies (89). 
 
The following trials are just some of the numerous thrombolytic trials conducted in 
the pre-hospital environment that demonstrate the potential value of pre-hospital 
thrombolysis on morbidity and mortality. 
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The first published study of pre-hospital thrombolysis was undertaken in 1985; it 
involved intravenous administration of 750,000 units of Streptokinase by 
physicians to 53 patients (9 treated at home and 44 in-hospital). This study 
demonstrated that patients treated in less than 1.5 hours after on-set of pain 
revealed the following in comparison with patients receiving treatment between 
1.5 to 4 hours from the on-set of pain: a significantly higher ejection fraction (56 ± 
15 versus 47 ± 14 %; p < 0.05); improved infarct-related regional ejection fraction 
(51 ± 19 versus 34 ± 20 %; p < 0.01); and a lower QRS score (5.6 ± 4.9 versus 8.6 
± 5.5; p < 0.01). Patients in the pre-hospital group of the study also had better-
preserved left ventricular function than patients treated in the hospital. The study 
concluded that thrombolytic therapy with Streptokinase is most effective when 
administered within 1.5 hours of on-set of symptoms of AMI. Although this study 
produced positive results, it lacked statistical power (due to a small sample size), 
but it served to highlight the importance of timely thrombolysis (100). 
 
The Grampian Region Early Anistreplase Trial (GREAT) is the most influential pre-
hospital thrombolysis based study. The aim of GREAT was to determine the time 
saved by thrombolysis when initiated at home by trained general practitioners / 
family physicians, compared to thrombolysis in-hospital. The general practitioners 
randomly assigned thrombolytic therapy to 311 patients with suspected AMI who 
had been divided into two treatment groups: pre-hospital thrombolysis; and 
thrombolysis after arrival at the hospital.  GPs selected patients on the basis of 
history of chest pain, from 20 minutes to 4 hours, with treatment initiated within 6 
hours of on-set of pain. Patients in the pre-hospital treatment group received 
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thrombolysis up to 130 minutes earlier than patients at hospital (101 minutes 
versus 240 minutes from on-set of symptoms), with a 50% reduction in mortality in 
the pre-hospital group: 17 (10.4%) versus 32 (21.6%). The greatest saving of time 
was seen in the rural environment and in areas where there were significant in-
hospital treatment delays (101). Importantly during the GREAT study, pre-hospital 
thrombolysis was undertaken using a single bolus thrombolytic agent.  
 
Patients enrolled into the GREAT study were followed up at five years and 
investigators noted that 25% of the pre-hospital treatment group had died, 
compared to 36% in the in-hospital treatment group (102). The GREAT study re-
confirmed the negative impact of time delays by demonstrating that delaying 
thrombolysis by one hour increased the hazard ratio of death by 20%, with an 
equivalent loss of 43 lives per 1000 patients treated at five years. In a sub-set 
analysis of GREAT patients, who met current ECG criteria for thrombolysis 
undertaken  after 10 ten years, a 16% difference in mortality was maintained 
between the two groups (103). The benefits seen in GREAT were significantly 
higher than those seen in any other thrombolysis study.  The long-term mortality 
patterns have not been replicated in other long-term (in-hospital) follow-up studies, 
like ISIS-2 (31) or GUSTO-1 (99). 
 
Although general practitioners (GP) did ECG recordings, it was not a requirement 
for trial admission. Trial admission was by strong clinical suspicion of AMI, 
allowing for the possibility of either an inclusion or exclusion bias. Selection bias 
was mitigated against in the GREAT study by adopting a randomised controlled 
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double-blind method, which involved random administration from an ampoule 
labelled either “home injection” or “hospital injection.”  However, there are some 
challenges with generalising data from the GREAT study: administration of a 
thrombolytic agent is never undertaken on clinical suspicion of acute STEMI alone 
and the role of a GP is not typical of current emergency medical systems. 
 
The European Myocardial Infarction Project (EMIP) (104) is the largest double-
blind randomised multi-national study (5469) to compare pre-hospital with in-
hospital administration of Anistreplase.  Patients were included based on on-set of 
symptoms within six hours and a qualifying 12-lead ECG. Patients treated in the 
pre-hospital group by emergency medical personnel received treatment a mean 55 
minutes sooner than those in the hospital group.  A non-significant reduction in 
mortality at 30-day follow-up was seen: 9.7% versus 11.1%; 95% CI: -0.1% - 
3.1%; p = 0.08. The strengths of this trial lie in the sample size (over 5 000 
patients) and in it being a multi-national study. A significant point of this study was 
the overall reduction of 15 minutes to thrombolysis in participants of the hospital 
group, which reduced the added benefit effects of pre-hospital thrombolysis in the 
comparative analysis with the pre-hospital call-to-needle time. 
 
The Myocardial Infarction Triage and Intervention (MITI) trial was a much smaller 
one (n = 360) done in an urban setting that had a well-established history of 
excellent emergency cardiac care. The purpose of the study was to determine the 
long-term influence of early thrombolysis for acute STEMI. As in EMIP, in-hospital 
treatment times were significantly reduced (40 minutes); however, both the 
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treatment groups had similar outcomes. No significant improvement was noted 
when thrombolysis was initiated out of hospital. Patients who were treated less 
than 70 minutes after on-set of symptoms had a 98% 2-year survival rate, 
compared to 88% when treated later (p = 0.12). At 2 years, the event free survival 
rate was 65% for patients in the early treatment group and 59% for those treated 
after 70 minutes (p = 0.8). The findings of this study were not generalisable, 
however, because thrombolysis by paramedics could only be undertaken after 
remote assessment of ECG results and clinical assessment by doctors, which 
introduced an the element of selection bias. In addition, the study was conducted 
in an urban setting with well-established cardiac care facilities.  These results can 
only be compared to studies in similar settings (105). 
 
These three trials and three other randomised trials were combined in a meta-
analysis undertaken by Morrison et al (106). The primary objective of this meta-
analysis was to critically appraise and summarise all randomised controlled trials 
of pre-hospital versus in-hospital thrombolysis for acute STEMI. The primary 
outcome was all-cause hospital mortality and the secondary outcomes, amongst 
others, symptom to treatment time and adverse events. The individual trials failed 
to demonstrate a statistically significant difference in all cause in-hospital mortality. 
This meta-analysis (involving 6434 patients) showed: a pooled benefit in that pre-
hospital thrombolysis reduced time to thrombolysis by approximately 60 minutes (p 
= 0.07), compared to in-hospital thrombolysis (104 versus 162 minutes); and 
reduced all-cause hospital mortality by 17%.  Perhaps the major criticism of the 
meta-analysis was the use of trials in which a variety of thrombolytic drugs were 
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used. However, Morrison et al (106) considered it reasonable to group the trials 
together, regardless of this variation, on the grounds of their broad clinical 
similarities. 
 
A clinical trial was undertaken in Helsinki, Finland by Voipio (107), to investigate 
the safety and efficacy of thrombolytic therapy for an acute myocardial infarction 
immediately after out-of hospital cardiac arrest.  Of the 68 patients treated, an 
accurate diagnosis was made in 64 patients.  Reperfusion was achieved in 71% of 
patients.  Sixty-three patients (93%) were admitted alive to hospital, with 36 
eventually surviving to discharge. Although this was a retrospective study, which 
lends itself to missing data and other inaccuracies, the results are generalisable, 
on the grounds that the reporting method used to establish the database is an 
established international collection tool that may have contributed to accurate and 
consistent reporting of all patients.  All patients in the study could be followed up 
with details of their responses to thrombolysis. 
 
Björklund et al (108) evaluated treatment delays and outcome in a large cohort of 
acute STEMI patients transported by ambulance and who were either 
thrombolysed by paramedics in the pre-hospital environment or thrombolysed in-
hospital.  Importantly, Björklund et al utilised data from the Swedish Register of 
Cardiac Intensive Care, drawing data from 75 hospitals. Although register-based 
data lacks the scientific controls seen within clinical trials, it is arguably more 
reflective of ‘real life’ clinical care. Following this study, Björklund et al were able to 
conclude that pre-hospital thrombolysis by paramedics in ambulances was 
38 
 
associated with reduced time to thrombolysis of almost 1 hour and reduced 
adjusted 1-year mortality by 30%. 
 
1.2.8.1 Paramedic-led pre-hospital thrombolysis 
The efficacy and safety of pre-hospital thrombolysis depends on several pre-
requisites (104, 108-110), i.e.: 
1. Ambulance personnel being trained to recognise symptoms and 
management of STEMI and its early complications. 
2. Diagnoses of STEMI using a 12 lead ECG that adds a few minutes delay 
time with or without computer assistance. 
3. Intravenous access to be established and the administration of reperfusion 
therapy to be initiated within strict treatment directives. 
4. During transportation, rhythm monitoring and advanced cardiac life support 
are mandatory. 
5. Early contact with the referring hospital by electronic transmission of the 12 
lead ECG appears to be necessary, allowing early preparation of further 
care that will also contribute to improving outcome. 
6. Availability of a consultant cardiologist for clinical support when required. 
7. On-going quality assurance. 
 
These and other trials help to confirm the feasibility and safety of pre-hospital 
thrombolysis in a wide variety of circumstances and settings, ranging from 
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traditional ambulance services through to use by ship-based medical teams 
(cruise ships) and deployed military medicine.  
 
1.2.8.2 Pre-hospital thrombolysis supported by early intervention 
There are a number of reperfusion strategies for acute STEMI, namely: 
1. Pre-hospital thrombolysis supported by rescue PCI for failed thrombolytic 
reperfusion.  
2. Pre-hospital thrombolysis plus pre-discharge or symptom/ischaemia driven 
PCI for those who evidence reperfusion. 
3. Facilitated PCI (reduced dose thrombolysis with planned PCI). 
4. Primary PCI. 
 
The ASSENT-4 PCI (111) study demonstrated that facilitated PCI, that is,  
thrombolysis immediately followed by PCI, has proven to be an unsuccessful 
intervention. 
 
The WEST study (112) investigated the use of a number of different reperfusion 
strategies: immediate pre-hospital thrombolysis plus usual in-hospital care 
(excluding routine PCI); pre-hospital thrombolysis with compulsory rescue PCI for 
failed thrombolysis against a primary PCI strategy. Key findings of the WEST 
study were: a lower incidence of cardiogenic shock in patients who received 
thrombolysis early (within 3 hours); and the importance of pre-hospital 
triage/decisions for reperfusion with delays to definitive treatment being shorter 
40 
 
when a decision was made in the pre-hospital setting. The WEST study also high-
lighted that thrombolysis used timeously remains an important treatment modality 
in early management of acute STEMI.  
 
The larger CAPTIM study (113) used a similar design to the WEST study, utilising 
pre-hospital decision/triage to pre-hospital thrombolysis (this time supported by 
compulsory rescue PCI) with pre-discharge coronary intervention compared to 
PPCI. The long-term 5-year follow-up of the CAPTIM study confirmed a significant 
reduction in mortality when thrombolysis was administered within 2 hours in the 
pre-hospital group, compared with primary angioplasty.  The relationship between 
reperfusion strategy and time from symptom on-set on 1 year mortality was 
examined in a pooled analysis of patients from the CAPTIM and WEST studies. A 
reduction in 1 year mortality was observed when thrombolytic treatment was 
initiated within 2 hours, compared to PPCI (2.8% versus 6.9%, p= 0.021, hazard 
ratio 0.43, 95% CI 0.20-0.91). However, no difference in mortality was observed 
between the two groups when thrombolytic treatment was initiated after two hours 
(6.9% versus 6.0%; p= 0.529; hazard ratio 1.23; CI 0.61-2.46)(114). The optimal 
design of a hybrid reperfusion service is yet to be determined, but the data from 
WEST and CAPTIM would support pre-hospital thrombolysis within the first three 
hours, as long as all patients were delivered to a receiving hospital with 
intervention cardiology capability. 
 
Pre-hospital thrombolysis can be initiated earlier than in-hospital thrombolysis or 
PPCI and it can be performed with limited equipment. The same minimum 
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equipment is required to perform pre-hospital thrombolysis as is required to 
identify pre-hospital patients requiring direct admission for PPCI. Data from WEST 
(paramedic decision-makers), CAPTIM (doctor decision-makers) and projected 
findings from STREAM (paramedic/nurse/doctor decision-makers) are intended to 
inform the debate as to whether a hybrid reperfusion system is appropriate within 
developed countries. Regardless of the reperfusion strategy put into place, 
empowering the pre-hospital emergency care provider is a pivotal strategy to 
success.  
 
1.2.8.3 Risk benefit and hazard considerations for pre-hospital thrombolysis 
Although thrombolysis has been determined to be a relatively safe procedure, the 
treatment is associated with risks and complications. Even with appropriate use, 
thrombolytic agents can have serious adverse effects; however the risks are off-
set by the considerable overall reduction in morbidity and mortality. Many patients 
with recognised vulnerability to the known hazards are treated in the hospital 
setting on the basis of a favourable risk-benefit ratio. Pre-hospital thrombolysis 
should, therefore, always be the result of a risk benefit calculation of: the acute 
STEMI, thrombolysis risks and PPCI availability. Thus, the emergency care 
practitioner should carefully consider the risk benefit ratio and consult with the 
receiving cardiologist as to the most appropriate treatment option (115). 
 
The hazards of thrombolytic therapy relate to: 
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• Haemorrhage due to the dissolution of haemostatic plugs and old thrombus 
outside the coronary arteries. The greatest risk is from cerebral 
haemorrhage, which occurs with a rate of 0.5% to 1%. This risk is 
minimised by avoiding treatment in the presence of hypertension, known or 
suspected cerebral tumours, history of cerebro-vascular accident, 
symptomatic cerebro-vascular disease, old age and recent trauma. Other 
contra-indications relating to internal or external bleeding include: mistaken 
diagnosis of pericarditis or dissecting aneurysm; recent surgery; peptic 
ulceration; known bleeding tendency (including anti-coagulant treatment); 
and prolonged chest compression from cardio-pulmonary resuscitation. 
Bleeding is usually minor and occurs at the sites of vascular puncture 
(70%) (116). 
• Complications that follow successful reperfusion of ischaemic tissue, 
resulting in life-threatening ventricular arrhythmias that may require 
immediate defibrillation (116). 
• Allergy and induced hypotension (particularly for Streptokinase). Allergy is 
rarely life-threatening and severe hypotension can usually be avoided by 
withholding treatment if blood pressure is already low (117).  
• Administration of a thrombolytic for patients without the patient having an 
acute STEMI may also lead to complications (118). 
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1.2.8.4 Ideal pre-hospital thrombolytic agent 
There are a number of thrombolytic agents available; however Tenecteplase 
(TNK) is the only single-use bolus agent available, making it most suitable for pre-
hospital use. Nevertheless, an ideal thrombolytic agent currently does not exist.  
 
The characteristics of an “ideal thrombolytic agent” are as follows: 
• Rapid reperfusion (15 - 30 minutes) 
• 100% efficacy at achieving 100% TIMI 3 in 30 minutes   
• Administered as a single intravenous bolus 
• Lower incidence of intra-cranial haemorrhage 
• Lower incidence of systemic bleeding and other complications 
• Specific for recent thrombi 
• Lower incidence for re-occlusion 
• Long-term sustained patency 
• No antigenicity 
• No negative interaction with adjunctive therapy 
• Affordable 
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Table 1: Characteristics of commonly used thrombolytic agents 
 Adapted from Opie (119). 
 Streptokinase 
(STK) 
Alteplase 
(tPA) 
Reteplase 
(rtPA) 
Tenecteplase 
(TNK) 
Fibrin selective No Yes Yes Yes 
Plasminogen binding Indirect Direct Direct Direct 
Duration of infusion 
(minutes) 
60 90 10 + 10 5-10 seconds 
Half-life (minutes) 23 <5 13-16 20 
Fibrinogen 
breakdown 
4+ 1-2+ Not known > tPA 
Early Heparin Yes Yes Yes Yes 
Hypotension Yes No No No 
Allergic reactions Yes No No No 
Approximate 
cost/dose  
R957/1.5 MU R6884/100 
mg 
R7197/20 
 unit kit 
R5762/50 
mg 
TIMI re-flow grade 3 
at 90 minutes 
32 45-54 60 > tPA 
Recommended use Up to 12 hours Up to 12 hours Up to 12 hours Up to 6 hours 
(typically used 
up to 12 
hours) 
 
The GUSTO trial (99) demonstrated the superiority of an accelerated regimen of 
tissue plasminogen activator (tPA, Alteplase) over STK, although there was a 
slightly greater risk of intra-cranial haemorrhage, especially in female patients over 
the age of 75 years. However, stroke after thrombolysis is a known risk; and in the 
GUSTO trial the stroke rate with STK was 1.19%, compared to 1.55% with tPA 
(120). The issue of stroke is an important consideration, as denying thrombolysis 
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does not decrease the stroke rate. This is because STEMI is an independent risk 
factor for stroke that is unrelated to thrombolysis, which is due to higher incidence 
of atrial fibrillation (AF) and poor left ventricular (LV) function caused by STEMI. 
Therefore, early treatment of STEMI with reperfusion, which reduces the incidence 
of AF and LV dysfunction, is an important aspect of stroke and morbidity reduction. 
 
Single bolus TNK is now the most widely used thrombolytic agent in developed 
countries, partly due to its improved efficacy, but also because of ease of 
administration and variable dosing.  TNK and Alteplase are equivalent with regard 
to 30-day mortality, but non-cerebral bleeding and blood transfusions are fewer 
with TNK.  
 
The dose of TNK is weight adjusted and administered in a single bolus over 5 
seconds; compared to 90 minutes of variable rate infusion with tPA, or a 30-60 
minute infusion of STK. Although a 30 minute infusion regime for STK exists, this 
is associated with increased risk of hypotension; however, by slowing the infusion 
rate of STK, the incidence of hypotension tends to decrease. Reteplase is a more 
fibrin-specific agent administered as a 10-unit twin bolus given 30 minutes apart. 
However, the time sensitive nature of the twin bolus administration of Reteplase 
can be problematic. Reteplase is equivalent to Alteplase in terms of reduction in 
mortality and haemorrhage rates. 
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The major benefit of bolus agents lies in ease of administration and in a simplified 
dosing regimen that reduces the risk of dosing errors. However, the cost of TNK 
and its manufacturer’s recommendation for use up to 6 hours makes the cheaper 
STK a more practical drug choice for use in the developing world. Thus, as for 
every one patient treated with TNK, five patients could be treated with STK (Table 
1) (121). Its use as a pre-hospital thrombolytic is worth consideration, particularly 
in remote health care settings, although its requirement for an infusion plus the 
incidence of hypotension makes it more labour intensive.  
 
The comparison of STK and TNK treatment regimes are summarised in Table 2. 
There are two key considerations for the use of STK in the pre-hospital 
environment. The first is duration of infusion and the requirement for an expensive 
infusion pump. Although an infusion pump offers better control of drug delivery, 
this is less of an issue with STK, as the delivery of STK is less time sensitive, 
compared to tPA. In static medical care environments (e.g. remote medical center) 
the infusion can be completed before hospital transfer, as STK can be delivered 
safely without an infusion pump using either: a small intravenous bag (100-250ml 
0.9% saline); or a paediatric burette supported by close clinician supervision. The 
use of a paediatric burette or a 100/250ml bag of saline is not an option for 
administration during ambulance transfer, as the low ceiling in an ambulance does 
not have the height to ensure fluid flow; this is further aggravated by ambulance 
movement. Novel techniques involving the use of low cost drip counters (that 
restrict flow through drip administration set), supported by a pressure infusion bag 
47 
 
to maintain constant pressure through the drip counter, are feasible, but yet to be 
proven. 
 
Table 2: Comparison of STK and TNK treatment regimes 
Streptokinase Tenecteplase 
1.5 mega units over 30-60 minutes (requires an 
infusion pump) 
Single weight adjusted bolus 
Aspirin 300mg  Aspirin 300mg 
Clopidogrel age adjusted (75-300mg)  Clopidogrel age adjusted (75-300mg) 
No Heparin (local policy may vary) Weight adjusted Heparin bolus followed by 
infusion or weight adjusted sub-cutaneous 
injection of Heparin: 
 
4000 unfractionated Heparin bolus followed by 
infusion (an infusion pump is mandatory) 
 
Age adjusted Enoxaparin   
Bradycardia (common) reversed by atropine Bradycardia (less common than STK) reversed 
by atropine 
High risk of drug induced hypotension 
responsive to fluid challenge stopping/slowing 
infusion 
No specific drug induced hypotension 
Labour intensive Not labour intensive 
Affordable (if no infusion pump is used)   Expensive 
 
The second consideration is a much higher incidence of hypotension and 
bradycardia. This is due to the release of bradykinin; it is not (as commonly 
thought) an allergic reaction and although anaphylaxis is more common with STK, 
it remains rare. Therefore, the treatment of hypotension consists of slowing or 
stopping the infusion and the administration of a 250-500ml crystalloid bolus. The 
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routine use of intravenous steroids and anti-histamines offers no clinical benefit 
and in the case of intravenous steroids use may adversely affect patient outcome 
by affecting myocardial scar tissue formation, thereby potentially increasing the 
risk of myocardial rupture.  
 
1.2.9 Adjunctive drug treatment 
1.2.9.1 Oxygen 
Oxygen is commonly administered during the management of patients during 
thrombolysis. Its routine use in patients with a pulse oximetry above 95% has been 
questioned, primarily due to the possibility of vaso-constriction and limited 
evidence of any benefit (122). Oxygen remains an important adjunctive therapy in 
the presence of left ventricular failure, although it is better provided as part of 
continuous positive airway pressure. Oxygen should routinely be administered in 
the presence of arrhythmias (e.g. ventricular tachycardia) (123), hypotension / 
hypo-perfusion and any post-cardiac arrest. 
 
1.2.9.2 Analgesia 
Analgesia is a priority therapy in the management of STEMI and intravenous 
opiates (morphine, diamorphine or fentanyl) that offer the most effective analgesia. 
However, the legal framework for administration of these drugs can be 
problematic, resulting in drugs such as Tramadol or Nubain being used if legal 
barriers to opiates do exist.  The use of inhaled nitrous oxide (Entonox™) remains 
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a useful supplementary analgesic (or primary analgesic if pre-hospital opiates are 
not available), providing both supplementary oxygen and analgesia; the use of 
Pentrane (common in Australia), is also a useful inhaled analgesic that allows a 
higher percentage of inhaled oxygen if required.  Thrombolysis also represents 
effective analgesia, as the restoration of myocardial blood flow results in pain 
relief, reflecting successful reperfusion. 
 
Non-pharmacological interventions (re-assurance, calm professional manner of 
the health-care provider) are important aspects of pain relief. The use of rapid road 
transfer with lights and sirens may induce greater patient anxiety (as well as the 
risk of traffic collision). However, if pre-hospital thrombolysis has been 
administered (with appropriate adjunctive therapy), there is little to be gained from 
rapid transfer to hospital. 
 
1.2.9.3 Nitrates 
Although there is no survival benefit to be gained from nitroglycerin, it remains a 
common early therapy that reduces ischaemia - and therefore angina - by 
reducing the pre-load and after-load of the left ventricle, thereby reducing wall 
stress and decreasing oxygen consumption. Nitroglycerin (0.4mg) is typically 
administered sub-lingually, although intravenous nitrates are also used: to manage 
on-going ischaemic chest discomfort; control hypertension; and for the 
management of pulmonary oedema. (Nitrates are a Class I recommendation for 
LVF).  Nitrates: should not be administered to patients who have received 
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phosphodiesterase inhibitors within 24 to 48 hours; and should be administered 
with care in patients with suspected right ventricular infarction, as it may induce 
marked hypotension. Despite this, nitrates are safe drugs for use by pre-hospital 
clinicians and it must be remembered that known cardiac patients may have 
already treated themselves with varying doses of nitrates prior to arrival of the pre-
hospital clinician. 
 
1.2.9.4 Anti-platelet agents: Aspirin and Clopidogrel 
Anti-platelets are vital in the management of all acute coronary syndromes 
(unstable angina, non-STEMI and STEMI). Within the context of STEMI 
management, anti-platelet therapy is as important as thrombolytic therapy. This is 
because: the intra-coronary thrombus responsible for re-infarction tends to be 
platelet rich; and thrombolysis may raise the possibility of thrombolytic-induced 
platelet aggregation (124). 
 
All patients with suspected ACS (unstable angina, non-STEMI and acute STEMI), 
should be considered for pre-hospital Aspirin treatment as there are relatively few 
contra-indications to a single dose of Aspirin (Class I recommendation). Despite 
this, Aspirin is often withheld due to concerns about: allergy; adverse drug 
interactions (e.g. Warfarin); confusion due to chronic on-going use of Aspirin; or 
uncertainty of diagnosis. Typically, unless a patient has a known documented 
allergic reaction (not just gastric irritation) to Aspirin or is actively bleeding from a 
gastro-intestinal tract ulcer, Aspirin at the 300mg dose should be given. The 
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choice of 300mg is typically the dose of a single Aspirin, with administration being 
initiated as early as possible and consideration being given to emergency call-
takers being empowered to recommend Aspirin before the arrival of emergency 
care providers (Class IIb recommendation).  
 
The benefit of Aspirin was established in the ISIS 2 trial (31), where 162.5 mg 
Aspirin resulted in 25 lives saved per 1 000 patients, primarily by: reducing the 
incidence of re-infarctions (10 non-fatal re-infarctions per 1 000); as well as 
preventing 3 non-fatal strokes per 1000 patients. The results from ISIS 2 trial 
highlighted that: the effectiveness of Aspirin alone was nearly as effective as STK 
without Aspirin (23% versus 25%); and that by combining Aspirin with STK, the 
magnitude of benefit was highly significant (42%). It is noteworthy that Aspirin 
administration during the ISIS 2 trial was anytime within the first 24 hours; but a 
meta-analysis by Freimark et al (125) demonstrated that early Aspirin 
administration (before thrombolysis) was an independent factor in patient survival 
at one year (5% versus 11%; p = 0.002; odds ratio 0.41; 95% CI 0.21-0.74). 
 
The benefits of Aspirin for acute STEMI are attributed to its inhibition of 
cyclooxygenase dependent platelet activation. The administration of an initial dose 
of 160-300mg Aspirin, ideally a non-enteric coated formulation that is chewed, is a 
Class I recommendation for acute STEMI. Intravenous or rectal Aspirin are also 
acceptable routes of administration.  
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Clopidogrel is a potent platelet inhibitor and the anti-platelet benefit of Clopidogrel 
in combination with Aspirin is to reduce ischaemic events in: non-ST-elevation 
acute coronary syndromes (126); and in patients undergoing percutaneous 
coronary intervention - PCI CLARITY study (127). The COMMIT-CCS 2 (128) trial, 
involving more than 45 000 patients (many post thrombolysis), demonstrated that 
administration of 75mg Clopidogrel  daily with 300mg Aspirin and standard 
treatment, safely reduced mortality and major vascular events. In the CLARITY-
TIMI 28 Trial (129), patients 75 years and younger with acute STEMI received: 
thrombolysis supported by a loading dose of 300mg Clopidogrel; followed by 75mg 
once daily; and either low molecular weight Heparin (LMWH) or unfractionated 
Heparin (UFH). The combination of dual anti-platelet therapy (Aspirin/Clopidogrel) 
with thrombolytic treatment demonstrated more favourable angiographic patency 
of the infarct related artery and a reduction in mortality. A major contributor to 
mortality reduction was the reduction in re-infarction rate in those patients 
receiving dual anti-platelet therapy. This was without an associated increase in the 
rate of bleeding.  
 
The importance of improved patency and a lower incidence of re-infarction was 
confirmed in the ECG CLARITY-TIMI 28 Study (129), where the use of Clopidogrel 
was shown to improve late coronary patency and clinical outcome in patients who 
achieve ST-segment resolution by preventing re-occlusion of open arteries, rather 
than by facilitating early reperfusion. The administration of 300mg loading dose of 
Clopidogrel in association with thrombolysis, to those less than 75 years of age, is 
a Class IIa recommendation and it is common practice to adjust the dose in the 
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over 75 year old patients to 75mg based on the COMMIT data. Newer oral anti-
platelet drugs, such Prasugrel and Ticagrelor, are now available with potentially 
improved anti-platelet action, but are yet to be studied in conjunction with 
thrombolytic therapy.   
 
1.2.9.5 Anti-coagulants 
Heparin is considered effective and is routinely given as an adjunct for PCI and 
thrombolytic therapy, although it is commonly withheld in the first twenty-four hours 
in those patients receiving STK. The role of Heparin is primarily to reduce re-
infarction, but the combination of dual anti-platelet therapy, thrombolysis and 
Heparin may increase the risk of bleeding. The American Heart Association 
guidelines call for careful weight-based dosing of Heparin with thrombolytic 
therapy in STEMI (130). 
 
The timing of Heparin therapy when using fibrin specific thrombolytic agents (tPA, 
Reteplase and TNK) is an important aspect of patient management. In an 
observational study of the United Kingdom MINAP (131) registry, the frequency of 
re-infarction during hospital admission after thrombolytic treatment of 35  356 
STEMI patients (during 2005–2006) was analysed. Re-infarction rates with in-
hospital treatment were similar for Reteplase (6.5%) and TNK (6.4%), but were 
higher for those patients treated by paramedics in the community. When the 
interval from pre-hospital treatment to hospital arrival was greater than 30 minutes 
re-infarction rates were 12.5% for Reteplase, and 11.4% for TNK. For intervals 
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shorter than 30 minutes, the re-infarction rates were significantly greater for TNK 
(9.3%) than Reteplase (4.2%). Overall, re-infarction rates were higher after pre-
hospital treatment with TNK than Reteplase (9.6% versus 6.6%, p = 0.005).  
 
The differences in re-infarction rates were considered primarily due to the different 
uses of adjunctive anti-thrombotic therapy. The UK paramedic thrombolysis 
protocols only allowed for a single bolus dose of Heparin prior to thrombolysis, 
with no on-going heparinisation until arrival in-hospital - compared to in-hospital 
practice of either an infusion of UFH (800-1000 IU per hour adjusted to aPTT) or 
weight adjusted LMWH. It was also noted that on arrival at hospital there was 
often a delay in commencing Heparin therapy, either due to confusion about the 
pre-hospital protocol or other time related pressures. In addition, Clopidogrel was 
commonly administered early in association with in-hospital thrombolysis, but only 
after arrival at hospital for those patients receiving pre-hospital thrombolysis (131). 
This may also have been a confounding factor, as Keeley et al (124) noted that 
thrombolysis induced platelet aggregation was a possible cause of re-infarction 
following thrombolysis. 
 
UFH was regarded as the anti-thrombotic agent of choice in the adjunctive 
treatment of patients with STEMI, until the introduction of Enoxaparin. The 
ASSENT-3 PLUS Trial (132) evaluated the feasibility, efficacy and safety of pre-
hospital Enoxaparin or UFH with Tenecteplase.  There was a reduction in the 
composite of 30-day mortality, in-hospital re-infarction or in-hospital refractory 
ischaemia in the Enoxaparin group (14.2% versus 17.4%., p = 0.08). However, 
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there was a tendency towards higher rates of intra-cranial haemorrhage (ICH) and 
major bleeding in the Enoxaparin group. The risk for ICH and major bleeding was 
mainly confined to patients > 75 years old. It must be noted that in the ASSENT-3 
PLUS trial, the dose of Enoxaparin was not weight adjusted.  The safety concern 
of Enoxaparin among elderly patients was addressed by the ExTRACT-TIMI-25 
Trial (133) that randomised more than 20 000 thrombolysed patients to receive 
either Enoxaparin or UFH. The ExTRACT-TIMI 25 study (133) was significantly 
changed from the ASSENT 3 PLUS study, with patients > 75 years of age: not 
receiving the IV bolus of Enoxaparin; and receiving a reduced dose of sub-
cutaneous Enoxaparin (75%) and with a maximum ceiling dose of subcutaneous 
Enoxaparin for the under 75 year olds being set at 100mg and at 75mg for the 
over 75 age group. The primary end-point of this study was all-cause mortality or 
non-fatal re-infarction at 30-days. Treatment with Enoxaparin was found to be 
superior to UFH, but was associated with an increase in serious bleeding 
episodes.  A telephone follow-up at 1 year showed a sustained reduction in 
mortality or re-infarction when using the Enoxaparin strategy (134). Data from a 
meta-analysis from 12 earlier trials (involving more than 49 000 patients) support 
these results (135). Enoxaparin is administered as an initial dose of 30mg 
intravenous bolus, followed by 1mg/kg sub-cutaneously within 15 minutes; this is a 
Class I recommendation. 
 
Enoxaparin offers a number of operational benefits for use with pre-hospital 
thrombolysis, but primarily in the absence of an infusion pump that is required 
when administering an infusion of UFH. Two single 100mg dose syringes of 
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Enoxaparin are adequate to support pre-hospital thrombolysis, with one syringe 
being used for the 30mg IV dose, followed by a subsequent sub-cutaneous dose 
(the maximum sub-cutaneous dose of Enoxaparin remains 100mg). The 
intravenous dose of Enoxaparin can be simply administered by decanting a 100mg 
dose of Enoxaparin into a 10ml syringe and then diluting with water to a total 
volume of 10mls for injection purposes - thereby providing 10mg Enoxaparin per 
ml. A multiple-use vial of Enoxaparin for IV administration is also available. 
 
1.3 Conclusion 
Morbidity and mortality from STEMI can be reduced significantly if patients and 
bystanders recognise symptoms early and/or activate emergency medical services 
early, which would reduce the time to definitive treatment. Patients and their 
relatives should be educated on recognising symptoms of a heart attack to reduce 
time from symptom on-set to calling for help. Patients with symptoms of AMI 
should ideally be transported by ambulance, rather than by friends or relatives, 
because of the proven association between ambulance use and early reperfusion 
therapy.  
 
Given the importance of patients using emergency medical systems for possible 
ACS all those involved need to have a mutually acceptable emergency protocol to 
ensure that patients with symptoms would be able to expeditiously access 
emergency medical services without barriers to timely evaluation and treatment, 
including: government policy makers, medical communities, health care insurance 
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providers, emergency medical systems and hospitals. Such protocols would 
incorporate rapid detection, evaluation and referral/treatment of patients within a 
regional system of care that would incorporate quality improvement measures for 
on-going monitoring and process improvement (136). 
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CHAPTER 2 
METHODOLOGY 
2.1 Research paradigm 
A paradigm is a world view, a general perspective, a way of breaking down the 
complexity of the real world. It is an interpretative framework that is guided by "a 
set of beliefs and feelings about the world and how it should be understood and 
studied." (137). This research was conducted within a pragmatic philosophy. 
Pragmatism as a research philosophy embraces the mixed methods approach to 
applied research questions. Pragmatism emphasises that the research question 
drives the inquiry, design and methods. The pragmatist works from a premise of 
ordinary experience and the desire for a better world (138). Pragmatists 
emphasise the practical function of knowledge as an instrument for adapting to 
reality and controlling it. The pragmatic position was chosen as the researcher 
believes that the following matters require development of an applicable 
awareness programme and acknowledgement of challenges to implementation of 
ECP thrombolysis prior to full roll-out: the problem of awareness of symptoms of 
acute STEMI by the layman; the appropriate response to these symptoms; and the 
implementation of emergency care practitioner led thrombolysis. The researcher’s 
own worldview is a pragmatic one and this fitted well with the chosen research 
study. It has been the researcher’s long-standing view that thorough 
understanding of ordinary experiences will lead to adaptation and improvement for 
a better life. 
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2.2 Research design 
According to Polit and Beck (139), the mixed methods approach enhances a study 
in a number of respects - mostly because it appears to hold promise for 
generalisability. This study used mixed methods, employing both qualitative and 
quantitative research techniques, to produce more complete knowledge needed to 
inform the theory and practice of acute STEMI.  Another strength of the mixed 
methods approach is that it can answer a broader and more complete range of 
research questions; this because it does not confine the researcher to only one 
method or approach. However, as experienced by the researcher, mixed methods 
research has several weaknesses as well.  Some disadvantages noted were: it 
can be difficult for a single researcher to carry out both techniques concurrently; it 
is more time consuming; and the researcher has to learn about multiple 
techniques and how to mix them appropriately (140). However, the limitations of 
each technique were off-set by integrating both quantitative data with qualitative 
data in this research. 
 
In this study, the mixed method approach was undertaken in four phases (See 
Table 3). The first phase (hereafter referred to as Phase One) analysed existing 
documentation for the purpose of identifying existing awareness programmes and 
using these findings to develop a comprehensive heart attack awareness 
programme. In Phase Two, existing documentation was studied (including 
education programmes, protocols, guidelines, site evaluations and interviews on 
pre-hospital thrombolysis) in order to produce an emergency care practitioner 
thrombolysis (ECPT) programme for the South African context. In the subsequent 
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two phases – Phase Three and Phase Four: the developed ECPT treatment 
protocol was implemented and reviewed by an expert panel; thereafter ECPT 
treatment data was compared to historical data. 
 
Table 3: Summary of research methods 
PARADIGM PHASE DESIGN METHOD ACTIVITY 
P
ra
gm
at
is
m
 
Phase 1 Qualitative 
Document 
analysis and 
expert panel 
validation using 
the Adapte 
process 
Development of a culturally 
sensitive and affordable 
chest pain awareness 
education programme 
Phase 2 Qualitative 
Document 
analysis, 
guideline reviews 
and interviews 
using the Adapte 
process 
Planning and designing 
thrombolysis by emergency 
care practitioners 
Phase 3 Quantitative and Qualitative 
Recording of raw 
data using a data 
collection tool and 
expert panel 
evaluation 
Implementation of the 
thrombolysis protocol 
Phase 4 Quantitative 
Comparison of 
raw data from two 
databases 
Comparison with historical 
data 
 
2.3 Research instrument 
The ADAPTE process (Appendix 14) was used in: Phase 1 – development of a 
culturally sensitive and affordable chest pain awareness education programme; 
and Phase 2 – planning and designing thrombolysis by emergency care 
practitioners. The ADAPTE process was created by the ADAPTE collaboration in 
partnership with Guidelines International Network. This was created to develop 
and validate a generic adaptation process to foster valid and high-quality adapted 
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guidelines and to enhance the users’ sense of ownership of the adapted guideline 
(http://www.adapte.org/www/rubrique/guideline-adaptation.php). 
 
2.4 Phase One: Development of a culturally sensitive and affordable chest 
pain awareness education programme using the Adapte process 
In line with the first objective of this study, a document review was undertaken on 
existing chest pain or heart attack awareness programmes, in order to gain 
baseline knowledge of what already exists nationally and internationally.  
 
2.4.1 Literature search for culturally sensitive and affordable chest pain 
awareness education programmes 
An internet literature search was conducted to find appropriate studies with 
current and best evidence on chest pain awareness programmes. The search 
began by accessing the Google search engine then progressed to the following 
databases: MEDLINE, PROQUEST, Pubmed, Science Direct, Cardiosource and 
Sae-Journal. The Google search engine was utilised extensively. An internet 
literature search was conducted to find existing chest pain awareness 
programmes using the Medical Subject Heading (MeSH) terms: acute myocardial 
infarction, heart attack, heart attack awareness, heart attack education and chest 
pain. These databases were initially searched from 1970 through to 2011. Despite 
an extensive result, the majority of results did not include chest pain awareness 
education programmes. 
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2.4.2 Selection criteria and general characteristics of the chest pain 
awareness programme sought 
All programmes were assessed for relevance to public awareness of chest pain, 
comprehensiveness, simplicity and affordability. Chest pain awareness education 
programmes from the United Kingdom, Canada and Australia were found to be 
relevant to the respective research objective and were used to inform the 
development of the chest pain awareness education programme. These programs 
used pictures, posters, booklets and various other print forms and were simple and 
easy to understand. Additional factors that were considered in the selection and 
design of the programme were that the South African population is made up of 
many different race groups, cultures, ethnic groups and linguistic groups. To 
deliver a general awareness programme, these factors will need to be considered, 
as culturally sensitive care targets the entire person and not just the physical 
ailment. The aim of the programme was to make all South Africans aware of the 
symptoms of a heart attack (regardless of race, age, ethnic group, gender, size, 
shape, or socio-economic status), thereby being culturally sensitive and being 
cognisant of the political history of South Africa. With this in mind, where 
applicable, the content of the various aspects of the programme was designed 
using neutral figures and colours. It is also the intention to translate the 
programme into isiZulu - the most widely spoken language in South Africa with 
10.7 million speakers (23.8%) (141); and thereafter into isiXhosa and Afrikaans, 
followed by the remaining official languages, as required. With these factors in 
mind, a poster, booklet and video were developed by the researcher. 
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2.4.3. Components of the chest pain awareness programme 
The components of the chest pain awareness programme presented in Chapter 3 
were developed with due consideration taken of the following: 
 
2.4.3.1 Process for the development of the poster 
While various countries used mainly text information in pamphlets, only the British 
Heart Foundation (BHF) focused on symptom awareness through a picture. This 
poster was adapted with permission from the BHF. The picture used a neutral form 
of person, i.e. did not differentiate between gender, and it clearly showed the 
areas of pain in the figure. The adaptations made by the researcher included: 
changing the colour of the figure to the internationally accepted colour symbol of a 
person; the written content was adjusted to reflect local requirements. 
 
Specific intentions with the poster were: to ensure the language was simple for 
ease of understanding and reading; the use of less text and more figures for ease 
of message translation; and for the poster to be visually appealing. A non-white 
figure was deliberately used, so as to not infer that the poster only targets the 
White population of South Africa. 
 
2.4.3.2 Process for the development of the information booklet 
Following a literature search, information booklets from the United States of 
America, Canada, the United Kingdom and Australia were analysed; this led to the 
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creation and development the “Heart Attack: Time is heart muscle” booklet. Care 
was taken to keep the booklet short in length, ensure it is visually appealing and to 
use simple medical language. It is intended that the booklet be made available 
free of charge to the general South African public. The content of the booklet was 
determined by the researcher and subsequently approved by the researcher’s 
supervisor. The dietary guidelines were endorsed by a registered dietician. A 
qualitative focus group assessment was conducted thereafter, as discussed 
below. 
 
2.4.3.3 Process for the development of the video 
The video was chosen as part of the heart attack awareness programme because 
there are a number of advantages to be gained from using a video (142).  Some of 
these are: 
• It is a moving medium – it is therefore well suited to the topic, as movement 
is integral to explanations 
• It has immediacy and relevance – the layman will be able to immediately 
identify with the message being screened 
• Video programmes can be tailored to meet exact needs 
• Videos target a wide audience at minimum cost. 
 
Following a search on YouTube, two short video clips aimed at heart attack 
awareness were found.  These video clips were from the United Kingdom and 
United States of America. The videos made use of local people and the general 
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information was appropriate for the local settings in each country and were 
therefore not suitable for the South African population. A video awareness 
programmes currently available in South Africa focuses on heart attack prevention 
and is part of an advertising strategy for a commercially available food product. 
There are currently no public viewing videos in South Africa that focus on 
recognition of symptoms and what should be done in response to a heart attack.  
 
The video was created by a production team that consisted of: the researcher as 
the producer; a third year animation artist student; and the researcher’s 
supervisor, Prof. K. Sliwa. The researcher wrote the script using salient factors 
identified while undertaking the literature search; this led to conceptualisation and 
development of the 6 frames for the video. The animation artist provided the 
technical expertise required for producing the video. The supervisor approved the 
script and provided intellectual input throughout the development process. The 
voice-over was done by the researcher. The video was to be restricted to 30 
seconds in length in order to keep production costs and screening costs to a bare 
minimum. The video was also animated so as not to use any specific ethnic group 
and to eliminate human error factors in the video. 
 
The focus of the video was symptom recognition and action to be to be taken by 
the patient or bystanders in the event of a heart attack. It included use of the 
current national EMS toll-free emergency number. In addition, the video showed a 
clock ticking to emphasise the need for prompt response to a heart attack and to 
support the catch phrase; “Think quick ... Act fast ... Time is heart muscle ...”.  
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2.4.4 External review of the chest pain awareness education programme by 
qualitative focus groups 
The entire chest pain awareness programme was subjected to validation by expert 
panels that consisted of cardiac nurses, consultants working in coronary care units 
and cardiologists from a specialist cardiac unit. An external review by laymen and 
determination of the impact of the chest pain awareness programme is intended 
as a follow-up of this study as on-going research. 
 
The first panel consisted of 20 nursing staff from the Soweto Cardiovascular 
Research, Chris Hani Baragwanath Hospital. A presentation was made of the 
programme and feedback was obtained through the completion of a questionnaire 
consisting of open-ended questions. 
 
The second panel consisted of nursing staff, consultants and cardiologists from 
Addington Hospital and Inkosi Albert Luthuli Central Academic Hospital. Additional 
evaluations were undertaken by the medical management teams at Wentworth 
and McCords Hospitals. The heart attack awareness programme was also 
presented: at the 10th Annual Congress of the South African Heart Association, 
held at Sun City, South Africa from 22-25 October 2009; and at the 2011 
Emergency Care Society of South Africa: Pre-Hospital Emergency Care 
Conference, held at University of Johannesburg, South Africa from 22-23 
September 2011. All comments and input received on the programme were 
considered and incorporated, where appropriate. All comments and input was 
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analysed to identify any errors in the presentation, the content and the format and 
to identify feedback from the various panels in terms of relevance to public 
awareness of chest pain, comprehensiveness, simplicity and affordability. 
 
2.5 Phase Two: Planning and designing thrombolysis by emergency care 
practitioners using the Adapte process  
In line with the second objective of this study (document review) an on-site 
evaluation and thrombolysis guideline review was undertaken on acute STEMI and 
the management thereof in order to provide in-depth knowledge for the design and 
implementation of emergency care practitioner thrombolysis.  
 
2.5.1 Literature search for thrombolysis guidelines 
An internet literature search was conducted to find appropriate studies with 
current and best evidence on in-hospital and pre-hospital thrombolysis. The 
search began by accessing the Google search engine and then progressed to the 
following databases: MEDLINE, PROQUEST, Pubmed, Science Direct, 
Cardiosource and Sae-Journal. An internet literature search was conducted to find 
information on thrombolysis using the Medical Subject Heading (MeSH) terms: 
acute myocardial infarction, heart attack, acute STEMI, thrombolysis, pre-hospital 
thrombolysis, fibrinolysis and pre-hospital fibrinolysis. These databases were 
initially searched from 1980 through to 2011. The search was extended back to 
1970 to include the initial small-scale publications on thrombolysis. 
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A document analysis was conducted by the researcher in two international settings 
(Australia and UK), where pre-hospital thrombolysis is within the scope of practice 
of paramedics. In addition, the education and training programme of the three 
South African universities offering paramedic training were assessed to determine 
the extent and depth of the academic development of acute STEMI management 
by the higher educational institutions. Furthermore, the researcher undertook two 
on-site visits (to South East Coast Ambulance Services in the UK and the 
emergency medical services in France - Service d'Aide Médicale Urgente 
(SAMU)), where pre-hospital thrombolysis is undertaken by paramedics and 
physicians respectively. 
 
2.5.2 Selection criteria of thrombolysis guidelines for acute STEMI 
management 
The education and training programmes were assessed to ensure that: they 
contained the critical components; were comprehensive; were of adequate 
academic depth; determined academic and skill competence; and included on-
going quality assurance. The equipment and system requirements of the various 
clinical settings were compared to identify the critical, common equipment and 
system requirements. Furthermore, the guidelines were reviewed against best 
practice guidelines for acute STEMI according to the scientific evidence available 
and endorsement of national and internationally recognised cardiology societies. 
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2.5.3 Guidelines for emergency care practitioner thrombolysis 
The emergency care practitioner thrombolysis educational program and the clinical 
skill and checklist was based on the European Society of Cardiology Guidelines 
for Management of Acute STEMI (89); it is presented in Chapter 3. 
 
2.5.4 External review by qualitative focus groups of emergency care 
practitioner thrombolysis 
The thrombolysis protocol was reviewed by cardiac consultants of the two regional 
hospitals involved in the study and the researcher’s supervisor before 
implementation by the researcher. This was undertaken to ensure that the 
thrombolysis protocol: is safe; is in line with international best practice guidelines 
for acute STEMI; and is appropriate for the South African context. 
 
2.6 Phase Three: Implementation of the thrombolysis protocol 
The validated thrombolysis protocol was implemented by the researcher as 
follows: 
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2.6.1 Study area 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Map of KwaZulu-Natal 
Source: (92) 
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This study was based in KwaZulu-Natal, which is located on the east coast of 
South Africa. It covers an area of approximately 94 500 square kilometres and is 
divided into eleven health districts (Figure 3) (92). KwaZulu-Natal has the second 
largest share of the South African population: 10,8 million of 50.5 million (21,4%). 
The proportion of urban and rural dwellers is 46% and 54% respectively (93). 
 
The study area was in one of the eleven health districts, namely eThekwini. The 
population density for eThekwini Health District (which is further categorised into 
urban and rural population densities) is shown in Table 4. The urban population 
category comprised urban settlements, informal settlements, recreational areas, 
industrial areas, institutions and hostels; the rural population category is made up 
of sparse, tribal settlement, farm and small holding categories. Population 
distribution by race groups for eThekwini Health District are: Black Africans - 
68.3%, Indians - 19.9%, Whites - 9% and Coloureds - 2.8% (143). 
 
2.6.2 KZN: Emergency Medical Rescue Service (EMRS) – eThekwini Health 
District (EHD) 
The EMRS control centre in EHD receives an average of 700 calls during a 24 
hour cycle. This district usually operates approximately 38 ambulance units and 3 
advance life support (ALS) response units for a population density of more than 
three million people. Calls received by the emergency control centre are coded by 
a call-taker, who dispatches an emergency vehicle to the patient; this may include 
an ALS response vehicle. The dispatch of an ALS is dependent on availability and 
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nature and coding of the emergency. The qualification of emergency dispatcher 
varies, with the majority of the personnel holding a four-week basic short course 
qualification; the remainder have completed an eight-week intermediate life 
support training programme. The level of experience of the call-taker also varies, 
with potentially very new and inexperienced personnel taking and triaging the call 
(144). 
 
2.6.3 Emergency care practitioner scope of practice 
Emergency Care Practitioners complete an intensive four-year degree programme 
that leads to an advanced life support scope of practice, which includes the clinical 
assessment, diagnosis and management of coronary events like acute STEMI.  
ECG training includes sessions on 12 lead ECG interpretation and practice 
sessions. Upon completion of the four-year qualification, the successful graduate 
is eligible for registration with the Health Professions Council of South Africa 
(HPCSA) as an Emergency Care Practitioner and is then allowed to practice 
independently. 
The	   decision	   to	   undertake	   thrombolysis	   was	   made	   in	   consultation	   with	   the	  
cardiac	  consultant	  at	  the	  receiving	  regional	  hospital	  or	  at	  a	  remote	  location	  after	  
normal	  working	  hours.	  The	  12	   lead	  ECG	  was	  either	   transmitted	  via	   facsimile	  or	  
via	  telemetry.	  Thereafter,	  the	  researcher	  contacted	  the	  consultant	  telephonically	  
to	   present	   the	   patient’s	   details;	   family	   history,	   medical	   history,	   clinical	  
presentation	  and	  the	  researcher’s	  interpretation	  of	  the	  12	  lead	  ECG.	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2.6.4 Hospital characteristics 
South Africa uses the District Health System (72)  to make health care available to 
all citizens as efficiently as possible.  Within each province, there is a referral 
system in which patients usually attend the local hospital (known as the district 
hospital) as the first point of contact with the health care system – also referred to 
as the primary hospital.  Thereafter, if the patient requires further management, 
especially for a higher level of care, the patient is referred to a regional hospital.  
Each health district usually has at least one regional hospital, but may have 
additional regional hospitals, depending on the population density of the health 
district. Regional hospitals may also have district level functions.  The eThekwini 
Health District has two regional hospitals: R. K. Khan Hospital and Addington 
Hospital. Both regional hospitals participated in the study and the two main district 
level hospitals that participated were Mahatma Ghandi Memorial Hospital and 
Wentworth Hospital.  Table 4 indicates: the referral status of the hospitals; 
availability of coronary care and intensive care facilities; total beds and patient 
population that they service. All other public and private sector hospitals within the 
eThekwini Health District were also invited to participate in the study. 
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Table 4: Hospital characteristics 
Source: (92) 
Health District Hospital 
 
Type of facility Bed 
Status 
Patient 
Population 
eThekwini 
Population density of 
3 199 699 (32% of 
KZN) with a 90% urban 
and 10% rural 
population distribution 
R. K. Khan 
(Regional & 
District 
Services) 
Coronary Care 
Unit 
543 + 850 000 
Addington 
(Regional & 
District 
Services) 
Coronary Care 
Unit 
524 + 620 000 
Mahatma 
Ghandi 
Memorial 
(District 
Service) 
No Coronary Care 
Unit 
350 + 1 million 
Wentworth  
(District 
Service) 
High Care only 220 + 450 000 
 
2.6.5 Population and sampling strategy 
The study population consisted of two groups of STEMI patients, being: 20 
patients treated by the researcher in his capacity as a registered Emergency Care 
Practitioner (ECP); this data was compared to historical data (the in-hospital 
doctor thrombolysed (IHDT) group) obtained from previous research on 78 
patients who were thrombolysed in-hospital by doctors (11). 
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2.6.6 Emergency Care Practitioner Thrombolysis (ECPT) Group 
A total of 20 patients, aged 18 years and older, were prospectively recruited by the 
researcher. These patients either presented with symptoms at home or were 
admitted with a diagnosis of acute STEMI to district level hospitals in Durban. This 
was carried out over a 6-month period (August – January 2010). (The statistician 
involved in this research confirmed that 20 patients would be sufficient for 
statistical comparison with historical data.) The number of patients included in the 
study was also limited to 20 due to financial constraints. The cost of the 20 
ampoules of Tenecteplase was almost R250 000.00; this was funded by third 
stream income generation at the researcher’s place of employment. 
 
2.6.7 Data collection 
Data collection, as detailed below, was undertaken from 2 August 2009 to 6 
January 2010.  
 
2.6.8.1 Patient treatment by the ECP 
Patients received routine treatment for a confirmed diagnosis of acute STEMI; this 
involved the administration of morphine, oxygen, nitrates, Aspirin (MONA) and 
Clopidogrel, as approved by HPCSA: Professional Board for Emergency Care 
(145). An emergency defibrillator and external pacemaker was always available. 
The drugs used in the study were previously approved for use by Emergency Care 
Practitioners by HPCSA: Professional Board for Emergency Care, following 
extensive consultation with the Medical and Dental Professional Board, the 
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Resuscitation Council of South Africa and Emergency Medicine Society of South 
Africa. Final approval was granted by the HPCSA upon conclusion of consultation 
and consideration of all inputs received. 
 
2.6.8.2 Thrombolytic treatment 
The fibrin specific thrombolytic agent used in this study was Tenecteplase 
(Metalyse).  Tenecteplase was given over 5 seconds according to body weight, 
together with Enoxaparin. Patients received Enoxaparin co-therapy as an 
intravenous bolus of 30mg, followed by the first sub-cutaneous dose of 1mg/kg 
about 15 minutes after the administration of Tenecteplase. This treatment strategy 
is in line with the American Heart Association / European Society of Cardiology 
guidelines and is also similar to what was done in the STREAM study 
(http://clinical trials.gov.show/NCT00623623). 
 
2.6.8.3 Electrocardiographic recordings 
Emergency Care Practitioners are taught to assess ECGs as part of their four-year 
program.  While this is a skill that is developed and assessed during the course of 
the four-year degree program, ECPs are encouraged to establish a system of 
consultation in the area in which they work.  As part of the development process 
towards being able to assess ECGs with confidence,  ECPs are required to consult 
with experienced cardiac consultants/nurses. The decision to undertake 
thrombolysis was made in consultation with the cardiac consultant at the receiving 
regional hospital or at a remote location after normal working hours. The 12 lead 
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ECG was either transmitted via facsimile or via telemetry. Thereafter, the 
researcher contacted the consultant telephonically to present the patient’s details; 
family history, medical history, clinical presentation and the researcher’s 
interpretation of the 12 lead ECG.	  
 
Reperfusion, defined as > 50% resolution of the ST segment, was assessed at 90 
and 180 minutes post-thrombolysis. The initial plan was for serial 12 lead ECG 
recordings to be taken at 30-minute intervals. 12 lead ECG recordings were taken: 
at the initial assessment, upon regional hospital admission, at 90 minutes or at 180 
minutes, depending almost entirely on whether it was practically possible to take 
the recording and usually in accordance with the respective hospital policy.  
Continuous transportation of the patient to hospital was favoured over stopping the 
ambulance for additional 12 lead ECG recordings. Stopping the ambulance on the 
side of the road is generally avoided as it is considered unsafe practice and would 
delay transportation of the patient to definitive care. Furthermore, the movement of 
the ambulance or idling of the ambulance engine affected the accuracy of a 12 
lead ECG recording, as it caused patient movement that appeared on the ECG as 
muscular artefacts. Continuous 3 lead ECG monitoring was undertaken to monitor 
and treat lethal reperfusion arrhythmias if necessary.  
 
2.6.9 In-hospital Doctor Thrombolysis (IHDT) Group 
This was an observational study in which 120 patients admitted to 20 hospitals in 
Durban and surrounding areas with a diagnosis of acute STEMI were 
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consecutively recruited between August and December 2006. Patients that died 
during early admission were not included in the study. Of these patients, 78 
received thrombolytics by doctors, with the choice of therapy being in accordance 
with local hospital policy. Two methods of data collection were used: direct patient 
interviews (primary data) were patients were approached to participate only after 
the patient’s condition had stabilized; and review of hospital records (secondary 
data). The 30-day follow-up was conducted telephonically. The 20 hospitals in this 
study group consisted of 5 regional, 9 district and 6 private hospitals - compared to 
2 district and 2 private hospitals in the ECPT group.  Two regional hospitals and 
two district hospitals based in the eThekwini Health District also participated in the 
ECPT Group. 
 
2.6.10 Patient eligibility 
The inclusion and exclusion criteria are as per Table 5. 
Table 5: Study inclusion and exclusion criteria 
INCLUSION CRITERIA 
• Patients who presented within 12 hours of the on-set of ischaemic chest pain. 
• ST-segment elevation of at least 0.1mV in two or more limb leads or at least 0.2 mV in two or 
more contiguous precordial leads, or presumed new on-set left bundle – branch block. 
• 18 years and older. 
EXCLUSION CRITERIA 
• An inability to give informed consent; and dementia. 
• Uncontrolled hypertension [systolic blood pressure of more than 180mmHg, diastolic blood 
pressure of more than 110mmHg on repeated measurements]; major surgery. 
• Biopsy of a parenchymal organ or substantial trauma within 2 months. 
• Any head injury or other trauma occurring after on-set of current myocardial infarction. 
• Any known history of stroke. 
• Any known structural damage to the central nervous system. 
• Current treatment with oral anti-coagulants. 
• Sustained cardio-pulmonary resuscitation of more than 10 minutes duration. 
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2.6.11 Demographic data 
After obtaining patient consent, demographic data was obtained from all 20 
patients.  This included: age, gender, ethnic grouping, and information on risk 
factors such as diabetes mellitus, hypertension, smoking status, dyslipidaemia, a 
previous history of angina or myocardial infarction, and a family history of vascular 
disease. All patients were of Black African, Indian, White, or Coloured origin.  
 
Additional information included: a detailed description of the time of on-set of 
ischaemic chest pain; the transportation times and mode of transport; the duration 
of time to treatment; and treatment received.  Reasons for any delay in the 
initiation of treatment were also recorded; these may have included: patient delay; 
lack of transport; and delay at the level of the general practitioner or the primary 
hospital or referral hospital. 
 
2.6.12 Patient follow-up 
In-hospital follow-up was conducted through the study of all patient hospital 
records, as these contained general information about: the patient, the patient’s 
clinical background, clinical condition and in-hospital clinical treatment. If data 
required was not clear or missing in the record, the researcher engaged with the 
attending medical consultant to clarify the matter or provide the information. The  
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30-day follow-up was conducted via a telephone interview between the researcher 
and the patient. 
 
2.6.13 Complications from STEMI 
All complications encountered during hospital admission and at 30-day telephonic 
follow-up were also documented.  These complications included: recurrence of 
angina or myocardial infarction, sustained ventricular arrhythmias (ventricular 
tachycardia / ventricular fibrillation), cardiac failure, cardiogenic shock, pericarditis, 
complete heart block and death. Re-infarction was defined as recurrent symptoms 
of ischaemia accompanied by new or recurrent ST-segment elevations of 0.1mV 
or more in at least two contiguous leads, lasting at least 20 minutes, and further 
increases in cardiac biomarkers (146).  Recurrence of angina was defined as 
symptoms of ischaemia, with ST-segment deviation or T-wave inversion persisting 
for at least 10 minutes despite medical management and not fulfilling the diagnosis 
of re-infarction (147).  Cardiac failure was based on the Framingham criteria, 
which includes: progressive resting dyspnoea associated with clinical signs of 
pulmonary; and/or peripheral congestion; and requiring treatment with diuretics 
(148). 
 
2.6.14 Cardiac enzyme laboratory analysis 
The cardiac biomarkers used to confirm the diagnosis of STEMI in-hospital were 
creatinine phosphokinase (CPK), creatinine kinase muscle brain iso-enzyme (CK-
MB), and or troponin T/I. Troponin T levels were measured using the Roche 
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Cardiac T Quantitative test, which is based on the Elisa test principle - the clinical 
discriminator value for myocardial infarction is 0.1ng/ml (detection range 0.010 – 
25.00ng/ml; sensitivity 100% and specificity 83.9% at 24 hours) (149-152). 
 
2.7 Design of data collection tool 
For purposes of this study, a data collection tool was developed to collect all 
clinical data in consultation with the clinical supervisor, Prof Karen Sliwa (Appendix 
1).  The database (and data collection tool) was designed using Microsoft Access 
in order to facilitate data collection and transfer of data to a statistical package for 
analysis. 
 
2.8 Research process 
The research process involved EMRS control centre paramedics or operational 
ALS paramedics alerting the researcher to patients suspected of having acute 
STEMI. Similarly, doctors at the district level hospitals were requested to alert the 
researcher when patients were admitted to emergency departments during the 
study period. The control centre staff and the doctors at district level were advised 
of their institution’s approval and participation in this study by the respective 
institution’s line management. The researcher also followed this up with reminders 
at the initial stages of the research. 
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The researcher then responded to the emergency call using Durban University of 
Technology: Emergency Medical Care and Rescue (DUT: EMCR) operational 
paramedic response vehicle, Techmed 1. This clinical operational response unit is 
an existing, well established service arrangement between DUT: EMCR and KZN: 
EMRS for purposes of augmenting KZN: EMRS paramedic resources during peak 
periods and providing operational clinical practice for students of DUT: EMCR. 
Permission was granted to the researcher by the Head of Department of DUT: 
EMCR to use this operational unit for this research. 
 
Once at the patient’s side, the patient was informed about the study. Permission 
was sought from the patient to administer thrombolysis as per the research 
protocol provided they met the inclusion. The researcher also obtained permission 
from the patient to access personal and clinical information from hospital records 
and to contact the patient or the patient’s next of kin 30-days from symptom on-set 
(this to enquire about their condition and establish early outcomes of treatment). 
The researcher then provided the initial routine treatment for a confirmed 
diagnosis of acute STEMI. This involved administration of morphine, oxygen, 
nitrates, Aspirin (MONA) and Clopidogrel. In some instances, some of these drugs 
had already been administered by the attending doctor or paramedic, in which 
case the initial drug treatment was adjusted accordingly. The thrombolytic 
treatment regime (as outlined above) was then continued. 
 
The study was described to the patient and a Letter of Information given to the 
patient (Appendix 5). The Letter of Information was translated from English to 
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isiZulu to accommodate non-English speaking patients (Appendix 6).  It must be 
noted that English and isiZulu are the most commonly spoken languages in 
KwaZulu-Natal. Patients who were willing to participate in the study were then 
given an Informed Consent Form to complete (Appendix 7).  The Informed 
Consent Form was also translated into isiZulu (Appendix 8). 
 
All 20 cases in which thrombolysis was instituted by the researcher were subjected 
to a local expert panel review. The local panel consisted of cardiologists from 
Inkosi Albert Luthuli Central Academic Hospital Cardiology Department. The 
purpose of this review was to obtain an external independent review by clinical 
experts in the field. The panel appraised the clinical summaries of all patients, in 
conjunction with treatment protocols used within the district health system. 
Feedback from the panel was intended to revise and improve overall clinical care 
of acute STEMI patients by emergency care practitioners and this will be 
discussed in Chapter 4. 
 
2.9 Phase 4: Comparison with historical data 
The clinical data for the 20 patients was assessed and compared to the 
researcher’s own historical control data. This historical data was obtained when 
the researcher undertook a Master of Science (Cardiology) degree through the 
University of Brighton. This study assessed the use of thrombolytic treatment in 
the management of patients presenting with acute STEMI in several primary and 
secondary hospitals in Durban and the surrounding areas.  In addition, the study 
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also addressed possible reasons for delay in the administration of thrombolytic 
treatment.   
 
2.10 Data documentation 
All data was initially captured at the patient’s bedside on the data collection tool 
designed in Microsoft Access Software 2007 after all treatment was administered.  
Thereafter, the data was entered into the database as the patients presented to 
the researcher. No editing took place, as the structure of the data collection tool 
was the same as the database.  The data was then converted into Microsoft Excel 
Software 2007 format for ease of transfer into IBM SPSS Version 20.0. 
 
Errors in the IBM SPSS Version 20.0 database were minimised by a verification 
audit undertaken by the researcher of all 20 entries (both the original and 
electronic databases). 
 
2.11 Statistical analysis 
Data was analysed using the IBM SPSS Version 21.0 and G Power 3.1. Statistical 
analysis was performed using the following techniques: descriptive statistics, 
correlation analysis, multi-variate analysis and measures of association. 
Descriptive statistics were used to summarise demographic and clinical 
characteristics. Categorical variables were summarised in terms of frequencies 
and percentages; and for each continuous variable, the mean and standard 
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deviation and/or median with minimum time, maximum time and inter-quartile 
ranges were calculated. In this study, there was no missing data on any of the 
measures. Descriptive techniques included the presentation of frequency 
percentage tables, cross-tabulations and graphs (pie, bar and line). Inferential 
statistics involved testing hypotheses about the means for times. Non-parametric 
testing procedures were utilized, as the variables were not normally distributed. 
These tests included Mann-Whitney Test, Wilcoxon Signed Rank Test, Chi-Square 
Test and Fisher’s Exact Test. Results with a p < 0.05 were considered significant. 
Where appropriate, the results are also expressed as mean ± standard deviation 
or medians with minimum time, maximum time and inter-quartile ranges or as 
proportions (%). 
 
2.12 Data quality 
2.12.1 Trustworthiness of Phase One and Phase Two qualitative data 
Lincoln and Guba's (153) criteria for establishing trustworthiness of qualitative data 
were adopted and are described hereafter:  
 
Credibility – the goal of credibility is to demonstrate that the inquiry was 
conducted in such a manner as to ensure that the subject was accurately identified 
and described (154). Furthermore, Lincoln and Guba (153) note that the strength 
of qualitative study (which is its credibility) is largely dependent on prolonged 
engagement, which provides scope, persistent observation and depth. In this 
study, considerable time was invested in data collection activities. This was 
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necessary to elicit an in-depth understanding of: awareness of heart attacks; the 
nature of programmes that exist; and also to consider characteristics of the local 
context. Furthermore, according to Polit and Beck (139), the credibility of a study is 
enhanced by the use of multiple methods to address a research problem - 
triangulation. Triangulation was used for the main component of the study (the 
qualitative evaluation of emergency care practitioner thrombolysis, including a 
clinical review of the implementation) and a quantitative assessment through 
descriptive comparison with historical data. The use of qualitative and quantitative 
research techniques off-set the limitations of each technique used in this study. 
Another technique for establishing credibility involves external checks on the 
inquiry. According to Lincoln and Guba (153) this can be achieved through peer 
presentations and input. Input on the heart attack awareness programme was 
solicited from cardiac nurses, cardiologists, medical practitioners and the study 
supervisor, who is an expert in the field of cardiology. 
 
Transferability – in Lincoln and Guba’s framework (153), transferability refers to 
the extent to which findings from data can be transferred to other settings or 
groups; it is thus similar to the concept of generalisability in quantitative research. 
The outputs for Phase One and Phase Two provided sufficient rich information to 
allow the reader to consider applicability to other similar settings. 
 
Confirmability and dependability – confirmability refers to the objectivity or 
neutrality of the data, such that two or more independent people would agree 
about the data’s relevance or meaning. Dependability refers to data stability over 
time and  across conditions. According to Polit and Beck (139), inquiry audits can 
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be used to establish both dependability and confirmability. Inquiry audits are 
usually a systematic collection of documentation that allows an independent 
auditor to come to conclusions about data. All source documents collected for 
Phase 1 and Phase 2 were reviewed using an established tool (Adapte process) 
and were reviewed by the study supervisor to establish confirmability and 
dependability.  
 
Researcher credibility - Patton (155) mentions that in qualitative studies, the 
researcher is the data collecting instrument. He or she is also the creator of the 
analytic process; and therefore the researcher’s training, qualifications and 
experience are important in establishing confidence in the data. The researcher 
holds a post graduate qualification (MSc in Cardiology) and is a registered 
emergency care practitioner with HPCSA, with close to 25 years of clinical, 
academic and research experience. Furthermore, the researcher has an excellent 
professional working relationship with healthcare professionals in the area, which 
has developed over a 20-year period. This created an excellent rapport between 
the researcher and healthcare professionals, thereby facilitating a collegial and 
friendly, yet respectful, working environment. 
 
2.12.2 Quantitative data quality 
2.12.2.1 Pilot study 
According to Brink (156) and Kelley et al (157), a pilot study, also known as a 
“preliminary study”, is a small scale study conducted to: investigate the feasibility 
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of the proposed main study; and to detect possible flaws in the research 
instrument. 
 
The data collection tool used in this study is very similar to an established data 
collection tool used by the researcher in a previous study. The previous data 
collection tool was developed from a well-established data collection tool used by 
a cardiac consultant from a regional hospital involved in this study. This cardiac 
consultant’s data collection tool has been in use for more than 5 years and was 
also used in the consultant’s postgraduate studies. The data collection tool used 
by the researcher in the previous study contained all aspects of the researcher’s 
current study. The data collection tool used in this study was assessed by the 
researcher’s supervisor and the two consultants at the coronary care units 
involved in the study in order to test for validity and reliability. These experts were 
requested to comment on the structure, appropriateness and accuracy of the 
demographic, risk factor, family history and clinical data. Minor modifications were 
made to make data capture more efficient (layout) and a few more fields were 
added to add clarity to information being collected (drugs administered). The pilot 
study was then conducted in one of the coronary care units involved in the study 
on one consenting stable pre-discharge post-acute STEMI patient. The results 
from the pilot test revealed that the data collection tool was structured correctly 
and that the data fields created were appropriate and accurate. 
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2.12.2.2 Validity and reliability of the data collection tool 
The central question, according to Brink (156), that determines the concept of 
validity and reliability, is whether or not the researcher yielded data that reflects 
the truth. The truth is achieved through both reliability and validity, as they share a 
close relationship. Reliability is the accuracy with which the research instrument 
measures the responses; whilst validity is the degree to which the instrument 
measures what it is supposed to measure. Polit and Beck (139) state that the 
research instrument must fulfil its purpose by collecting the intended data in order 
to provide the correct information to describe the area of enquiry. To ensure 
reliability and validity of the research instrument, the researcher applied face and 
content validity. Face validity, although regarded as a weak measure (156) was 
used to determine readability and clarity of the variables. Content validity was 
used to assess how well the research instrument represents all components of the 
variable to be measured. By applying content validity, the assessment measured 
overall suitability for use by evaluating what the research instrument measured 
and also what it did not measure (156). All fields of the research instrument were 
interrogated: internally by the expert panel; and externally through the pilot study. 
The data collection tool used for this study was developed from a data collection 
tool used by the researcher in a previous study, to which the researcher made 
changes relevant to this study.  
 
2.12.2.3 Internal and external validity of the study 
Polit and Beck (139) state that internal validity denotes the degree to which it is 
possible infer that the independent variable is truly causing or influencing the 
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dependant variable. Possible threats to the study’s internal validity could be 
selection threat, which encompasses bias when people are not assigned randomly 
to groups. For this study, participants were sampled through convenience 
sampling. In addition, data entered into the data collection tool were reviewed 
randomly and independently by the consultants of the respective coronary care 
units - this by cross-checking against the patient’s ambulance report form and 
hospital records.  
 
According to Polit and Beck (139), external validity is the degree to which 
relationships hold true to different people, conditions and settings. Replication is 
an important concept relevant to external validity, as multiple site studies are 
powerful and produce more confidence in the generalisability of the results. The 
diverse sample of the study can test whether study results are replicated in sub-
groups. The participants in this study and from the historical data were from 20 
hospitals. 
 
2.13 Ethical aspects and approval  
An application for the research proposal and ethical approval was submitted to 
and subsequently approved by the University of the Witwatersrand Research 
Ethics Committee – Ethical Clearance Number: M080822 (Appendix 2 and 
Appendix 3). Upon receiving ethical clearance from the University of 
Witwatersrand, permission to undertake this study was granted by KwaZulu-Natal: 
Department of Health (Appendix 4). Once this approval was granted from the 
KwaZulu-Natal Provincial Government, permission was sought from the respective 
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hospital managers and the manager of Emergency Medical Rescue Services to 
undertake the study in the respective units. It must be noted that complete 
documentation had to be submitted to the respective hospitals for further ethical 
clearance by each hospital’s institutional review board.  
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CHAPTER 3 
RESULTS 
 
3.1 A simple, culturally sensitive and affordable chest pain awareness 
programme for South Africa 
Following approval from the respective validation panels, a poster, an information 
booklet and an animated video on heart attack awareness were finalised as 
follows: 
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3.1.1 Poster 
 
Figure 4: Heart attack poster 
The poster is also attached as Appendix 10. While this poster (Figure 4) is 
designed primarily for dissemination in the public domain, it can be adapted for 
display in receiving/waiting areas of emergency departments of health 
establishments. 
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3.1.2 Information booklet 
The information booklet is attached as Appendix 10. The contents of the booklet 
are as follows: 
1. What is a heart attack? 
2. What causes a heart attack? 
3. Are there any warning signs and symptoms of a heart attack? 
4. What are the symptoms of a heart attack? 
5. How is a heart attack diagnosed? 
6. What is an ECG? 
7. What to do? 
8. What treatment may be administered by paramedics? 
9. What treatment may be administered by doctors at hospital? 
10. If I have already had a heart attack, can I have another? 
11. What brings on a heart attack? 
12. What happens to the heart after a heart attack? 
13. What are some simple exercise tips for being physically active after a 
heart attack? 
14. What are some general dietary tips for healthy eating after a heart 
attack? 
15. What are some dietary and lifestyle goals for reducing the risk of 
cardio-vascular disease? 
16. Dietary guidelines. 
17. Dietary recommendations. 
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3.1.3 Animated video 
The animated video (Figure 5) is attached as Appendix 10. The storyboard of the 
video is as follows: 
Title page Scene 1: Person sitting in lounge, watching 
television. 
  
Scene 2: Person gets chest pain. Scene 3: Person calls for help. 
  
(The storyboard is continued on the following page.)  
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(The storyboard continues from the previous page.) 
Scene 4: Ambulance arrives at person’s house. Scene 5: Ambulance transporting patient to 
hospital with oxygen, drip and ECG. 
  
Scene 6: Ambulance arriving at hospital and 
handing patient over to doctor. 
 
 
 
Figure 5: Storyboard 
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3.2 Thrombolytic therapy for acute STEMI by emergency care practitioners 
3.2.1 Education programme for emergency care practitioner thrombolysis 
The foundation theoretical knowledge required for the practice of thrombolysis 
should begin with an in-depth study of anatomy and physiology of the cardio-
vascular system. This should be followed by a study of the patho-physiology of 
acute coronary syndromes. The complications of acute coronary syndromes, more 
specifically acute STEMI, must be covered, as this will prepare the emergency 
care practitioner for complications that may arise during clinical practice. In-depth 
training will need to be provided on 12 lead ECG analyses, with a focus on 
recognition of acute STEMI from an ECG. The evidence-based thrombolysis 
clinical skill (Appendix 15) with supporting drug information (Appendix 13) that has 
been approved by the HPCSA: Professional Board for Emergency Care, will need 
to be taught (whilst taking into consideration the operational requirements for 
practical implementation of the protocol). Classroom practice through the use of 
simulated clinical patient scenarios for the following will prepare and improve 
clinical practice: stable angina, unstable angina, infarctions of the various 
territories including right ventricular infarction, and scenarios where thrombolysis is 
contra-indicated. This theoretical and practical classroom education and training 
will need to be supported by clinical exposure in an authentic environment, e.g. 
coronary care units, cardiac clinics and cardiac catheterisation facilities. 
 
Upon successful completion of the recommended education and training 
programme, implementation of the skill must be undertaken using the thrombolysis 
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checklist (Appendix 16). An ECG monitor with data transmission, pacing and 
defibrillation capabilities, as well as on site access resuscitation drugs, is 
mandatory; and it is highly recommended that a specialist clinician experienced in 
acute STEMI management is consulted at the initial implementation of 
thrombolysis. 
 
An on-going continuous professional development programme, which would 
incorporate quality improvement measures for on-going monitoring and process 
improvement, is also mandatory for safe emergency care practitioner 
thrombolysis. 
 
3.2.2 Clinical skill: Emergency Care Practitioner Thrombolysis Protocol 
The developed documents for Emergency Care Practitioner Thrombolysis are 
provided as appendices: Emergency Care Practitioner Thrombolysis Protocol 
(Appendix 15), Thrombolysis Checklist (Appendix 16) and Patient Consent Form 
(Appendix 17). 
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3.3 Thrombolytic therapy for acute STEMI by emergency care practitioners: 
Results of a pilot study involving 20 patients compared to historical data 
3.3.1 Summary of 20 patients thrombolysed 
Implementation of the thrombolysis skill was undertaken as per the expert panel 
and HPCSA: PBEC approved protocol using the checklist and consent form.  A 
summary of all 20 patients thrombolysed by the researcher is as per Appendix 18: 
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3.3.2 Demographic data 
Table 6: Demographic data 
 Total ECPT 
Group 
IHDT 
Group p-Value Power Analysis 
N (%) N (%) N (%) 
98 (100) 20 (100) 78 (100)   
Gender 
Male 72 (73.5) 15 (75) 57 (73.1) 
0.862 a 0.054 
Female 26 (26.5) 5 (25) 21 (26.9) 
Age 
Median 57.75 57.5 58 -  
30 - 39 5 (5.1) 1 (5) 4 (5.1) 
0.488 b 0.054 
40 - 49 23 (23.5) 7 (35) 16 (20.5) 
50 - 59 25 (25.5) 3 (15) 22 (28.2) 
60 - 69 33 (33.7) 6 (30) 27 (34.6) 
70 -79 10 (10.2) 2 (10) 8 (10.3) 
80 -89 1 (1) 1 (5) 1 (1.3) 
Ethnic Group 
Black 6 (6.1) 1 (5) 5 ( 6.4) 
0.196 b 0.053 
Coloured 3 (3.1) 2 (10) 1 (1.3) 
Indian 81 (82.7) 15 (75) 66 (84.6) 
White 8 (8.1) 2 (10) 6 (7.7) 
Type of Infarct 
Inferior 57 (58.2) 11 (55) 46 (59) 0.748 a 0.058 
Posterior 11 (11.2) 7 (35) 4 (5.1) < 0.001 b 0.244 
Anteroseptal 27 (27.6) 3 (15) 24 (30.8) 0.159 a 0.114 
Anterolateral 24 (24.5) 9 (45) 15 (19 .2) 0.038 b 0.220 
High Lateral 3 (3.1) 0 (0) 3 (3.8) 1.00 b 0.053 
Key: ECPT – Emergency care practitioner thrombolysis 
IHDT – In-hospital doctor thrombolysis 
a - Pearson Chi-Square Test 
b - Fisher’s Exact Test 
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The demographic characteristics of all patients are shown in Table 6. The total 
study population of 98 (100) patients comprised: 20 patients in the ECPT group; 
and 78 patients in the IHDT group. 73.5% were males. The majority of patients 
were of Indian origin (82.7%) with a median age of 57.75 years. No statistically 
significant differences for gender, ethnic group and median age between the 
groups were noted. 
 
The most common type of infarct was in the inferior territory (58.2%). A statistically 
significant difference between the two groups for the posterior (p < 0.001) and 
anterolateral (p = 0.038) types of infarction were noted.  
 
A family history of premature atherosclerotic coronary heart disease was prevalent 
in 41.8% of the patients; while 27.6% and 22.4% had a family history of diabetes 
and hypertension respectively (Table 7). Common conventional risk factors 
evident in all patients included: smoking (56.1%); hypertension (52%); and 41.8% 
were diabetics. No statistically significant differences were noted between the 
groups for family history and risk factors. 
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Table 7: Family history and risk factors 
 Total ECPT 
Group 
IHDT 
Group 
p-Value 
Power 
Analysis 
 N (%) N (%) N (%) 
98 (100) 20 (100) 78 (100) 
Family History of Vascular Diseases 
Premature CHD 41 (41.8) 12 (60) 29 (37.2) 0.065 a 0.222 
CVA 3 (3.1) 0 (0) 3 (3.8) 1.000 b 0.053 
Hypertension 22 (22.4) 2 (10) 20 (25.6) 0.228 b 0.109 
Diabetes Mellitus 27 (27.6) 3 (15) 24 (30.8) 0.159 a 0.114 
Risk Factors 
MI 17 (17.3) 3 (15) 14 (17.9) 1.000 b 0.052 
Angina 10 (10.2) 3 (15) 7 (9) 0.426 b 0.057 
Diabetes Mellitus 41 (41.8) 9 (45) 32 (41) 0.748 a 0.055 
Hypertension 51 (52) 10 (50) 41 (52.6) 0.838 a 0.053 
Dyslipidaemia 10 (10.2) 2 (10) 8 (10.3) 1.000 b 0.050 
Smoker 55 (56.1) 14 (70) 41 (52.6) 0.161 a 0.184 
Key: ECPT – Emergency care practitioner thrombolysis 
IHDT – In-hospital doctor thrombolysis 
CHD – Coronary Heart Disease 
CVA – Cerebro-vascular Disease 
MI – Myocardial Infarction 
a - Pearson Chi-Square Test 
b - Fisher’s Exact Test 
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3.3.3 Patient outcomes 
The most common complications observed (Table 8) in the two groups during 
hospital stay and at 30-day follow-up included: cardiac failure (12.2% versus 
12.2%); death (9.2% versus 7.1%); recurrence of angina (10.2% versus 6.1%); 
and recurrent myocardial infarction (1.0% versus 3.1%). Pericarditis was not 
observed during in-hospital stay and at 30-day follow-up. 
Table 8: In-hospital and 30-day complications 
 
In-hospital Complications 30-day Complications 
TOTAL ECPT 
Group 
IHDT 
Group p-Value Power Analysis 
TOTAL ECPT 
Group 
IHDT 
Group p-Value Power Analysis 
N (%) N (%) N (%) N (%) N (%) N (%) 
98 (100) 20 (100) 78 (100)   98 (100) 20 (100) 78 (100)   
Recurrence 
of angina 10 (10.2) 2 (10.0) 8 (10.2) 0.973 
a 0.050 6 (6.1) 1 (5.0) 5 (6.4) 0.810 a 0.050 
Recurrence 
of infarction 1 (1.0) 0 1 (1.0) 0.498
 a 0.050 3 (3.1) 0 3 (3.1) 0.238 a 0.053 
Ventricular 
arrhythmias 2 (2.0) 1 (5.0) 0 0.073
 a 0.055 1 (1.0) 0 1 (1.0) 0.498 a 0.050 
Cardiac 
failure 12 (12.2) 3 (15.0) 9 (11.5) 0.680
 a 0.053 
12 
(12.2) 0 
12 
(12.2) 0.015
 a 0.100 
Cardiogenic 
shock 3 (3.0) 3 (15.0) 0 0.002
 a 0.093 0 0 0 - - 
Pericarditis 0 0 0 - - 0 0 0 - - 
Complete 
heart block 4 (4.0) 2 (10.0) 2 (2.5) 0.011
 a 0.069 0 0 0 - - 
Death 9 (9.2) 4 (20.0) 5 (6.4) 0.085 a 0.050 7 (7.1) 1 (5.0) 6 (7.7) 0.664 a 0.051 
Key:  ECPT – Emergency care practitioner thrombolysis 
IHDT – In-hospital doctor thrombolysis 
a - Fisher’s Exact Test 
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3.2.4 Treatment time frame 
None of the 20 patients in the ECPT group received thrombolytic treatment within 
two hours of on-set of symptoms; whilst 35% received thrombolytic treatment 
within 2 to 4 hours following the commencement of symptoms; and 60% received 
treatment from 4 to 6 hours. Five percent of the patients received treatment after 6 
hours. In the IHDT group, 7 (9%) patients presented to the hospital in less than 2 
hours from symptom on-set received thrombolytic treatment; whilst 20.5% 
received thrombolytic treatment within 2 to 4 hours; 24.4% from 4 to 6 hours; 23.1 
% from 6 hours to 12 hours; and 23.1 % after 12 hours (Figure 6). 
 
 
Figure 6: Treatment time frames 
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The median time differences to treatment are shown in Figure 7. For the ECPT 
patient group, the median time to calling for help from symptom on-set was 3 
minutes (range 0 – 255; IQR 86).  The median time taken for transportation of 
patient, that is, the time taken from calling for help to hospital presentation, was 95 
minutes (range 20 – 245; IQR 102); while the door-to-needle median time was 140 
minutes (range 30 – 265; IQR 97).  For the IHDT patient group, the median time to 
calling for help from symptom on-set was 18 minutes (range 0 – 810; IQR 150).  
The median time taken for transportation of patient, that is, the time taken from 
calling for help to hospital presentation was 30 minutes (range 0 – 860; IQR 105); 
while the door-to-needle median time was 188 minutes (range 25 – 1250; IQR 
275) 
 
The median time from symptom on-set to thrombolysis for the ECPT group was 
280 minutes (Range 145 – 400; IQR 146); while the median time from symptom 
on-set to thrombolysis for the IHDT group was 338 minutes (Range 45 – 1785; 
IQR 466). The mean time from symptom on-set to thrombolysis for the ECPT 
group was 272 ± 79 minutes; while the mean time from symptom on-set to 
thrombolysis for the IHDT group was 486. ± 373 minutes (p = 0.055 – calculated 
using Mann-Whitney Test). The power calculation using G Power 3.1 = 0.593. 
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Figure 7: Median time differences to treatment  
 
3.2.5 Transportation of patients 
The use of the ambulance service was 12.2% versus private transportation of 
87.8% by patient group (p = 0.070). The ECPT group comprised 5 (25%), with the 
majority of patients choosing private transport (15 (75%)); while the use of 
ambulances in the IHDT group was 7 (9%), with the majority of patients also 
choosing private transport - 71 (91%) (Table 9). 
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Table 9: Patient mode of transport 
 Total ECPT 
Group 
IHDT 
Group 
N (%) N (%) N (%) 
 98 (100) 20 (100) 78 (100) 
Ambulance 12 (12.2) 5 (25) 7 (9) 
Private 86 (87.8) 15 (75) 71 (91) 
p-Value 0.070 a N/S N/S 
Power Analysis 0.496   
 
Key:  a - Fisher’s Exact Test 
 
Utilisation of ambulance transportation resulted in thrombolytic therapy being 
administered in a mean time of 119 ± 46.60 minutes; while the mean time for 
those using private transport was 127 ± 118.60 for the ECPT group. The median 
times were 141 minutes (Range 46 - 163; IQR 22) and 140 minutes (range 30 - 
265; IQR 50) respectively. Utilisation of ambulance transportation resulted in 
thrombolytic therapy being administered in a mean time of 273.29 ± 175.05 
minutes; while the mean time for those using private transport was 289 ± 269.33 in 
the IHDT group. The median times were 227 minutes (range 60 - 585; IQR 108) 
and 180 minutes (range 25 - 1250; IQR 138) respectively. 
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Figure 8: Transport mode and time to treatment  
However: the mean door-to-needle time for the ECPT group was 124.9 ± 58.64 
minutes; while the mean door-to-needle time for the IHDT group was 288.01 ± 
261.44 minutes (p = 0.003 - calculated using Wilcoxon Signed Ranks Test) (Figure 
8). The power calculation using G Power 3.1 = 0.056. 
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CHAPTER 4 
DISCUSSION 
4.1 Heart attack awareness programme 
The development of this simple, culturally-sensitive and affordable chest pain 
awareness programme for South Africa has highlighted the paucity of programmes 
aimed at symptom recognition and action to be taken when experiencing a heart 
attack. The general lack of recognition of a serious medical event among 
populations in the developing world (resulting in prolonged delay to treatment) is 
well documented (35).  
 
The developed poster (intended for general public display) could also be adapted 
for in-hospital waiting areas. The average waiting time for treatment at an 
emergency department of major hospitals in a developing country is often 
prolonged prior to triage and treatment (158, 159). The developed poster and 
instructional video could utilise patients’ waiting time for educational purposes, as 
identified in Nigeria and Saudi Arabia (158, 159). The poster and instructional 
video are simple, bold and eye-catching, which would encourage patients to take 
notice of this aspect of the heart attack awareness programme. Furthermore, 
broad strategies - like the use of billboards and national television prime time 
viewing, as well as talk show programmes like ‘3 Talk with Noleen’ - are essential 
for dissemination of this information. Video interventions may be helpful at 
teaching poorly educated, illiterate populations about health issues in the 
developing world (160). The patient encounter with the doctor is often rushed, with 
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many doctors being unable to spend time during the patient encounter to convey 
basic health concepts and preventative knowledge. The information booklet 
produced would offer information in simple layman's language about heart attack 
and heart attack prevention.  This booklet can also be disseminated through 
primary health care centres and ischaemic heart clinics, as it is designed to be 
used by all heath care professionals and not only by doctors. 
 
Knowledge of the nature of ACS and the importance of calling the emergency 
medical services system is necessary, but it may not be sufficient to reduce patient 
delay.  It has been shown that even patients who have had a previous MI do not 
reduce delay time (43). The heart attack awareness programme addresses these 
concerns partially, as it contains basic information on symptoms of a heart attack 
and what actions to be taken for a heart attack. Dissemination of information to 
patients in the developing world has been an on-going public health struggle, due 
to limited health access and illiteracy (19, 39, 50, 74). It is for these reasons that 
the poster and video used animation and simple language. In addition to patient 
education, Moser et al (43) recommend that: the social, cognitive and emotional 
factors that contribute to delay need to be examined; new interventions that target 
high risk populations need to be tested. This is to systematically apply empirical 
knowledge to the education of patients who are at risk for ACS and to focus on 
previously under-studied and under-served populations. The impact of the heart 
attack awareness programme on patient education would also need to be 
assessed through scientific research processes. 
 
111 
 
4.2 Emergency care practitioner thrombolysis 
4.2.1 Feedback from clinical expert panel 
The clinical notes of all 20 patients thrombolysed by the researcher were critically 
assessed by an expert panel of cardiologists from Albert Luthuli Central Academic 
Hospital. Two main concerns were raised by the expert panel, the first being the 
lack of risk stratification of the patients. The expert panel pointed out that a 
number of the patients were high risk patients and should have been transferred 
directly to a specialist facility for further management. The second point revolved 
around clarification as to why the researcher, an emergency care practitioner, 
would have to go into hospitals to thrombolyse patients where doctors with the 
necessary drugs were available and that waiting for the researcher may have 
delayed definitive treatment. Other points raised by the expert panel were related 
to missing clinical information, assessment of reperfusion and unclear reporting of 
the symptom to definitive time categories. These points were corrected 
immediately. 
 
In terms of risk stratification of patients, for the intention of direct admission to a 
tertiary level hospital, this was not considered in the planning and implementation 
of emergency care practitioner thrombolysis. The researcher complied with the 
referral patterns of the District Health System (DHS), which requires that patients 
be transferred primarily to the regional hospital within the designated catchment 
area. In terms of the DHS, EMS personnel are not allowed to deviate from this 
patient drainage system (72). Risk stratification must be included in the education 
programme as part of the initial assessment of the patient (Appendix 14); and 
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operational arrangements will need to be made with the respective tertiary level 
hospital for direct admission of high risk patients for possible cardiac 
catheterisation of patients thrombolysed by emergency care practitioners (64).  
Early risk stratification into low, intermediate and high risk categories to identify 
which acute STEMI patients will benefit from early coronary intervention. Several 
risk scores have been developed to classify acute STEMI risk like the widely 
known TIMI and GRACE risk scores (161, 162). However, these scores are not 
applicable to the pre-hospital environment, as these risk models are bedside 
scores used in hospital.  A simple risk score, based on age, heart rate and systolic 
blood pressure (developed by Morrow et al (163)), is the only risk score for acute 
STEMI appropriate for the pre-hospital phase. Furthermore, a simple system of 90 
minute post-thrombolysis ST segment resolution (> 50%), for assessing post 
thrombolysis reperfusion (164-166), must be included in the education and training 
programme and in the thrombolysis protocol for emergency care practitioners 
(Appendix 14). This 90 minute post-thrombolysis assessment is essential for 
identifying failed thrombolysis, thereby further triaging patients into those who 
would require rescue PCI (115). 
 
To address the concern with regard to the researcher undertaking thrombolysis in 
the hospital, the following points were discussed with the expert panel of 
cardiologists from Albert Luthuli Central Academic Hospital: 
1. From previous research undertaken (11), it was seen that at least 50% of 
patients who presented to district level hospitals received thrombolysis, 
which meant a delay in definitive treatment for the balance of the patients.  
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2. Some doctors revealed inexperience and required assistance at times as 
they lacked the ability to interpret the ECG. This was also seen in the 
research undertaken in Cape Town by Maharaj et al (33), where delays to 
thrombolysis were found: 28.6% due to consultation with a senior doctor; 
and 18.6% due to difficulty in interpreting the ECG. On five occasions, the 
researcher was called by junior doctors to treat patients who did not require 
thrombolysis. Some doctors were reluctant to use Streptokinase due to their 
lack of experience in the administration process of the agent. It was 
observed that this scenario became worse during the start of new rotations 
of doctors between hospitals or departments within the hospital. 
3. Some of the hospitals did not have a thrombolytic agent available or ran out 
of stock and therefore called the researcher to thrombolyse and transfer the 
patient to the regional hospital. District level hospitals that do thrombolyse 
use Streptokinase only, due to its affordability. 
4. The researcher observed that there was no apparent in-hospital triage for 
chest pain in the participating hospitals. In addition, given the workload and 
the administrative challenges, it appeared as though there was little to no 
emphasis on “time is heart muscle” by attending doctors in-hospital. The 
South African Triage Score (a scoring system recommended and tested in 
the South African context), if implemented, will ensure appropriate 
prioritisation of patients in emergency departments. According to the South 
African Triage Score, chest pain requires an urgent response (i.e. less than 
10 minutes), with clear clinical management guidelines given by the 
receiving medical team (167, 168).   
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5. The focus of attending doctors appeared to be obtaining a bed in a regional 
hospital and getting permission from the regional hospital to transfer the 
patient, rather than to thrombolyse the patient. Doctors at primary hospitals 
will not thrombolyse a patient unless permitted to do so by the receiving 
regional hospital. 
6. The researcher was also called to assist with the first patient at the district 
hospital, because: there were no beds available for the patient at the 
receiving regional hospital; and the referring hospital did not have 
Streptokinase. This patient was admitted to the emergency centre of the 
district hospital within 1 hour of symptom on-set and therefore could have 
potentially been thrombolysed within recommended guidelines (89). If the 
researcher did not respond to the district hospital, the patient would have 
been admitted to the ward in the district hospital without the benefit of 
thrombolysis. 
7. The researcher’s involvement started to speed up the in-hospital processes, 
as door-to-needle median time was 140 minutes (Range 30 – 265). While 
doctors were liaising with regional hospitals to obtain a bed, the researcher 
travelled to the district hospital and usually administered TNK within 10 
minutes of arrival - the travel time to the participating hospitals did not 
exceed 15 minutes. Previous research in the South African context has 
shown that the median door-to-needle time in Durban and its surrounding 
areas was 188 minutes (Range 25 – 1250) (11). 
8. Except for Patient 2, who was initially assessed by a paramedic at the 
patient’s home, all other patients presented to a district level hospital first. 
The EMS dispatch to this patient was for an attempted hijacking.  The 
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patient was shot at. Fortunately the bullet missed the patient, who then 
suffered a heart attack. 
9. The process of confirmation of acceptance of the patient at the regional 
hospital (after sending the 12 lead ECG and clinical notes) needs to be 
reviewed. This is usually exacerbated by personality differences between 
transferring and receiving doctors, and access to the receiving doctor 
outside normal working hours. Doctors at district level hospitals need to be 
encouraged to focus on clinical management and stabilisation of the patient 
as a priority and to thereafter concentrate on arrangements for admission 
and transfer to a regional hospital.  
10. Ideally all patients thrombolysed by an emergency care practitioner should 
have direct access to tertiary facilities, especially for patients with 
complications from acute STEMI. 
 
4.2.2 Some specific patient related observations 
In keeping with other studies, which showed that 40 to 60% of AMI patients use 
EMS for transportation to hospital (38, 62, 67), there was limited use of EMS by 
the patients in this study: most patients preferred to use private transportation, as 
they felt it would be quicker. There appears to be a general expectation of delayed 
arrival of the local public sector emergency medical services. In addition, most 
patients reported that they did not realise they were having a heart attack, as they 
did not recognise the symptoms. This is not unusual, as most patients are not 
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aware of typical symptoms of AMI (39, 46, 48). Furthermore, registries have 
shown that at least 30% of patients present with atypical symptoms (169). 
 
4.2.3 Some specific EMS related observations 
Despite recommendations for pre-hospital use of EMS for the diagnosis, triage 
and treatment for acute STEMI, the following observations were noted (115, 170, 
171). 
• There was no evidence that medical advice was given by the receiving call 
taker. 
• Advanced life support paramedics were not routinely dispatched to patients 
who did activate EMS; except for one patient, which was initially 
dispatched as a gunshot to the body. 
• Furthermore, there was no evidence in the ambulance patient report form 
that ALS assistance was requested for chest pain, nor whether or not 
Aspirin was administered and whether or not the hospitals were pre-alerted 
to the patient, despite the ambulance crew making a provisional diagnosis 
of chest pain of cardiac origin.  
 
4.3 Comparative analysis of acute STEMI patients thrombolysed 
This study found a high proportion of the Indian population with AMI - 82 (82.75%), 
which does not fit the ethnic group profile of South Africa. Currently, Indians make 
up just 2.46% of the South African population and 8.47% of people in KwaZulu-
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Natal (93). Furthermore, it also does not fit the ethnic group profile within the study 
area, eThekwini Health District, which is: Black Africans - 68.3%; Indian - 19.9%; 
White - 8.98%; and Coloured - 2.82% (143). In a study conducted at R. K. Khan 
Hospital (172), it was reported that cardiac disease has reached epidemic 
proportions in South African Indians. The high proportion of Indians in the study 
therefore cannot be generalized to the rest of South Africa. 
 
While the incidence of acute myocardial infarction in the Black African population 
in this study is relatively low 6 (6.1%), this data may herald the emergence of a 
new epidemic of coronary disease in the Black African population. This was 
previously reported as being quite uncommon (12-14). These observations raise 
the question of an epidemiological transition due, possibly, to: urbanisation, 
changes in the traditional Black African diet to a “fast food” one – high in saturated 
fats - and the effect of emerging affluence due to economic growth in South Africa. 
The most prevalent risk factor identified by Tibazarwa et al (15) was obesity 
(43%), with significantly more obese women than men (55% versus 23%, or 1.76 
95% CI 1.62 to 1.91: p < 0.001). 
 
The most common type of infarct was in the inferior territory (58.2%). Although a 
statistically significant difference between the two groups for the posterior (p < 
0.001, power calculation = 0.0244) and anterolateral (p = 0.038, power calculation 
= 0.220) types of infarction were noted, these results need to be interpreted 
cautiously due to the small number of patients in each group which may have 
resulted in a Type II error. 
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A family history of premature coronary heart disease, diabetes mellitus and 
hypertension accounted for almost one-third of the study population (41.8%, 
27.6% and 22.4% respectively) (See Table 7). The high incidence of premature 
coronary heart disease (41.8%) is consistent with the findings of Ranjith et al (10). 
The mean age of all patients (57.8 years) is also very young. 
 
Smoking and hypertension risk factors were present in more than 50% of the 
patients (56.1% and 52% respectively), while 41.8% were diabetic; these are well-
known risk factors (173). While only 10.2% of patients were reported to have 
dyslipidaemia, this data must be interpreted cautiously, as some patients were not 
aware of their cholesterol status.  
 
A key benefit of prompt reperfusion therapy is the improvement in morbidity, 
typically reducing the incidence of heart failure and arrhythmias. It must be noted 
that patients in this study generally had a higher incidence of heart failure. By 6 
hours there is limited viable myocardium and the impact of thrombolytic therapy is 
greatly reduced despite having a clinical impact on patient outcome up to 12 hours 
from symptom on-set (29). While the ECPT group had a higher mortality rate (4 of 
20 (20%) in-hospital, compared to 5 of 79 (6.4%) in the IHDT group), these results 
need to be interpreted with caution, due to the small number in the ECPT group. 
Furthermore, the in-hospital group did not include patients that died in the acute 
phase of acute STEMI simply because the ethical provisions of the study only 
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allowed the researcher to approach patients for consent to participate in the study 
when the patient was in a clinically stable condition. 
 
The mean symptom-to-needle time of 272 ± 79 minutes and 486 ± 373 minutes for 
the ECPT and IHDT groups respectively constitutes a major delay, compared to 
the symptom-to-needle time recommendation of less than 60 minutes (22). While 
the symptom to treatment time was reduced in the ECPT group (p = 0.055), further 
reductions are critical to realise the goals of reduced morbidity and mortality from 
STEMI. However, concentrating on delivery of thrombolytic therapy at point of 
patient presentation to a health care facility/professional would have a significant 
impact on treatment delay. To achieve point-of-contact thrombolytic therapy, the 
emergency care practitioner needs to be at the patient’s side within at least 15 
minutes from activation of the emergency medical services; district and regional 
hospital emergency departments need to be able to initiate reperfusion therapy 
within 30 minutes of arrival at hospital (22).  
 
Patient delay often constitutes the longest period of delay to treatment (32) and 
should not be longer than 15 minutes, according the European Society of 
Cardiology (22). The mean time taken for patients to call for help was: 48 ± 77 
minutes for the ECPT group; and 109 ± 59 minutes for the IHDT group. Many 
patients reported that they were not sure of the pain and did not think that it was 
serious.  A number of factors were associated with patient’s decision time, 
including: the type of acute coronary syndrome, the nature and localisation of 
symptoms, the place where symptoms occurred, the patient’s interpretation of 
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symptoms and knowledge (48). Various registries of patients with AMI have shown 
that the time from symptom on-set to hospital presentation was: ≥ 4 hours in 50% 
of the patients; > 6 hours in 40%; and > 12 hours in 9 – 31% (38). Internationally, 
patient delays have proven to be difficult to reduce as this requires a continuous 
education programme (35).  
 
The majority of patients were transported privately to hospital 86 (87.8%); while 
only 12 (12.2%) utilised the ambulance service; this is low compared to other 
published data (38, 68). It must be noted that only 1 of the 5 patients transported 
by ambulance was treated by the emergency care practitioner at home; therefore, 
greater time saving could have been achieved if thrombolysis was initiated in the 
pre-hospital environment by EMS. Despite informing the control center of the study 
and delivering repeated presentations to staff and the officers in charge, the 
researcher was not informed of calls received about patients with chest pain of 
cardiac origin. The converse also applied sporadically, the researcher was advised 
of all calls received, without proper screening, e.g. the researcher was informed of 
patients with chest pain secondary to tuberculosis. The researcher was also not 
informed by the ambulance crew about the 5 patients transported. These patients 
had a provisional diagnosis of chest pain of cardiac origin at the patient’s home. 
The ambulance crews elected to transport the patients directly to hospital. 
Although there was a marginal difference in time to treatment between ambulance 
and private transportation, in-hospital treatment is usually faster when patients are 
transported by ambulance (62). The results of this study must also be interpreted 
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with caution, as the study was conducted mainly in an urban setting and not in a 
rural setting where there are prolonged transportation times.  
 
There was a clear indication of significant delays in the treatment of STEMI at the 
receiving hospital: 125 ± 59 minutes in the ECPT group; and 288 ± 261 minutes in 
the IHDT group. The significant delays at hospital were due to: non-triage (not 
assessed) of patients with chest pain; non-availability of a thrombolytic agent; lack 
of sufficient; and appropriate acute care training by the attending medical officer. 
There were also indications that some district hospitals have the resources to 
initiate thrombolysis but it was not being applied consistently. The focus of the 
attending medical officer appeared to be on securing a bed for the patient in the 
respective coronary care unit and obtaining permission to initiate thrombolysis.  
Further research needs to be undertaken to identify the reasons for under-
utilisation of thrombolysis at district level hospitals. Local medical officers need to 
be encouraged to initiate thrombolytic treatment before referral and confirmation of 
a bed at regional hospital coronary care units. This delay is unacceptable, 
considering the international recommendation for time to thrombolysis within the 
hospital is within 30 minutes (30).  While the reasons for delay to treatment within 
the hospital environment were not the scope of this study, most patients reported 
long waiting periods within the emergency department. Door-to-needle time was 
significantly reduced when thrombolysis was initiated by the emergency care 
practitioner (p < 0.003). A recent study undertaken by Maharaj et al (33) at three 
regional hospitals in Cape Town concluded that a significant number of patients 
were not thrombolysed within 30 minutes of presentation due to: a lack of senior 
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doctors (28.6%); difficulty in interpreting ECGs (18.6%); atypical presentation 
(12.9%); patients going into cardiac arrest (11.4%); hypertension 7.1%; shift 
change (7.1%); obtaining a chest X-ray (4.3%); fibrinolytics agent not available in 
emergency centre (4.3%); and other system challenges (5.7%). 
 
When comparing the results of the treatment timeframes with the United Kingdom 
MINAP database (where more than 75% of patients were treated within 6 hours 
from symptom on-set (27)) the South African performance i.t.o. delivery of 
reperfusion therapy requires urgent review - despite the reduction in call-to-needle 
time by emergency care practitioner involvement. Within the United Kingdom, a 
national ‘treatment target’ of ‘door-to-needle’ (DTNT) (and more recently ‘call-to-
needle time’ (CTNT)) has been enforced since 2000. The timeframe of DTNT of < 
30 minutes and CTNT of < 60 minutes represent guidance from the European 
Cardiac Society. There has been a significant improvement in time to delivery of 
reperfusion therapy, with: > 85% of patients now receiving thrombolysis within 30 
minutes of arrival in-hospital; and > 60% receiving therapy in under 60 minutes 
after calling for professional help. In comparison, performance in Durban was poor 
(174). Key to the success achieved in United Kingdom has been: clinical audit, 
training of medical/nursing/paramedics, and publication of individual hospital 
performance to “name and shame” poor-performing hospitals (175). 
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4.4 Limitations of the study 
Several limitations of this study have been identified. Being a feasibility study, the 
results from ECPT group cannot be generalised; and no statistically significant 
conclusions can be made due to the small number of patients treated. 
Furthermore, comparisons made between the two groups may be flawed as the 
ECPT group involved just 2 district hospitals, while the IHDT group included 20 
hospitals of various types (this group included regional hospitals, district hospitals 
and private hospitals). Apart from varying in type, the hospital’s policies, facilities 
and equipment varied as well. No provision was made in this study for chance or 
participant bias for the generally improved time to ECP thrombolysis. A further 
reduction in symptom to treatment could have been achieved if patient recruitment 
was primarily at the site where the patient initially had the chest pains, i.e. at home 
or work - as is intended by emergency care practitioner thrombolysis. A limited 
number of district level hospitals participated in the ECPT group. Data from the 
IHDT group has shown that several hospitals without PCI capabilities do not 
consistently initiate thrombolytic treatment for confirmed acute STEMI patients, 
resulting in significant treatment delays. The emergency care practitioner’s 
response time to the patient was not recorded. Although every attempt was made 
to limit the response time and time to lyses to the bare minimum when at the 
patient’s side, the actual times would have been beneficial, if they had been 
recorded. Inferences from the results of this study cannot be generalised to private 
sector hospitals in the research area. It must be noted that some private sector 
hospitals have PCI facilities and that management strategies for acute STEMI vary 
considerably from one private hospital to another. While serial 12 lead ECG 
recordings were planned to be undertaken at 30 minute intervals to assess for 
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reperfusion, this was not always practically possible, e.g. the patient may have 
been in the process of transferring from hospital into the ambulance or vice versa 
or in transit from one hospital to another. The most practical time for following 
thrombolysis for a 12 lead ECG recording was found to be during admission at the 
receiving CCU. 
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CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Conclusions 
South Africa is a developing nation that is experiencing economic growth, 
urbanisation and general improvement in basic services. The net benefit of this is 
contributing to higher disposable income, which in turn leads to behaviour changes 
that promote a sedentary lifestyle, increase in smoking and changes to diets to 
mimic that of the Western world. It is, therefore, critical to ensure the earliest 
possible initiation of treatment to reduce morbidity and mortality from AMI. The 
most effective system will integrate key components to deliver continuous patient 
care, that is: reduce the time to making the call for help from symptom on-set; 
reduce transportation time to hospital using a well-resourced emergency medical 
services; and overall reduction of door-to-needle or door-to-balloon time at 
hospital. 
 
ECP thrombolysis resulted in a statistically significant reduction in symptom-to-
needle time and door–to-needle time. The findings of this study clearly 
demonstrate that there is prolonged time to definitive treatment in each component 
(that is: the patient, transportation and in-hospital treatment), resulting in delayed 
thrombolysis. 
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5.2 Recommendations 
5.2.1 Prevention 
Government public awareness initiatives should be aimed at emphasising 
prevention and reducing the risks of cardio-vascular diseases. National 
government needs to play an active role in promoting a healthy life style, which 
involves healthy eating and exercise. The issue of obesity, especially amongst 
teenagers, and dependency on convenience foods also needs to be addressed. 
Major risk factors for the development of coronary heart disease, (smoking, family 
history, adverse lipid profiles and hypertension) are well established, therefore 
more educational programmes (through schools, prime time television screening, 
clinics) need to be introduced to reduce ignorance and rectify misconceptions and 
stereo typical thinking about cardio-vascular diseases. 
 
Some of these initiatives may be achieved through health policies endorsing 
healthy products and banning harmful products e.g. smoking. Community health 
workers should be trained on disease prevention as part of their primary health 
care responsibilities. Other specific initiatives include a structured cardiovascular 
disease awareness programme, such as September Heart Awareness Month. 
More specific to this study, further research needs to be undertaken to examine 
AMI awareness in a group randomised to the chest pain awareness programme or 
not, with comparison to probable action in the short to long-term. 
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Given the alarmingly high incidence of AMI amongst the Indian population group, 
carefully monitored intervention strategies aimed at reduction needs to be 
implemented as soon as possible. Furthermore, a multi-centred prospective study 
is necessary to determine the emergence of acute coronary syndromes in the 
Black African population; and preventative interventional strategies need to be 
implemented to limit the deleterious lifestyle changes associated with socio-
economic improvements in South Africa.  
 
5.2.2 Cardiac care network 
A network for acute STEMI management should be developed at national and 
regional levels by government, health care professionals, health care insurance 
providers, hospitals and emergency medical services. The network needs to have 
a mutually acceptable emergency protocol to ensure that patients with cardiac 
symptoms are able to access emergency medical services without barriers to 
timely evaluation and treatment. External surveillance registries, like MINAP and 
the Swiss registries and cardiac care networks like the Vienna STEMI (176) and 
Bologna (177) networks, would provide valuable information on trends for both 
pre-hospital and in-hospital management of acute STEMI; they should therefore 
be established and used to reduce treatment timeframes and improve clinical 
outcomes. 
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5.2.3 Patient delay and transportation 
Patients and bystanders should be educated to ensure they are able to recognise 
symptoms early, activate the emergency medical services early - and thereby 
reduce the time to reperfusion treatment. Patients with chest pain should also 
ideally be transported by ambulance, rather than by friends or relatives because of 
the proven association between arrival at the hospital emergency department and 
early reperfusion therapy. 
 
5.2.4 Pre-hospital management  
EMS providers should be encouraged to make a pre-hospital diagnosis to allow for 
preparation before arrival of the patient at the emergency department, which may 
result in an important improvement in the delivery time of thrombolysis.  There is a 
need for a well-structured educational programme to ensure safe early acute 
STEMI diagnosis with 12-lead ECG at home or in the ambulance by emergency 
care practitioners. A system of consultation and 12-lead ECG transmission with 
CCU nurses or a senior paramedic or specialist clinician who is experienced in 
STEMI management is highly recommended at initial implementation of 
thrombolysis and for on-going clinical support in difficult cases.  Furthermore, 
paramedics could fast-track acute STEMI patients to CCU by by-passing the 
developing emergency departments and by-passing local hospitals to deliver the 
patient to a hospital with an on-site catheterisation laboratory for either rescue 
angioplasty or pre-discharge angioplasty.  
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An on-going continuous professional development programme that incorporates 
quality improvement measures obtained by on-going monitoring of pre-hospital 
thrombolysis via clinical audit and feedback must be mandatory for continued safe 
pre-hospital thrombolysis and staff development. A clinical review team, 
incorporating all role players, would need to meet regularly to appraise all cases of 
pre-hospital thrombolysis. In settings where the frequency of performance of 
thrombolysis is low, an on-going programme of refresher training would be 
essential to maintain skill competence. Furthermore, pre-hospital thrombolysis 
should be done within a prospective research project to measure the effects of 
early initiation of treatment on acute STEMI within the South African context.  
 
5.2.5 In-hospital management  
All hospitals need to develop a guideline-based protocol for triaging and managing 
patients presenting to the emergency department with acute STEMI. The delay, 
from patient arrival time at the emergency department (either by self-presentation 
or by emergency care providers) to initiation of thrombolytic treatment, should 
ideally be less than 30 minutes to be in line with evidence-based best practice 
guidelines. Patients with chest pain must be triaged immediately to reduce the 
reported long waiting periods in queues by patients. The poster designed by the 
researcher, which is aimed at the general public, can be modified to alert patients 
with chest pain in the hospital queues to seek help from the nurse or doctor in 
charge of the emergency department. Frontline doctors or nurses should undergo 
continuous professional development programmes to encourage prompt 
thrombolytic therapy independently and with confidence. Better co-operation will 
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need to be fostered between prehospital emergency care providers and 
emergency medicine specialists in the emergency department.  “Fast tracking” to 
CCU, when emergency departments are not operationally ready for thrombolysis, 
may be a necessary option to reduce delays. A system of consultation and 12-lead 
ECG transmission with CCU nurses or a specialist clinician experienced in STEMI 
management (and for on-going clinical support in difficult cases) is also 
recommended for inexperienced, junior doctors and nurses in emergency 
departments.  
 
Every attempt must be made to reduce the in-hospital drug acquisition and 
administration delays to thrombolysis. The use of Tenecteplase, which can be 
administered by bolus injection, could be another way of reducing time to 
thrombolysis. Regardless of the agent used, the drug could be kept in the 
emergency department. The hospital’s performance should be continually 
monitored as part of the strategy to shorten in-hospital delays; and if the average 
delay is longer than 30 minutes for patients, the process must be examined and 
improved. 
 
While thrombolysis by ECPs offers a significant improvement in reducing 
symptom-to-needle time in treating acute STEMI, systems to facilitate various 
approaches need to be implemented. Until reperfusion strategies are delivered 
effectively, the promise of reduced morbidity and mortality from AMI will not be 
realised. This, however, can be realised by re-organisation of the respective 
components of the current South African health care system.  
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Appendix 2: Research Proposal Approval – University of the Witwatersrand 
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Appendix 3: Human Research Ethics Committee Approval – University of the 
Witwatersrand 
 
 
136 
 
Appendix 4: Ethical Approval – KwaZulu-Natal Health Department 
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Appendix 5: Patient Information Document – English 
 
PARTICIPANT INFORMATION DOCUMENT 
Study title: Thrombolytic therapy for acute myocardial infarction by emergency 
care practitioners. 
 
Greeting: Hello Sir / Madam. My name is Raveen Naidoo and I am doing research 
that involves early treatment of heart attack patients by emergency care 
practitioners (paramedics).  
 
Introduction: 
You are being invited to take part in this research study. Research is just the way 
to learn the answer to a question. Before you decide whether or not to participate, 
it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Please ask me if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part. 
 
Why have I been chosen? 
You have been chosen because you are a patient who has suffered a heart attack.  
In this study we want to learn about safe initiation of thrombolytic treatment for 
heart attack patients by emergency care practitioners (paramedics) in the South 
African context, in particular, in Durban and the surrounding areas.  The procedure 
known as “thrombolysis” involves administration of a drug that will break down a 
dangerous clot in the blood vessels of the heart. The earliest possible time for 
starting thrombolysis is critical to lower the effects of a heart attack. Thrombolysis 
is a well-established method of treatment for heart attacks in-hospital; however, 
unlike in other countries, it does not occur outside hospital in South Africa. In this 
part of the study, we would like to find out: how long did it take for the heart attack 
patient to receive thrombolytic treatment by an emergency care practitioner; and 
what is the overall effect of this treatment on the patient. The results of this study 
will provide valuable information and will guide the national roll-out of emergency 
care practitioner-led thrombolysis in South Africa. 
 
What is involved in the study? 
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I need your permission to give you the thrombolytic agent, i.e. the drug that will 
break down the clot in your heart.  I will also need your permission to read your 
patient file later at the hospital to obtain information relevant to the study and to 
contact you or your next of kin in a month’s time to follow-up on your well-being. I 
will make every effort not to cause any discomfort or distress to you or your family. 
The information I require is specific information about your clinical treatment and 
some laboratory results. 
What are the possible risks of taking part? 
There are some risks to you as a patient, because the treatment being offered to 
you, although well established treatment regime undertaken in the hospital 
environment, is not without side effects and complications. Some patients have 
reported experiencing side effects such as bleeding - predominantly at the 
injection site. Successful treatment with the thrombolytic agent may be 
accompanied by arrhythmias. Your blood pressure may also drop.  You may be 
nauseas and may experience vomiting. You may also have mild pain, swelling and 
mild local irritation of the skin from the injection given.  
 
What are the procedures for handling adverse events and what 
arrangements have been made for compensation? 
Most of these complications do not need further treatment; however, should 
treatment be necessary, this will first be provided by me in my capacity as a 
paramedic and then by the doctor in charge at your hospital.  Compensation is 
provided through professional indemnity, student indemnity cover and in-hospital 
provisions. 
 
What are the possible benefits of taking part? 
Research has already shown that earlier administration of thrombolytic agents 
improves patient outcome after a heart attack, which may be a direct benefit to 
you. In addition, the information obtained through your participation will be useful 
i.t.o. future care of heart attack patients. The information obtained from this study 
will provide guidance to health care professionals (especially paramedics) on how 
to start the  thrombolysis procedure outside hospital.  It may provide guidance to 
government officials on how to improve cardiac care. 
 
Are there alternative procedures or courses of treatment that might be 
advantageous to me? 
There is no alternative treatment. 
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Do I have to take part? 
No; your participation is entirely voluntary. Your routine treatment will not be 
affected in any way if you decide not to take part in the study or if you decide to 
withdraw from it. 
 
Are there reimbursements for “out of pocket” expenses? 
You will not be paid to participate in this study and there will not be any 
reimbursements, as this is not applicable in this study. 
 
Will my taking part in this study be kept confidential? 
All participant information will be kept confidential. All information will be stored 
electronically and will be password-protected for a period of five years.  After that, 
all information will be deleted. Only the researcher and the researcher’s supervisor 
will have access to the information. All information will be coded and will not be 
made public. The findings of the study will be used for research purposes only. 
However, absolute confidentiality cannot be guaranteed as personal information 
may be disclosed if required by law, or organisations may inspect and/or copy your 
research records for quality assurance and data analysis. These organisations 
may include groups such as the Research Ethics Committee and the Medicines 
Control Council. 
 
What will happen to the results of the study? 
The results of the study will hopefully be published in a peer-reviewed journal and 
will be made available to relevant professional boards and government 
departments. The results will also be made available to participants upon request. 
You have the right to be informed of any new findings that are made if you request 
such information. 
 
Who has reviewed the study? 
This research project has been reviewed and approved by the University of the 
Witwatersrand Research Ethics Committee.  In addition, permission to undertake 
the study has been granted by: KZN Health Department; KZN Emergency Medical 
Rescue Services; and the Hospital Manager of your hospital. 
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You are welcome to contact me or my supervisor if you have any questions to 
which you would like answers or to report any study related adverse effects. If you 
are not satisfied with any area of the study, please feel free to forward any 
concerns to my supervisors. The name of the Research Ethics Committee (REC) 
administrator and chair are provided below for purposes of reporting complaints or 
problems. 
 
Contact for further information 
Name of Researcher: 
Mr Raveen Naidoo 
Director: Postgraduate Development and Support (Acting) 
Durban University of Technology 
Tel:  031 3732846 
 
Name of Supervisor: 
Prof K. Sliwa 
Director: Soweto Cardiovascular Research Unit 
Associate Professor of Medicine and Cardiology 
Department of Cardiology 
CH Baragwanath Hospital 
University of the Witwatersrand 
Tel:  011 9338197 
 
Name of REC Administrator and Chair: Prof P. E. Cleaton Jones. 
 
141 
 
Appendix 6: Patient Information Document – isiZulu 
 
IPHESHANA LOKWAZISA KOZOBAMBA IQHAZA NEMVUME YOKUBAMBA 
IQHAZA 
 
Isihloko socwaningo: Ukwelashwa ngendlela yokuncibilikiswa kwehluli legazi 
elihambisana nesifo senhliziyo ngabasebenzi bosizo oluphuthumayo.   
 
Isibingelelo: Sawubona, igama lami ngingu Raveen Naidoo ngenza ucwaningo 
oluhambisana nokwelashwa ngokushesha kokuhlaselwa isifo senhliziyo 
ngabasebenzi bosizo oluphuthumayo. 
 
Isendlalelo:  
Uyamenywa ukuthi ubambe iqhaza kulolucwaningo.  Ucwaningo luyindlela 
yokuthola impendulo yombuzo othile.  Ngaphambi kokuba uthathe isinqumo 
kubalulekile ukuthi uqonde kahle isizathu socwaningo nokuthi yini elindelekile. 
Ngicela uthathe isikhathi sakho ufunde leminingwane elandelayo ngokucophelela 
futhi ukhulumisane nabanye uma ufisa ukwenze njalo. Ungangibuza uma kukhona 
okungacacile noma ufuna eminye iminingwane.  Zinikeze isikhathi sokuthi wenze 
isinqumo sokuthi uyalibamba iqhaza yini kulolucwaningo noma qha. 
 
Kungani ngikhethiwe? 
Ukhethwe ngoba uke waphathwa isifo senhliziyo ngaphambilini. 
 
Kulolucwaningo sifuna ukufunda ngesikhathi esiphephile sokuqalisa ukwelapha 
okuvimbela ukwakheka kwamahluli egazi kulezoziguli eziphethwe isifo senhliziyo 
uma zelashwa abosizo oluphuthumayo eNingizimu Afrika, ikakhulukazi eThekwini 
namaphethelo. Indlela yokwelapha ebizwa ngokuthi i”thrombolysis” 
(ukuncibilikiswa kwegazi) isebenzisa uhlobo lwemithi encibilikisa amahluli ayingozi 
emithanjeni yegazi esenhlizweni. 
 
Ukuqalisa ukwelapha ngokushesha kusetshenziswa ukuncibilikiswa kwegazi 
kubalulekile ekwehliseni imiphumela engemihle yesifo senhliziyo. Ukwelapha 
ngokuncibilkisa igazi indlela yokwelapha eyamukelekile esetshenziswa 
esibhedlela, kodwa eNingizimu Afrika akufani nakwamanye amazwe ngoba 
lendlela yokwelapha ayisetshenziswa ngaphandle kwesibhedlela. 
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Ngalolucwaningo sifisa ukuthola ukuthi kuthathe isikhathi esingakanani ukuthi 
isiguli esihlaselwe isifo senhliziyo sithole ukwelashwa ngokuncibilkiswa kwegazi 
abosizo oluphuthumayo.  Sifuna nokuthola ukuthi ukuthi ithini imiphumela 
yokwelashwa ngaloluhlobo.  Imiphumela yalolucwaningo izonikeza ulwazi 
olubalulekile oluyosiza ekunikezeni umhlahlandlela ekwethulweni kokwelapha 
ngaloluhlobo ngabezimo eziphuthumayo lapha eNingizimu Afrika.   
 
Ngabe lolucwaningo luqhutshwa kanjani? 
Ngidinga ukuthi unginikeze igunya lokuthi ngikunikeze umuthi wokwelapha 
ngokuncibilikisa igazi i.e. umshanguzo uzobulala amahluli egazini. Ngizodinga 
ukuthi unginikeze igunya lokuthi ngihlole izincwadi zakho zasesibhedlela ukuze 
ngithole iminingwane eqondene nocwaningo negunya lokuthi ngixhumane 
nomunye wezihlobo zakho ukuze ngithole ukuthi uqhuba kanjani.  Imininingwane 
engiyidingayo ileyo eqondene ngqo nokwelashwa kwakho esibhedlela neminye 
yemiphumela yokuhlolwa kwakho.  
 
Ingabe yibuphi ubungozi obuhambisana nokubamba iqhaza? 
Kukhona ubungozi obhekene nabo wena njengesiguli esibambe iqhaza 
kulolucwaningo ngenxa yokuthi yize umshanguzo ozonikezwa wona ujwayelekile 
ukusetshenziswa esibhedlela, kodwa lomshanguzo unakho ukungaziphathi kahle 
eziguli. Ezinye iziguli kuyenzeka zibike imiphumela engemihle yalomshanguzo, 
lemimiphumela okubalwa kuyo ukopha ikakhulukazi lapho kungene khona umjovo. 
Ukulashwa okuyimpumelelo kungahambisana nokushaya kwenhliziyo ngendlela 
engejwayelekile. Kungenzeka futhi wehlelwe umfutho wegazi (blood pressure).  
Ungaba nenhliziyo encane ehambisana noma ingahambisani nokuphalaza. 
Kungenzeka ube nobuhlungu kanye nokuvuvukala lapho ujovwe khona. 
 
Ingabe iziphi izindlela zokuvikela imiphumela engemihle futhi iziphi izinhlelo 
ezilungiselelwe ukunxephezela labo ababambe iqhaza? 
Isikhathi esiningi lemiphumela engemihle ayidingi okunye ukwelashwa kodwa uma 
kwenzeka kube nesidingo sokwelashwa, lokhu kwelashwa kuyonikezwa yimina 
njengomsebenzi wezimo eziphuthumayo bese welashwa nawudokotela 
wasesibhedlela sakho. Ukunxephezelwa kulungiselelwe ngokomsebenzi 
engiwenzayo, ukuba umfundi kwami kanye nezimiso zasesibhedlela. 
 
 
Ingabe ikhona yini inzuzo ngokubamba iqhaza kulolucwaningo? 
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Ucwaningo lwangaphambilini luye lwakuveza ukuthi ukusheshe kunikezwe 
imishanguzo yokuncibilikisa igazi emva kokuhlaselwa isifo senhliziyo kunikeza 
imiphumela emihle.  Ngaphezulu kwalokho, ulwazi oluyotholakala ngokubamba 
kwakho iqhaza kulolucwaningo luyosiza ekunakekelweni kweziguli ezihlaselwa 
isifo senhliziyo esikhathini esizayo.  Ulwazi oluyotholakala kulolucwaningo 
luyosetshenziswa njengomhlahlandlela kazwelonke kubasebenzi bezempilo, 
ikakhulukazi abezimo eziphuthumayo, mayelana nokuthi kuqaliswa kanjani 
ukulashwa ngalendlela yethrombolysis ngaphambi kokuba isiguli sifike 
esibhedlela.  
 
Ingabe zikhona yini ezinye izindlela ezingasetshenziswa ezingangisebenzela 
kangcono? 
Ayikho enye indlela yokwelapha engasetshenziswa. 
 
Ngiphoqelekile yini ukuthi ngibambe iqhaza? 
Qha, ukubamba kwakho iqhaza ukwenza ngokuzikhethela wena.  Indlela yakho 
ojwayele ukwelashwa ngayo angeke iphazamiseke uma uthatha isinqumo 
sokubamba iqhaza kulolucwaningo noma ungalibambi iqhaza. 
 
Ingabe kukhona yini ukunxeshezelwa mayelana nezindleko zami? 
Angeke ukhokhelwe ngokubamba iqhaza kulolucwaningo futhi angeke kube khona 
ukunxeshezelwa ngoba lokhu akudinengekile kuloluhlobo locwaningo. 
 
Ingabe ukubamba kwami iqhaza kulolucwanigno kuyogcinwa kuyimfihlo? 
Yonke imininingwane yababambe iqhaza iyogcinwa iyimfihlo.  Yonke 
imininingwane iyogcinwa kwicomputer eyovikelwa ngamagama ayimfihlo isikhathi 
esiyiminyaka emihlanu.  Emva kwalokho yonke imininingwane iyokwesulwa. 
Umcwaningi kanye nombheki wakhe kuphela abayokwazi ukuhlola noma 
ukubheka imininingwane. Yonke imininingwane ngeke isebenzise amagama 
eziguli futhi ngeke yaziswe emphakathini. Imiphumela yocwaningo 
iyosetshenziselwa lolucwaningo kuphela. Nomakunjalo, angeke sinikezwe 
ngokuphelele isiqiseko sokugcinwa kwemininingwane iyimfihlo ngoba kungenzeka 
kube nesidingo sokwazisa imininingwane ngokomthetho  noma 
kubenezinhlangano ezifuna ukuhlola iminingwane ukuze ziqinisekise ukuthi 
ucwaningo luqhutshwe ngendlela efanele.  Lezi zinhlangano zingafaka 
izinhlangano ezifana nekomidi elebhekelela ubulungiswa bocwaningo (Research 
Ethics Committee) nenhlangano elawula ukusetshenziswa kwemithi (Medicines 
Control Council). 
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Kuyokwenzekani ngemiphumela yocwaningo? 
Kunethemba lokuthi imiphumela yalolucwaningo iyokwaziswa ngokhishwa 
emabhukwini ezemfundo noma aqondene nocwaningo futhi iyokwaziswa 
kubaqondisi babasebenzi  abathintekayo kanye nohulumeni. Imiphumela 
iyokwaziswa futhi nakulabo abambe iqhaza uma benze isicelo. Unelungelo 
lokwaziswa ngemiphumela etholakalayo uma wenza isicelo sokwaziswa. 
 
Ingabe ubani ohlolisise uhlelo lwalolucwaningo? 
Lolucwaningo lubhekisiswe futhi lwahlolwa ikomidi elibhekene nocwaningo 
enyuvesi yaseWitwatersrand. Ngaphuzulu kwalokho igunya lokwenza 
lolucwaningo linikezwe umnyango wezempilo waKwaZulu-Natal, umnyango 
wabosizo oluphuthumayo KwaZululu-Natal kanye nomphathi wesibhedlela 
olashwa kuso. 
 
Wamukelekile ukuthi uxhumane kanye nami okanye umbheki walolucwaningo 
uma unemibuzo odinga ukuthi iphenduleke noma ufuna ukubika okungahambi 
kahle ngocwaningo. Uma unganelisekile noma ngani kulolucwaningo, 
ungadlulisela ukngeneliseki kwakho kumbheki wocwaningo.  Igama likamabhalane 
wekomidi elbhekele ucwanigno lifakiwe lapha ngezansi ukuze ukwazi ukuthintana 
naye uma kukhona udinga ukukubika. 
 
Mayelana neminye imininingwane ungathintana nalaba: 
Igama lomcwaningi: 
Mr Raveen Naidoo 
Director: Postgraduate Development and Support (Acting) 
Durban University of Technology 
Tel: 031 3732846 
 
Igama lombheki wocwaningo: 
Prof K. Sliwa 
Director: Soweto Cardiovascular Research Unit 
Associate Professor of Medicine and Cardiology 
Department of Cardiology 
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CH Baragwanath Hospital 
University of the Witwatersrand 
Tel: 011 9338197 
 
Igama lomqondisi wekomidi lobulungiswa bocwaningo nosihlalo welelikomidi. 
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Appendix 7: Informed Consent Form – English 
 
CONSENT FORM 
 
• I hereby confirm that I have been informed by the researcher, Raveen 
Naidoo, about the nature, conduct, benefits and risks of this study -  
Protocol Number: M080822, Title: Thrombolytic therapy for acute 
myocardial infarction by emergency care practitioners. 
• I have also received, read and understood the above written information 
(Participant Information Document) regarding the study. 
• I am aware that the results of the study, including personal details regarding 
my gender, age, date of birth, initials and diagnosis will be anonymously 
processed into a study report. 
• In view of the requirements of the research, I agree that the data collected 
during this study can be processed by the researcher using a computer 
system. 
• I may, at any stage, withdraw my consent and participation in the study 
without prejudice,. 
• I have had sufficient opportunity to ask questions and (of my own free will) 
declare myself prepared to participate in the study. 
• I understand that significant new findings developed during the course of 
this research, which may relate to my participation, will be made available 
to me.  
 
 
________________  __________  ___________________ 
Name of Participant  Date / Time  Signature / Thumbprint 
 
 
I, Raveen Naidoo, herewith confirm that the above participant has been fully 
informed about the nature, conduct and risks of the above study. 
 
 
_________________ __________  ___________________ 
Name of Researcher Date / Time  Signature / Thumbprint 
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Appendix 8: Informed Consent Form – isiZulu 
 
IMVUME YOKUBAMBA IQHAZA OCWANINGWENI 
 
• Ngiyaqinisekisa ukuthi umcwaningi uRaveen Naidoo ungazisile ngohlobo 
locwaningo, indlela oluzoqhutshwa ngayo, usizo olungatholakala ngalo 
nobungozi obuhambisana nalolucwaningo. Inombolo yocwaningo: M080822  
Ishihloko socwaningo: Ukwelashwa ngendlela yokuncibilikiswa kwehluli 
legazi elihambisana nesifo senhliziyo ngabasebenzi bosizo oluphuthumayo.   
• Ngiyitholile, ngayifunda futhi  ngayiqonda imininingwane ebhalwe lapha 
ngenhla mayelana nalolucwaningo. 
• Ngiyaqonda ukuthi imiphumela yalolucwaningo, kuhlangene 
nemininingwane eqondene nami, ubulili, ubudala / iminyaka yami, usuku 
lokuzalwa, nohlobo lokugula kwami kuyovezwa ngaphandle kokwazisa 
igama lami kulolucwaningo. 
• Ngiyavumelana nokuthi yonke imininingwane eqondene nalolucwaningo 
umcwaningi ayihlaziye ngecomputer njengokumiselwe lolucwaningo. 
• Ngiyaqonda futhi ukuthi ngivumelekile ukuthi ngingakuhoxisa ukubamba 
kwami iqhaza kulolucwaningo noma yini ngaphandle kokuthi ngibandlululwe 
ngandlela thile. 
• Ngithole ithuba elanele lokubuza imibuzo futhi ngokuzikhethela kwami 
ngizobamba iqhaza kulolucwaningo. 
• Ngiyaqonda ukuthi ulwazi olusha nolubalulekile oluyovela kulolucwaningo 
olumayelana nokubamba kwami iqhaza ngiyokwaziswa ngalo. 
 
________________  __________  ___________________ 
Igama lobambe iqhaza Usuku   Isignature 
 
Mina Raveen Naidoo ngiyaqinisekisa ukuthi lona obambe iqhaza kulolucwaningo 
ngimazise ngokuphelele ngohlobo locwaningo, indlela oluzoqhutshwa ngayo 
kanye nobungozi obuhambisana nocwaningo.  
 
_________________ __________  ____________________ 
Igama lomcwaningi  Usuku   Isignature 
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Appendix 9: Registered Trademark 
Application Number: 2010 / 11215 
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Appendix 10: Heart Attack: Time is Heart Muscle Poster, Booklet & Video 
 
The compact disc contains the poster, booklet and video.  The software required 
to play the video has also been loaded onto the compact disc. 
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Appendix 11: Published Conference Proceedings 
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Appendix 12: Chapter in Book 
Pre-hospital Thrombolysis: It’s all a Matter of Time in Ischemic Heart 
Disease 
STATEMENT OF ORIGINALITY 
 
NAME RESPONSIBILITY 
Raveen Naidoo 
University of Witwatersrand 
Durban University of Technology 
Principal author in the dissertation. 
Involved in chapter writing and review. 
Nicholas Castle 
Durban University of Technology 
Involved in chapter writing and editing. 
CANDIDATE: I declare that this work is 
wholly my own, except where 
acknowledged as being the work of 
others (as listed above). I also 
acknowledge the contribution of others 
(as listed above) to this work in this 
STATEMENT OF ORIGINALITY. 
 
Raveen Naidoo 
SUPERVISOR: I hereby certify that all-
co-authors have provided their consent 
for inclusion of the manuscripts in the 
dissertation and that the co-authors 
accept the candidate’s contribution to 
the paper, as described in this 
STATEMENT OF ORIGINALITY. 
 
Professor Karen Sliwa 
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Appendix 13: Medications 
(117); (178) 
Tenecteplase (TNK) 
 
DESCRIPTION: 
• Classification  : Enzymatic preparation 
• Trade name  : Metalyse® 
• Schedule   : 4 
 
PHARMACOLOGICAL ACTION: 
• Tenecteplase is a recombinant fibrin-specific plasminogen activator. 
• The molecule differs from the native tissue-type plasminogen activator (t-Pa) 
by modifications at three sites of the protein structure, thus increasing its fibrin 
specificity and resistance and inactivation by its endogenous inhibitor. 
• It binds to the fibrin component of the thrombus and selectively converts 
thrombus bound plasminogen to plasmin, which degrades the fibrin matrix of 
the thrombus. 
 
PHARMACOKINETICS: 
• Dominant half-life: 24 + 5,5 minutes (18 to 30 minutes). 
• Terminal half-life: 129 + 87 minutes (40 minutes to 4 hours). 
 
INDICATIONS: 
• Thrombolytic therapy for acute phase of myocardial infarction. 
 
ADVERSE EFFECTS: 
• Haemorrhage: Predominantly at the injection site, gastro-intestinal, genito-
urinary or gingival bleeding occurred occasionally. Haemo-pericardium, retro-
peritoneal bleeding, cerebral haemorrhage and epistaxis have been observed. 
• Cardiovascular: Successful reperfusion for AMI is often accompanied by 
arrhythmias. Hypotension may also occur.  Tenecteplase therapy may lead to 
cholesterol crystal embolisation or thrombotic embolism (in rare cases). 
• Anaphylactoid reaction: Anaphylactoid reactions (e.g. rash, urticaria, 
bronchospasm, laryngeal oedema) have been reported. 
• Other: Nausea, and/or vomiting and fever were the most frequently reported 
remaining adverse events. 
 
CONTRA-INDICATIONS: 
• Uncontrolled hypertension [systolic blood pressure of more than 180mmHg, 
diastolic blood pressure of more than 110mmHg on repeated measurements]; 
• Major surgery: biopsy of a parenchymal organ, substantial trauma within 2 
months;  
• Any head injury or other trauma occurring after on-set of current myocardial 
infarction; 
• Any known history of stroke;  
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• Bleeding tendency; 
• Any known structural damage to the central nervous system; 
• Current treatment with oral anti-coagulants; 
• Sustained cardio-pulmonary resuscitation of more than 10 minutes’ duration; 
• Active peptic ulceration within the last 6 months; 
• Pregnancy; nor has the patient delivered within the last 2 weeks. 
 
PRECAUTIONS: 
• There might be complications if Tenecteplase is given without the patient 
having an infarct (but had pneumonia). 
 
PACKAGING: 
• Metalyse® 8 000 U: 1 vial contains 8 000 units (40mg) Tenecteplase. 1 pre-
filled syringe (Metalyse® solvent) contains 8 ml of water for injection. 
• Metalyse® 10 000 U: 1 vial contains 10 000 units (50mg) Tenecteplase. 1 pre-
filled syringe (Metalyse® solvent) contains 10 ml of water for injection. 
 
DOSAGE AND ADMINISTRATION: 
• Tenecteplase should not be administered in a line containing dextrose. 
• Any unused solution should be discarded. 
• Tenecteplase is to be administered IVI over 5 to 10 seconds according to body 
weight as per the table below. 
 
 
Patient’s weight 
(kg) 
Corresponding volume 
of reconstituted 
solution (ml) 
Tenecteplase 
(U) 
Tenecteplase 
(mg) 
< 60 6 6 000 30 
60 – 69 7 7 000 35 
70 – 79 8 8 000 40 
80 – 89 9 9 000 45 
≥ 90 10 10 000 50 
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Streptokinase (STK) 
 
DESCRIPTION: 
• Classification  : Enzymatic preparation 
• Trade name  : Streptase® 
• Schedule   : 4 
 
PHARMACOLOGICAL ACTION: 
• Anti-thrombotic enzymes convert plasminogen to plasmin, which in turn 
degrades fibrin thrombi and fibrinogen. 
• Streptokinase is antigenic and will induce antibody formation. 
• Generally reperfusion of occluded arteries will occur within 20 minutes to 2 
hours of initiation of therapy (average is 45 minutes). The hyper-fibrinolytic 
state will disappear within a few hours after discontinuation of administration. 
• Streptase® is highly purified Streptokinase derived from the culture filtrate of 
beta-haemolytic streptococci.  
 
PHARMACOKINETICS: 
• Half-life: 23 minutes. 
 
INDICATIONS: 
• Thrombolytic therapy for acute phase of myocardial infarction in adults. 
 
ADVERSE EFFECTS: 
• Early reactions: Headaches, pain in the back and allergic-anaphylactic reaction 
with flushing and dyspnoea may occur. Allergic reactions can be avoided by 
giving the intravenous infusion slowly. 
• Pyrexia, chills and rashes: Chills with or without pyrexia may occur during 
treatment. 
• Haemorrhage: Predominantly at the injection site. 
• Hypotension: Streptokinase can induce hypotension when given too rapidly.  
The infusion should run over a 1-hour period (400-500 IU/kg/minute). 
 
CONTRA-INDICATIONS: 
• Known hypersensitivity to Streptokinase. 
• Existing or recent haemorrhage: 
o all forms of reduced blood coagulation 
o local lesions with risk of bleeding 
o recent operations 
o recent abortion or delivery 
o diseases of the urogenital tract with existing or potential sources of 
bleeding. 
• Recent streptococcal infections. 
• Endocarditis. 
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• Uncontrolled hypertension [systolic blood pressure of more than 180mmHg, 
diastolic blood pressure of more than 110mmHg on repeated measurements]. 
• Impaired liver or kidney function. 
• Recent stroke or cerebro-vascular abnormalities. 
• Pulmonary diseases with cavitation (e.g. open tuberculosis) or severe 
bronchitis. 
• Acute pancreatitis or proliferative diabetic retinopathy. 
• Advanced age with arteriosclerotic cerebral disease. 
 
PRECAUTIONS: 
• Should not be given during the first 18 weeks of pregnancy unless absolutely 
necessary. 
• Caution is necessary with patients with mitral valve defect or fibrillation 
because of the danger of cerebral embolisation. 
 
PACKAGING: 
• Freeze-dried white powder sealed in a single dose in a clear glass vial.  In 
reconstitution, a colourless, clear to opalescent solution for intravenous use is 
obtained. 
• One vial of 1 500 000 IU Streptokinase in individual cartons. 
• One vial of 750 000 IU Streptokinase in individual cartons. 
 
DOSAGE AND ADMINISTRATION: 
• Streptokinase should not be administered between 5 days and (a minimum of) 
2 years following initial treatment as antibodies persist for at least 2 years. 
• Streptokinase does not contain any preservatives; therefore it should be 
reconstituted immediately before use. 
• Do not add any other medication to the container with Streptokinase. 
• Slowly add 5ml sodium chloride injection or dextrose 5% injection to the 
Streptokinase vial, directing the diluent to the side of the vacuum-packed vial 
rather than into the drug powder. 
• Roll and tilt the vial gently to reconstitute. Avoid shaking (shaking may cause 
foaming). 
• Withdraw the entire reconstituted contents of the vial; slowly and carefully 
dilute further into 200ml normal saline. 
• Infuse the 1 500 000 IU solution intravenously within 60 minutes. 
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Enoxaparin 
 
DESCRIPTION: 
• Classification  : Anti-coagulant 
• Trade name  : Clexane® 
• Schedule   : 4 
 
PHARMACOLOGICAL ACTION: 
• Enoxaparin is a low molecular weight Heparin that has a greater anti-
thrombotic activity (anti-factor Xa) than a thrombolytic effect (anti-factor IIa 
activity) in vivo. 
• It is well absorbed after sub-cutaneous injection. 
 
PHARMACOKINETICS: 
• Half-life: 4,5 hours. This is increased to 6,7 hours in the elderly. 
 
INDICATIONS: 
• Enoxaparin is indicated as co-therapy to Tenecteplase for thrombolytic therapy 
for acute phase of myocardial infarction by Emergency Care Practitioners. 
 
ADVERSE EFFECTS: 
• Haemorrhage: During Enoxaparin therapy, bleeding may occur in the presence 
of associated risk factors, such as organic lesions liable to bleed, invasive 
procedures or the use of medications affecting haemostasis. 
• Thrombocytopenia: Transient asymptomatic thrombocytopenia has been 
reported during the first days of therapy. Rare cases of immune-allergenic 
thrombocytopenia (with or without thrombosis) have been reported. 
• Local reactions: Pain, haematoma and mild local irritation may follow sub-
cutaneous injection of Enoxaparin. Rarely, hard inflammatory nodules have 
been observed at the injection site. Cases of skin necrosis have also been 
reported. 
• Others: Cutaneous or systemic allergic reactions may occur. Asymptomatic 
and reversible increases in platelet counts and lever enzyme levels have been 
reported. 
• Enoxaparin co-therapy should be discontinued should bleeding occur. 
 
CONTRA-INDICATIONS: 
• Hypersensitivity to Enoxaparin, Heparin or its derivatives, including other low 
molecular weight Heparins. 
• Patients who are haemorrhaging (normal menstruation excluded). 
• Patients at risk of haemorrhage: haemorrhagic blood disorders, 
thrombocytopenia, peptic ulcers, cerebro-vascular disorders, bacterial 
endocarditis and severe hypertension. 
 
PACKAGING: 
• Clexane 40: Enoxaparin 40mg per 0,4ml 
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• Clexane 60: Enoxaparin 60mg per 0,6ml 
• Clexane 80: Enoxaparin 80mg per 0,8ml 
• Clexane 100: Enoxaparin 100mg per 1,0ml 
• Clexane 300: Per multi-dose vial. Enoxaparin sodium 300mg, benzyl alcohol 
(preservative) 1, 5%m/v, water for injection to 3, 0ml. 
 
DOSAGE AND ADMINISTRATION: 
• Patients will receive Enoxaparin co-therapy as an intravenous bolus of 30mg, 
followed by the first sub-cutaneous dose of 1mg/kg about 15 minutes after the 
administration of Tenecteplase. 
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Heparin 
 
DESCRIPTION: 
• Classification  : Anti-thrombotic agent 
• Trade name  : Intramed Heparin Sodium®, Heparin Novo® 
• Schedule   : 4 
 
PHARMACOLOGICAL ACTION: 
• Unfractionated Heparin is a heterogenous mixture of strongly acidic 
mucopolysaccharide and has molecular weights varying from 3 000 to 30 000. 
• It is a direct anti-coagulant that prevents the formation of venous thrombi and 
the extension of existing thrombi. 
• It acts by potentiating the inhibitory effect of anti-thrombin III (Heparin co-factor) 
on the activated forms of clotting factors XII, XI, IX, X and thrombin. 
• Low molecular weight Heparins are manufactured chemically from 
unfractionated Heparin and have average molecular weights between 4000 
and 5000. 
 
PHARMACOKINETICS: 
• Half-life: 1 – 6 hours (average 1.5 hours) – dependent on dose, route and 
patient variability. 
• It is best given by continuous infusion for sustained effect. 
• Heparin is administered sub-cutaneously or intravenously; on-set of action is 
immediate after IV injection and usually within 1-2 hours when given sub-
cutaneously. 
 
INDICATIONS: 
• Co-therapy for acute phase of myocardial infarction. 
 
ADVERSE EFFECTS: 
• Risk of bleeding increases with dose (less when given by continuous infusion 
than by intermittent bolus injection). 
• Hypersensitivity reactions include fever, chills, urticaria and anaphylactic 
shock. 
• Mild thrombocytopenia is common, but is mostly transient and harmless. 
• Skin necrosis may occur at the injection site. 
 
ABSOLUTE CONTRA-INDICATION: 
• Known hypersensitivity. 
 
RELATIVE CONTRA-INDICATION: 
• Impaired coagulation 
• Thrombocytopenia 
• Severe hepatic disease 
• Active intestinal bleeding 
• Suspected intra-cranial bleeding 
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• Cerebral aneurysm 
• Threatened abortion 
• Visceral carcinoma 
• Bacterial endocarditis 
• Active cavitating tuberculosis 
• During or after eye, brain or spinal cord surgery 
• Prior to lumbar puncture or regional anaesthetic block 
 
 
PACKAGING: 
• Intramed Heparin Sodium®  
Injection, 1000 IU, 5000 IU, 12 500 IU, 25 000 IU/ml. 
• Heparin Novo® 
Injection, 5000 IU/ml 
 
DOSAGE AND ADMINISTRATION: 
• Administer 5000 units of Heparin IVI. Reduce to 4000 units for initial bolus for 
patients weighing < 67kg. 
 
  
160 
 
Appendix 14: Adapte Process 
 
  
161 
 
Appendix 15: Emergency Care Practitioner Thrombolysis 
CLINICAL SKILL: THROMBOLYSIS 
Procedure 
1. Take universal precautions, including protective gloves, facemask and eyewear. 
2. Calm, reassure and place patient in a comfortable position. 
3. Undertake a full clinical and 12 lead ECG assessment of the patient.  
4. Consider direct transfer of high risk patients to PCI facility. 
5. Undertake a 12 LEAD ECG within 10 minutes; thereafter every 15 minutes for the first hour if not continuous. 
6. Manage patient according to MONA mnemonic (morphine; oxygen; nitrates; Aspirin). 
1. Administer Clopidogrel (300mg for < 75 years; 75mg > 75 years). 
7. Determine if thrombolysis is indicated. 
8. Exclude the contra-indications for thrombolysis: 
9. Explain the procedure and its risks to the patient and obtain consent. 
10. Establish a large-bore IV line in a large peripheral vein. 
11. Following consultation with your local receiving physician (as applicable), administer thrombolytic agent using 
one of the following regimens: 
 
11.1. Tenecteplase 
Single weight-adjusted dose IV bolus: 
Patient’s weight (kg) Corresponding volume of 
reconstituted solution (ml) 
Tenecteplase 
(U) 
Tenecteplase 
(mg) 
< 60 6 6 000 30 
60 – 69 7 7 000 35 
70 – 79 8 8 000 40 
80 – 89 9 9 000 45 
≥ 90 10 10 000 50 
or 
11.2. Streptokinase 
Infusion of 1.5 million units of Streptokinase over 60 minutes (via syringe driver) in solution with 0.9% 
normal saline, 5% D/W or Ringer’s Lactate. (In the event of hypotension, halve the infusion rate or 
terminate infusion, as appropriate).  
12. Initiate anti-thrombotic co-therapy. 
12.1. Enoxaparin 
Administer Enoxaparin 30mg IV bolus, followed by the first sub-cutaneous dose of 1mg/kg about 15 
minutes after the administration of Tenecteplase. If patient’s age is > 75 years, no IV bolus and start with 
reduced sub-cutaneous dose. 
or 
12.2. Heparin 
Administer 5000 units of Heparin IVI. Reduce to 4000 units for initial bolus for patients weighing < 67kg. 
13. Pre-alert receiving hospital and assess the patient regularly en route to hospital. 
14. Undertake a clinical re-assessment (pain reduction) and 90-minute post lysis ECG (> 50% reduction of ST 
segment) to assess for successful reperfusion. 
15. If ST segment resolution is less than 50%, consider transfer of patient to PCI facility for Rescue PCI. 
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Appendix 16: Thrombolysis Checklist 
Indications: Acute ST-elevation myocardial infarction within 12* hours of on-set of 
symptoms. 
 Primary assessment: Can you confirm the following? Yes No 
1 The patient is conscious and coherent and able to understand that clot dissolving drugs will 
be used? 
  
2 The patient has symptoms that are characteristic of a heart attack (severe, continuous pain 
in a typical distribution of 15 minutes duration or more without remission?) 
  
3 The symptoms started less than 12 hours ago? 
NOTE: Consider “stuttering start” MI – many infarcts start this way. 
  
4 The pain built up over seconds and minutes, rather than starting abruptly?   
5 Breathing does not influence the severity of the pain?   
6 Systolic blood pressure is more than 80mmHg and less than 180mmHg and diastolic is 
below 110mmHg despite treatment? i.e. Analgesia & GTN for blood pressure and fluid 
challenge / atropine for hypotension). 
  
7 The electrocardiogram (ECG) shows abnormal ST-elevation of 2mm or more in at least 2 
standard leads or in at least 2 adjacent pre-cordial leads, not including V1.  
NOTE: ST-elevation can sometimes be normal in V1 and V2. 
  
8 The QRS width is 0.16 seconds (4 small squares) or less, and the left bundle branch block is 
absent from the tracing? 
NOTE: RBBB is permitted only with qualifying ST elevation. 
LBBB = QRS 140 ms or greater; small narrow R wave in V1 & V2 with big S wave; tall 
upright monophasic R in standard Lead 1 and V6. 
  
 Secondary assessment (contra-indications): Can you confirm the following? Yes No 
9 The patient is not likely to be pregnant, nor has delivered within the last 2 weeks?   
10 The patient has not had an active peptic ulcer within the last 6 months?   
11 The patient has not had a stroke of any sort within the last 12 months and does not have any 
permanent disability from a previous stroke? 
  
12 The patient: has no diagnosed bleeding tendency. has had no recent blood loss (except 
normal menstruation); and is not taking Warfarin (anti-coagulant) therapy? 
  
13 The patient has not had any surgical operation, tooth extractions, significant trauma, or head 
injury within the last 4 weeks?  
  
14 The patient has not been recently treated for any other serious head or brain condition?   
15 The patient is not being treated for liver failure, renal failure, or any other severe systemic 
illness? 
  
If all answers are YES ... Thrombolysis should commence.  
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Appendix 17: Patient Consent Form 
 
PATIENT CONSENT 
 
NOTE:  
Many patients with acute myocardial infarction (AMI) may not be legally ‘competent’ to give 
informed consent, and the EMERGENCY CARE PRACTITIONER must act in the individual 
patient’s best interest. Prior to administration, you must ensure the patient understands the risk and 
benefits of thrombolysis, as set out below. 
 
 
Initial Consent 
“It is likely that you are having a heart attack and the best treatment available to you is a clot 
dissolving drug called Tenecteplase/Streptokinase. The quicker you receive this drug, the lower 
the risks of a heart attack, which is why doctors recommend that the treatment is started as soon 
as possible.  These drugs can cause serious side effects in a small minority of patients, which I can 
explain to you in more detail if you so wish; but the risks attached to this treatment are very much 
less than the likely benefit.  Would you like me to give you the injection or would you prefer to be 
given more details?” 
 
I hereby consent to the treatment: 
 
________________  _____/_____  ___________________ 
Name of patient   Date / Time  Signature / Thumbprint 
 
In the unlikely event that the patient does want more information, the following information 
should be provided: 
 
Further information 
“Treatment at this stage saves the lives of about 1 in every 25 patients treated. But, it can 
sometimes cause serious bleeding. The biggest risk is stroke, which affects about 1 patient in 
every 200 treated.  Some patients also have an allergic reaction and other side-effects that do not 
usually cause any major problems. Would you like me to give you the injection?” 
 
If the patient refuses treatment at this stage, please record this on the patient record, 
transport the patient to hospital as quickly as possible and hand the patient over to the 
doctor -in charge. 
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Appendix 18: Summary of 20 patients thrombolysed 
 
Patient Number: 1 - 020809 
Ethnic 
group 
C Gender M Age 49 
Respiration 20 Pulse 91 
HGT 7.4 BP 140/90 
AVPU Alert Symptom/s Central chest pain 
Family History Nil 
Risk Factors Smoker 
ECG: Initial: Inferior, lateral, posterior. ECG @ 90 minutes: Reperfusion 
arrhythmias. 
Treatment At district hospital: Oxygen; ASA. 
Raveen Naidoo: Clopidogrel (300mg), Morphine7.5mg), TNK (7000U), 
Enoxaparin (30mg IVI, 70mg SC). 
Timeframes Symptom to call for help Notified wife 
immediately. 
Transportation time (from time call 
received to patient drop-off at hospital) 
01H27 by ambulance 
GP time N/A 
Primary hospital time 02H43 
Symptom to definitive treatment 04H10 
In-hospital Outcome No complications – discharged 06/08/09. 
30-day Outcome No complications. 
Researcher 
Reflective Practice 
Patient’s notified wife timeously. From time of EMS notification to admission > 
1hour. (EMS crew recognised that patient was having AMI). Time at district 
hospital with basic treatment - almost 3 hours. 
Symptom-to-needle could have been reduced further by: 
1. On-scene thrombolysis – within 1 hour. 
2. Quicker dispatch, response, on-scene time and transportation by 
ambulance services. 
3. Pre-alerting hospital by ambulance crew. 
4. Earlier in-hospital thrombolysis activation– within 30 minutes of arrival. 
Points to note: 
1. No medical advice given by EMS control centre. 
2. No ALS dispatch by EMS control centre. 
3. No ASA administration by EMS ambulance crew. 
4. No request for ALS assistance by EMS ambulance crew. 
5. No pre-alerting of receiving hospital. 
6. The importance of a cardiac care network was highlighted – direct 
admission to CCU, a system of consultation essential for safe ECP 
thrombolysis.  
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Patient Number: 2 - 220809 
Ethnic group I Gender M Age 47 
Respiration 14 Pulse 103 
HGT 11 BP 140/80 
AVPU Alert Symptom/s Severe central chest pain 
Family History Unknown 
Risk Factors Diabetic, Smoker 
ECG Initial: Anterior infarct. ECG @ 90 minutes: Resolving ST-elevation. 
Treatment At district hospital: Oxygen; ASA, GTN, Morphine (2mg) 
Raveen Naidoo: Clopidogrel (300mg), Morphine(3mg), TNK (9000U), 
Enoxaparin (30mg IVI, 80mg SC). 
Timeframes Symptom to call for help 4H15 
Transportation time 20min – privately 
GP time 30min – treated for 
ulcer prior to severe 
chest pain. 
Primary hospital time 1H23 
Symptom to definitive treatment 05H58 
In-hospital Outcome No complications – discharged 28/08/09. 
30-day Outcome No complications. 
Researcher Reflective 
Practice 
Patient had intermittent pain from the day before (20/09/09). Saw GP at 
17H15 on 21/08/09 and was treated for ulcers and sent home.  Patient 
delayed at home on the basis that he had ulcers. 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Notification and use of EMS. 
3. Accurate GP diagnosis. 
4. Earlier in-hospital thrombolysis activation – delivery within 30 minutes 
of patient arrival. 
Points to note: 
1. The importance of an awareness programme as well accuracy of GP 
diagnosis. 
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Patient Number: 3 - 220809 
Ethnic 
group 
I Gender M Age 47 
Respiration 24 Pulse 99 
HGT 15.5 BP 196/120 
AVPU Alert Symptom/s Central chest discomfort/pain 
Family History Diabetes 
Risk Factors Diabetic, Hypertension, Dyslipidaemia, Smoker 
ECG Initial: anterolateral infarct 
ECG @ 90 minutes: reperfusion noted. 
Treatment Raveen Naidoo: Oxygen; ASA, GTN,  Clopidogrel (300mg), Morphine(4mg), 
TNK (8000U), Enoxaparin (30mg IVI, 80mg SC). 
Timeframes Symptom to call for help 00H00 
Transportation time (From time call 
received to patient drop off at 
hospital) 
01H49min by ALS 
and ambulance. 
GP time N/A 
Primary hospital time N/A 
Symptom to definitive treatment CCU time 46 min. 
Total time: 02H25 
In-hospital Outcome: No complications – discharged 26/08/09. 
30-day Outcome: No complications. 
Researcher Reflective 
Practice 
Patient could not be lysed on scene, as the BP was above permissible 
parameters. Following consultation with Dr Ranjith telephonically, the patient 
was admitted directly to CCU.  Nitrocine infusion was commenced.  Raveen 
Naidoo thrombolysed patient when BP dropped below 180/110 mmHg in 
CCU. 
Symptom-to-needle could have been reduced further by: 
1. ECP use of Nitrocine 
Points to note: 
1. Nitrocine should be included in the scope of practice of ECP (pain and 
reduction of BP).  Paramedics are currently undertaking inter-hospital 
patient transfers with nitrocine infusion, when paramedics are trained 
on the use of nitrates (GTN). 
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Patient Number: 4 - 270809 
Ethnic 
group 
I Gender F Age 66 
Respiration 16 Pulse 72 
HGT 14.3 BP 88/45 
AVPU Voice Symptom/s Central chest pain 
Family History Brother died at a young age of heart problems. 
Risk Factors Diabetic, Hypertension 
ECG Initial: Inferior, Anterolateral infarct. 
ECG @ 90 minutes: Not done; patient in cardiac arrest at ADD 60 minutes 
later. 
Treatment At hospital: Mount Edgecombe - Nitrocine infusion, Clopidogrel (75mg); ASA. 
At hospital: MGMH – Oxygen; stopped Nitrate infusion and commenced 
Dobutamine infusion (20mls/hr). 
Raveen Naidoo: TNK (8000U), Enoxaparin (30mg IVI, 70mg SC). 
Timeframes Symptom to call for help 03H00 
Transportation time 20 minutes – 
privately. 
GP time Initial private hospital 
01H10 
Primary hospital time 01H00 
Symptom to definitive treatment 05H30 
In-hospital Outcome Patient went into cardiac arrest upon arrival at regional hospital CCU.  CPR 
and ALS management was undertaken for 15 minutes. Resuscitation attempt 
terminated at 04H30. 
30-day Outcome Not applicable. 
Researcher 
Reflective Practice 
Administration of TNK delayed by 30 minutes, as the patient was in 
cardiogenic shock.  
Symptom-to-needle could have been reduced further by: 
1. Reducing patient decision time. 
2. Administration of TNK at private hospital. 
3. Quicker commencement of inotropic support. 
Points to note: 
1. Inotropic support (Dobutamine) should be included in the scope of 
practice of ECP. Paramedics are currently undertaking inter-hospital 
patient transfers with inotropic infusions and are trained on its use. 
2. Only 75mg Clopidogrel (as opposed to the minimum of 300mg) given at 
private facility. 
3. Need additional ALS crew assistance to optimise management when 
transferring critically ill patients. 
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Patient Number: 5 - 060909 
Ethnic 
group 
I Gender M Age 66 
Respiration 18 Pulse 105 
HGT 20 BP 120/85 
AVPU Alert Symptom/s Central chest pain 
Family History Unknown 
Risk Factors Diabetic, Hypertension, Smoker 
ECG Initial: Anterolateral infarct. 
ECG @ 90 minutes: 12 lead not done as patient went in cardiac arrest en 
route to regional hospital. 
Treatment At hospital: Mount Edgecombe – No treatment. 
At hospital: MGMH – Oxygen, ASA, Actrapid. 
Raveen Naidoo: Clopidogrel (300mg), Morphine (2mg),GTN, TNK (9000U), 
Enoxaparin (30mg IVI, 80mg SC) 
Timeframes Symptom to call for help 0H30 
Transportation time 2H00 patient waited 
for private transport. 
GP time Initial private hospital 
02H00 
Primary hospital time 0H35 
Symptom to definitive treatment 05H05 
In-hospital Outcome Patient went into cardiac arrest en route to regional hospital; re-routed CPR 
in progress back to district hospital.  CPR and ALS management 
undertaken for 45 minutes. Resuscitation attempt terminated at 21H55. 
30-day Outcome Not applicable. 
Researcher Reflective 
Practice 
Patient kept saying that he was going to die. 
Symptom-to-needle could have been reduced further by: 
1. Reducing patient decision time, 
2. Administration of TNK at private hospital, 
Points to note: 
1. Had to call for additional ALS support when patient went into cardiac 
arrest. 
2. Sudden cardiac arrest after approx 30 second convulsion; PEA – VF-
Asystole. 
3. Need additional personnel to optimise cardiac arrest management in 
the back of an ambulance. 
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Patient Number: 6 - 170909 
Ethnic 
group 
W Gender M Age 44 
Respiration 18 Pulse 96 
HGT 6 BP 140/80 
AVPU Alert Symptom/s Severe central chest pain 
Family History Mother CABG 
Risk Factors Smoker 
ECG Initial: Infero-Anterolateral infarct. 
ECG @ 90 minutes: Reperfusion noted. 
Treatment At hospital: WW – Oxygen, ASA, Morphine (4mg), Nitrate infusion 
(3mls/hr). 
Raveen Naidoo: Clopidogrel (300mg), Morphine (4mg), TNK (8000U), 
Enoxaparin (30mg IVI, 75mg SC). 
Timeframes Symptom to call for help 0H00 
Transportation time (from time call 
received to patient drop off at 
hospital) 
42 minutes; patient 
walked to pick-up 
point. 
1H10 minutes  
GP time N/A 
Primary hospital time 01H40 
Symptom to definitive treatment 03H25 
In-hospital Outcome No complications – transferred to tertiary hospital for angiogram, EF 35%. 
30-day Outcome Angina on stress and physical exertion; relieved by rest.  TVD, booked for 
CABG. 
Researcher Reflective 
Practice 
Symptom-to-needle could have been reduced further by: 
1. Reducing EMS activation time. 
2. Reducing EMS on scene time. 
3. EMS activation of ECP for on scene thrombolysis. 
4. EMS pre-alerting receiving hospital. 
5. Administration of TNK at private hospital. 
6. Earlier in-hospital thrombolysis activation– delivery within 30 minutes 
of patient arrival. 
Points to note: 
1. No medical advice given by EMS communications centre. 
2. No ASA administration by EMS ambulance crew. 
3. No request for ALS assistance by EMS ambulance crew. 
4. No pre-alerting of receiving hospital. 
5. ECP in-hospital TNK administration delayed due to referring doctor’s 
interest in PHT and the lack of in-hospital casualty fax facilities. 
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Patient Number: 7 - 250909 
Ethnic 
group 
W Gender F Age 74 
Respiration 12 Pulse 96 
HGT 5.7 BP 165/95 
AVPU Alert Symptom/s Central chest pain 
Family History Parents died of MI; Mother (57); Father (62). 
Risk Factors Previous MI, Hypertension, Smoker 
ECG Initial: Inferior Infarct. 
ECG @ 90 minutes: No ECG changes. 
Treatment At hospital: Oxygen, ASA, GTN, Morphine 
Raveen Naidoo: Enoxaparin (40mg SC) Clopidogrel (300mg),  TNK (8000U). 
Timeframes Symptom to call for help 0H30 
Transportation time 02H30 minutes 
transport delay 
Private 
GP time N/A 
Primary hospital time 02H27 
Symptom to definitive treatment 05H27 
In-hospital Outcome No complications – Patient discharged on 28/09/09, 3 days later, no elevation 
of cardiac enzymes. 
30-day Outcome Patient had chest pains one week later and had a CABG the day after in 
Vereeniging. Patient fine thereafter. 
Researcher 
Reflective Practice 
Patient was initially planned to be transferred to a private hospital for TNK but 
could not due to lack of medical benefits. 
Symptom-to-needle could have been reduced further by: 
1. Reducing transportation time. 
2. Administration of TNK at private hospital/ 
3. Earlier in-hospital thrombolysis activation– delivery within 30 minutes of 
patient arrival/ 
Points to note: 
1. The patient did not infarct as evidenced by the normal cardiac enzymes 
during in-hospital stay. 
2. ST elevation in inferior leads incorrectly diagnosed and missed by all - 
RBBB. 
3. Patient diagnosis – unstable angina. 
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Patient Number: 8 - 250909 
Ethnic 
group 
I Gender M Age 36 
Respiration 28 Pulse 68 
HGT 5.7 BP 70/50 
AVPU Alert Symptom/s Central chest pain 
Family History Mother and father AMI, deceased @ 57 and 62 respectively. 
Risk Factors ? Previous MI was treated for ulcers beginning of May 2009. 
ECG: Initial: Inferior Posterior Infarct. 
ECG @ 65 minutes: Reperfusion noted. 
ECG @ 90 minutes: Not done. 
Treatment: At hospital:  Oxygen, ASA, GTN (2 puffs), Voluven (500mls X2), Dobutrex 
(10mls/hour). 
Raveen Naidoo: Clopidogrel (300mg), TNK (9000U), Enoxaparin (30mg IVI, 
80mg SC). 
Timeframes: Symptom to call for help 00H00 
Transportation time 01H30 minutes 
waited for transport – 
private. 
30 minutes travel 
time. 
GP time N/A 
Primary hospital time 01H40 
Symptom to definitive treatment 03H40 
In-hospital Outcome: Patient died approximately 01H30 after admission to CCU. LVF. 
30-day Outcome: N/A 
Researcher 
Reflective Practice 
Patient was hypotensive and was given Voluven to increase BP at hospital. 
BP remained below 80mmHg after 1 liter of Voluven. Dobutrex commenced 
thereafter. TNK administered 20 minutes later (12H20) BP at this stage 91/58 
mmHg. Patient developed pulmonary oedema approx 25 minutes later – 
sudden on-set, positive pressure ventilated to CCU (O2 sats 92%). 
Symptom-to-needle could have been reduced further by: 
1. Reducing transportation time. 
2. Inotropic support commenced earlier. 
3. Earlier in-hospital thrombolysis activation– delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. The use of Voluven (colloid) for hypotension is questionable. 
2. My management had to be defended. 
3. Pulmonary oedema possibly due to fluid over-load. 
4. Infero-posterior MI and sudden on-set = ?papillary muscle rupture. 
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Patient Number: 9 - 091009 
Ethnic 
group 
I Gender M Age 60 
Respiration 20 Pulse 54 
HGT 10 BP 97/64 
AVPU Alert Symptom/s Mild central chest pain 
Family History Nil 
Risk Factors Smoker 
ECG Initial: Inferior Posterior Infarct. ECG @ 120 minutes: Reperfusion noted. 
Treatment At district hospital: Oxygen; ASA. 
Raveen Naidoo: Clopidogrel (300mg), GTN (3 tabs), TNK (8000U), 
Enoxaparin (30mg IVI, 75mg SC). 
Timeframes Symptom to call for help 03H00 
Transportation time 00H25 – Private 
GP time 00H05 
Primary hospital time 03H10 
Symptom to definitive treatment 06H40 
1H10min delay due 
to discussions with 
receiving hospital.  
In-hospital Outcome No complications – discharged 13/10/09 
30-day Outcome 081109. No complications 
Researcher 
Reflective Practice 
Several delays occurred at the district hospital that were related to admission 
to CCU.  Had to wait for confirmation at receiving hospital of acceptance of 
patient by medical registrar, who then requested that the patient be lysed and 
post lyses ECG be faxed, before confirmation of admission to CCU – resulted 
in a 1h10 minute delay. 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Notification and use of EMS. 
3. Earlier in-hospital thrombolysis activation– within 30 minutes of arrival 
4. Easy access to consultant after hours. 
Points to note: 
1. Patient had active bleeding haemorrhoids mid September. This delayed 
thrombolyses, as I wished to discuss this with a consultant.  Go ahead 
given by Dr Bayat for lyses regardless of 40 minutes outside 6 hour cut 
off. 
2. Access to specialist essential for consultation of PHT – especially in 
early stages of PHT. Solution may be access to cardiologist on call at 
IALAH. 
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Patient Number: 10 - 250909 
Ethnic 
group 
I Gender F Ag
e 
60 
Respiration 24 Pulse 44 - 92 
HGT 17.1 BP 100/60 
AVPU Alert Symptom/s Central chest pain 
Family History Sister and brother died of a heart attack within last year. 
Risk Factors Unstable angina since 2007, Diabetes, Hypertension, Dyslipidaemia, Smoker. 
ECG Initial: Inferior Infarct with first degree block. ECG @ 90 minutes: Not done; 
patient arrested at Addington Hospital. 
Treatment At hospital:  Oxygen, ASA.  
Raveen Naidoo: Clopidogrel (300mg), GTN (2 puffs), TNK (9000U), 
Enoxaparin (30mg IVI, 80mg SC). 
Timeframes Symptom to call for help 00H05 
Transportation time (From time call 
received to patient drop off at hospital) 
35 minutes by 
ambulance to clinic. 
5 minutes by son’s 
car from clinic to 
MGMH. 
GP time 2H05 minute delay at 
Phoenix Clinic 
Primary hospital time 02H23 
Symptom to definitive treatment 05H53 
In-hospital Outcome Patient died approximately 22H55; approximately 50 minutes after admission 
to CCU. 
30-day Outcome N/A 
Researcher 
Reflective Practice 
Patient was initially hypotensive and was started on Voluven IV by hospital 
staff – stopped after 10mls by Raveen Naidoo (BP 100/60). Patient 
developed pulmonary oedema at CCU upon admission - went into cardiac 
arrest, resuscitated and then arrested again. 
Symptom-to-needle could have been reduced further by: 
1. EMS activation of ALS. 
2. EMS admission to district hospital rather than clinic. 
3. Pre-alerting receiving hospital. 
4. Earlier in-hospital thrombolysis activation– delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. No medical advice given by EMS control centre. 
2. No ALS dispatch by EMS control centre. 
3. No ASA administration by ambulance crew. 
4. Consulted with Dr Harku re recent tooth extraction. Extraction was well 
healed, uninfected, compressible area and not a deep-root canal. 
5. Reperfusion noted en route to hospital on Lead II, III. 
6. 12 lead ECG monitor failure- Called for operational Paramedic. Lysed on 
hospital ECG. 
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Patient Number: 11 - 161009 
Ethnic 
group 
C Gender F Age 80 
Respiration 18 Pulse 86 
HGT 6 BP 168/91 
AVPU Alert Symptom/s Discomfort/mild central chest pain 
Family History Unknown 
Risk Factors Hypertension, Asthmatic, Mild CVA 1986. 
ECG Initial: Inferior, anterolateral Infarct. 
ECG @ 60 minutes: Reperfused. 
Treatment At private clinic: Oxygen; ASA, GTN, Morphine (6mg). 
Raveen Naidoo: Clopidogrel (75mg), GTN (3 tabs), TNK (6000U), Enoxaparin 
(40 mg SC). 
Timeframes Symptom to call for help 00H15 
Transportation time 00H45 – waited for 
private 
transportation. 
Transportation time: 
15 minutes 
GP time N/A 
Primary hospital time 01H15 
Symptom to definitive treatment 02H30 
In-hospital Outcome No complications – discharged 20/10/09. 
30-day Outcome 15/11/09. No complications 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Quicker transportation. 
2. Earlier in-hospital thrombolysis activation– within 30 minutes of arrival. 
Points to note: 
1. Pleasing outcome. 
 
175 
 
Patient Number: 12 - 261009 
Ethnic 
group 
Black 
African 
Gender M Age 51 
Respiration 18 Pulse 107 
HGT 11 BP 164/109 
AVPU Alert Symptom/s Severe central chest pain 
Family History Unknown 
Risk Factors Possibly undiagnosed Hypertension, Diabetic 
ECG Initial: Inferior, posterior lateral Infarct. 
ECG @ 90 minutes: Reperfused. 
Treatment At district hospital: Oxygen; ASA, Nitrate infusion (5mls/hr), Morphine (2mg).  
Raveen Naidoo: Clopidogrel (300mg), GTN (2 tabs), Morphine (10mg), 
Metoclopramide (10mg), TNK (10000U), Enoxaparin (30mg IVI, 80 mg SC). 
Timeframes Symptom to call for help 00H00 
Transportation time 00H35 – Private 
(waited 30 minutes) 
GP time  
Primary hospital time 02H20 
Symptom to definitive treatment 02H55 
In-hospital Outcome Patient discharged on 021109.  No complications. Patient diagnosed as 
hypertensive. 
30-day Outcome 251109. No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Notification and use of EMS. 
3. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Patient pain free and comfortable upon admission to CCU. 
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Patient Number: 13 - 311009 
Ethnic 
group 
I Gender M Age 57 
Respiration 24 Pulse 40 
HGT 17,4 BP 92/54 
AVPU Alert Symptom/s Severe central chest pain 
Family History Brother died of MI at 52 
Risk Factors Diabetes, Hypertension, Smoker 
ECG Initial: Inferior Infarct; Complete heart block. 
ECG @ 120 minutes: Reperfused, but patient in complete block. 
Treatment At district hospital: Oxygen; ASA, Nitrate infusion (5mls/hr). 
Raveen Naidoo: Clopidogrel (300mg), Morphine (7.5mg), Metoclopramide 
(10mg), TNK (10000U), Enoxaparin (30mg IVI, 80 mg SC). 
Timeframes Symptom to call for help 00H00 
Transportation time 01H15 – Private 
GP time  
Primary hospital time 02H55 
Symptom to definitive treatment 04H10 
In-hospital Outcome Patient discharged on 061109.  Patient had to be externally paced and put on 
double inotropic support at CCU. 
30-day Outcome Patient stable at 30-day follow-up.  Patient in first degree block – no further 
complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Notification and use of EMS. 
2. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Direct admission to IALAH should have been considered. 
2. Patients pulse and BP increase to 55 and 102/56 en route to hospital. 
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Patient Number: 14 - 021109 
Ethnic 
group 
I Gender F Age 58 
Respiration 18 Pulse 76 
HGT 11 BP 165/95 
AVPU Alert Symptom/s Severe central chest pain 
Family History Parents and siblings. 
Risk Factors Angina, Diabetes, Hypertension 
ECG Initial:  Anterolateral Infarct. 
ECG @ 180 minutes: Reperfused. 
Treatment At district hospital: Oxygen 
Raveen Naidoo: ASA, Clopidogrel (300mg), GTN (1 tabs), TNK (7000U), 
Enoxaparin (30mg IVI, 65 mg SC). 
Timeframes Symptom to call for help 00H48 
Transportation time (From time call 
received to patient drop off at hospital) 
01H27 via 
ambulance 
GP time  
Primary hospital time 02H10 
Symptom to definitive treatment 04H25 
In-hospital Outcome No complications. Patient discharged on 06/11/09. 
30-day Outcome 051209 – No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. (Differentiate 
between angina and AMI.) 
2. EMS activation of ECP. 
3. Pre-alerting receiving hospital. 
4. Earlier in-hospital thrombolysis activation– delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. No medical advice given by EMS control centre. 
2. No ALS dispatch by EMS control centre – this was considered but the 
local operational ALS unit was not available. 
3. No ASA administration by Ambulance crew. 
4. Patient pain free and comfortable upon admission to CCU. 
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Patient Number: 15 - 051109 
Ethnic 
group 
I Gender M Age 63 
Respiration 12 Pulse 80 
HGT 11 BP 111/77 
AVPU Alert Symptom/s Central chest pain 
Family History Unknown 
Risk Factors None 
ECG Initial: Inferior with posterior extension. 
ECG @ 90 minutes: Complete reperfusion. 
Treatment At district hospital: Oxygen, ASA 
Raveen Naidoo: Clopidogrel (300mg), Morphine (2.5mg), TNK (7000U), 
Enoxaparin (30mg IVI, 65 mg SC), Metoclopramide (10mg), Atropine 
(0.25mg). 
Timeframes Symptom to call for help 0H30 
Transportation time 00H05 – Private to 
PHX Clinic. 
00H05 to MGMH 
GP time 00H55 
Primary hospital time 01H15 
Symptom to definitive treatment 02H50 
In-hospital Outcome No complications. Patient discharged on 09/11/09. 
30-day Outcome 051209 – No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time.  
2. Notification and use of EMS.  
3. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Mild pain and comfortable upon admission to CCU. 
2. Time to ECP activation and in-hospital treatment time reduced. 
3. Reperfusion changes occurred within 10 minutes of TNK. Bradycardia 
with severe pain experienced.  Bradycardia (46) responded to 0.5mg 
Atropine. 
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Patient Number: 16 - 111109 
Ethnic 
group 
I Gender M Age 70 
Respiration 16 Pulse 115 
HGT 14 BP 80/60 
AVPU Alert Symptom/s Central chest pain 
Family History Siblings 
Risk Factors Hypertension, Smoker 
ECG Initial: Anterior Infarct. 
ECG @ 180 minutes: Some perfusion. 
Treatment At district hospital: Oxygen, ASA, Dobutrex infusion 
Raveen Naidoo: Clopidogrel (300mg), TNK (8000U), Enoxaparin (30mg IVI, 
80mg SC) 
Timeframes Symptom to call for help 02H00 
Transportation time 02H45 – Private; 
patient delayed at 
home. 
GP time  
Primary hospital time 1H10 minutes 
Symptom to definitive treatment 05H55 
In-hospital Outcome Developed pulmonary oedema at Add CCU, transferred to IALAH, triple 
inotropic support, weaned off. TVD (Triple stent) – for CABG. Patient 
discharged on 171109 from IALAH 
30-day Outcome Patient died on 301109 – Patient collapsed suddenly at 21H00.  Patient was 
diagnosed of a gastric ulcer the same day at IALAH. Declared dead by 
Raveen Naidoo at 21H15. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Notification and use of EMS. 
3. Earlier in-hospital thrombolysis activation– delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Patient had differing pulse and BP. 
2. Time to ECP activation and in-hospital treatment time reduced. 
3. Overall improvement in time to treatment for patient in all health sectors. 
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Patient Number: 17 - 161109 
Ethnic 
group 
I Gender M Age 49 
Respiration 16 Pulse 91 
HGT 13.5 BP 131/86 
AVPU Alert Symptom/s Central chest pain 
Family History Mother – Cardiac 
Risk Factors Smoker 
ECG Initial: Anteroseptal Infarct. 
ECG @ 60 minutes: No change. 
ECG @ 4 hours later: Resolution noted. 
Treatment At district hospital: Oxygen, ASA, GTN X 2 tablets. 
Raveen Naidoo: Clopidogrel (300mg), TNK (7000U), Enoxaparin (30mg IVI, 
65mg SC), GTN X 2 tablets. 
Timeframes Symptom to call for help 0H00 
Transportation time 02H25 Patient delayed 
transportation 
GP time 0H05 PHX Clinic 
Primary hospital time 03H00 
Symptom to definitive treatment 05H30 
In-hospital Outcome Nitrate infusion started due to on-going mild central chest pain. No 
complications. Patient discharged on 20/11/09.  
30-day Outcome 15/12/09 – No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Patient had pain for more than two weeks, self-medicated for ulcers. 
2. Q waves in septal territory with hyperacute ST changes and ongoing 
chest pain. 
3. Pain subsided after initial pain @ 03H00; therefore, patient went home 
after clinic. Went to MGMH when pain started again @ 05H25. 
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Patient Number: 18 - 171109 
Ethnic 
group 
I Gender M Age 49 
Respiration 16 Pulse 89 
HGT 11.3 BP 143/97 
AVPU Alert Symptom/s Central chest pain 
Family History Brother – Cardiac 
Risk Factors Smoker 
ECG Initial: Anteroseptal Infarct. 
ECG @ 60 minutes: No reperfusion. 
ECG @ 160 minutes: No reperfusion. 
Treatment At district hospital: Oxygen, ASA, Nitrocine infusion, Enoxaparin (80mg SC). 
Raveen Naidoo: Clopidogrel (300mg), TNK (6000U), Enoxaparin (30mg IVI), 
GTN X 2 tablets, Morphine (2.5mg), Metoclopramide (10mg). 
Timeframes Symptom to call for help 02H00 
Transportation time 01H00 
Waited for 
employer’s help. 
GP time Initial private hospital 
50 minutes 
Primary hospital time 2H20 
Symptom to definitive treatment 06H10 
In-hospital Outcome Complete AV block night of admission at Addington. Temporary external 
pacemaker. Cardiac arrest and VT when temporary internal pacemaker 
attempted at Addington. Transferred to Albert Luthuli Hospital 
Stent inserted in LAD. On IABP and inotropic support. Off pump 23/11/09. 
Patient discharged on 02/12/09. 
Failed lyses? 
30-day Outcome 15/12/09 – No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time. 
2. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Q waves in septal territory with hyper-acute ST changes and ongoing 
chest pain. 
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Patient Number: 19 - 191109 
Ethnic 
group 
I Gender M Age 68 
Respiration 18 Pulse 75 
HGT Not 
done 
BP 110/59 
AVPU Alert Symptom/s Central chest pain 
Family History Mother – Cardiac 
Risk Factors Smoker 
ECG Initial: Anteroseptal Infarct. 
ECG @ 90 minutes: Reperfused. 
ECG @ 180 minutes: Reperfused. 
Treatment At district hospital: Oxygen, ASA, Enoxaparin (40mg SC). 
Raveen Naidoo: Clopidogrel (300mg), TNK (7000U), Enoxaparin (30mg IVI, 
30mg SC), GTN X 1 tablet, Morphine (2.5mg), Metoclopramide (10mg). 
Timeframes Symptom to call for help 0H00 
Transportation time 00H30 
GP time  
Primary hospital time 4H25 
Symptom to definitive treatment 4H55 
In-hospital Outcome Nitrate infusion started due to on-going mild central chest pain. No 
complications. Patient discharged on 23/11/09.  
30-day Outcome 18/12/09 – No complications, patient still smoking 5 cigarettes a day. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Nil. 
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Patient Number: 20 - 061209 
Ethnic 
group 
I Gender M Age 46 
Respiration 12 Pulse 125 
HGT  BP 149/107 
AVPU Alert Symptom/s Central chest pain 
Family History Mother – Cardiac, died at 68; Father – Cardiac, died at 50. 
Risk Factors Diabetic 
ECG Initial: Anterolateral Infarct. 
ECG @ 90 minutes: Did not reperfuse. 
Treatment At district hospital: Oxygen, ASA, GTN X 1 spray 
Raveen Naidoo: Clopidogrel (300mg), TNK (7000U), Enoxaparin (30mg IVI, 
730mg SC) 
Timeframes Symptom to call for help 0H00 
Transportation time 00H25 – patient 
waited for private 
transport. 
GP time  
Primary hospital time 2H55 
Symptom to definitive treatment 3H20 
In-hospital Outcome No complications. Patient discharged on 10/12/09. Patient diagnosed with a 
laminated thrombus in apex via echo. No increase in CPK, but elevated Trop 
I. Patient did not benefit from TNK. 
30-day Outcome 05/01/10. No complications. 
Researcher 
Reflective Practice 
Symptom-to-needle could have been reduced further by: 
1. Earlier patient symptom recognition and decision time - Influence of 
diabetes on pain? 
2. Earlier in-hospital thrombolysis activation – delivery within 30 minutes of 
patient arrival. 
Points to note: 
1. Initial pain started at 05H00 the same day, but subsided. Although 
patient did not delay when pain became severe at 20H00, patient could 
have sought medical help much earlier. 
2. Given the benefit administration of STK up to 12 hours, the 
administration of STK should have been considered. 
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